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ABSTRACT 
The structure-function relationship explains how the human erythrocyte glucose transport 
protein (GLUT1) catalyzes sugar transport across the plasma membrane. This work 
investigates the glucose transport mechanism, the structural arrangement and dynamics of 
GLUT1 membrane-spanning α-helices, the molecular basis for glucose transport 
regulation by ATP, and how cysteine accessibility contributes to GLUT1 structure. 
A rapid kinetics approach was applied to examine the conformational changes GLUT1 
undergoes during the transport cycle. To transition from a global to molecular focus, a 
novel mass spectrometry technique was developed to resolve GLUT1 sequence that is 
associated either with membrane embedded GLUT1 subdomains or with water exposed 
domains. By studying accessibility changes of specific amino acids to covalent 
modification by a Sulfo-NHS-LC-Biotin probe, specific protein regions associated with 
glucose transport modulation by ATP were identified. Finally, mass spectrometry was 
applied to examine cysteine residue accessibility under native and reducing conditions. 
This thesis presents data supporting the isolation of an intermediate, occluded GLUT1 
conformational state that temporally bridges import and export configurations during 
glucose translocation. Our results confirm that amphipathic α-helices line the 
translocation pathway and promote interactions with the aqueous environment and 
substrate. In addition, we show that GLUT1 is conformationally dynamic, undergoes 
reorganization in the cytoplasmic region in response to ATP modulation, and that 
GLUT1 contains differentially exposed cysteine residues that affect its folding.  
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CHAPTER I 
INTRODUCTION: 
CARRIER-MEDIATED TRANSPORT AND GLUT1 LITERATURE REVIEW 
WHY STUDYING CARRIER-MEDIATED TRANSPORT IS IMPORTANT 
The human body maintains its internal environment at a steady state in which flux and 
demand are balanced, a process known as homeostasis. Cells utilize integral membrane 
proteins to monitor and regulate interactions with the surrounding environment to 
maintain homeostasis. Virtually every cell system requires integral membrane proteins to 
catalyze necessary biological processes such as metabolism, cell signal recognition, and 
ion transport to maintain optimum conditions for cell survival [1]. Examining the 
fundamental properties and functions of this important protein class and the structure-
function relationships that govern and regulate their activity, therefore, is vital to 
understanding the mechanism of numerous biological processes. This thesis will focus 
primarily on the type I facilitative glucose transporter (GLUT1), a member of the Major 
Facilitator Superfamily (MFS), one of the largest groups of integral membrane transport 
proteins. By studying and examining how integral membrane proteins operate at the 
molecular level, we can appreciate the biological process from the standpoint of cells and 
organisms. 
THE PLASMA MEMBRANE 
All prokaryotic and eukaryotic cells are surrounded by a plasma membrane composed of 
amphipathic phospholipids and cholesterol. Phospholipid molecules combine a 
hydrophilic head group, which interacts with the external interstitial fluid or internal 
cytoplasm, with a hydrophobic tail of uncharged, nonpolar long chain fatty acids that 
associate with one another to form a tightly packed phospholipid bilayer [2]. The plasma 
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membrane, therefore, effectively seals the cell from its external environment and, owing 
to its intrinsically impermeant nature, controls and maintains intracellular volume and 
cellular composition.  
In addition to lipids, various classes of proteins are associated with the plasma 
membrane. Peripheral membrane proteins are noncovalently attached to the bilayer 
surface (predominantly cytoplasmic surface). Integral membrane proteins penetrate the 
bilayer and are permanently associated with the plasma membrane. Monotopic integral 
membrane proteins reside within the bilayer, bitopic proteins cross the membrane once 
and have one extracellular and one intracellular terminal end. Finally, transmembrane 
proteins, such as GLUT1, span the bilayer multiple times. The fluid mosaic model 
describes the plasma membrane as a discontinuous lipoprotein bilayer in which integral 
membrane proteins are partitioned at the surface and buried within the hydrophobic core 
due to the amphipathic nature of the protein regions [2,3]. The plasma membrane and its 
associated proteins control the passage of molecules into and out of the cell.  
TYPES OF DIFFUSION 
Small, uncharged, hydrophobic molecules such as gases (e.g. carbon dioxide and 
oxygen), unionized drugs (e.g. anesthetics), and endogenous compounds (e.g. steroids, 
ethanol, urea) are lipid soluble and pass through the membrane by simple diffusion. The 
rate of entry into or exit from the cell is modulated by hydrophobicity, molecular 
permeability, membrane thickness, and the concentration gradient. Smaller, more 
hydrophobic molecules display the most rapid rates of penetration and diffusion across 
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the bilayer [2]. In contrast to these small, nonpolar molecules, large, charged, and polar 
molecules such as nutrients, amino acids, and ions cannot pass through the membrane via 
simple diffusion. These molecules cross the membrane by facilitated diffusion, a process 
that requires integral membrane proteins to mediate passage into the cell (Figure 1.1).  
INTEGRAL MEMBRANE PROTEINS 
Integral membrane proteins such as pores, channels, and carriers all mediate facilitated 
diffusion, however, they differ in permeation pathway, transport mechanism, and solute 
movement. Pore proteins form cross membrane pathways that are always open and 
present simultaneous access to both sides of the plasma membrane. Aquaporin (AQP1), a 
tetrameric pore protein that spans the lipid bilayer, facilitates the simple diffusion of 
water across the membrane in single file motion [4]. Channels are more closely regulated, 
and structured in such a way that a terminal end acts as the gate that controls whether the 
channel is closed or open. A selectivity filter controls what class (positive or negative) 
and type of ions can pass through the open-channel pore [2]. Sodium, potassium, 
calcium, and chloride are the most common charged ions that enter and exit the cell. 
Channel transport rates are governed by open probability, the number of channels 
expressed at the cell surface, single channel conductance capability, and are saturable [2]. 
Sensors on the channel respond to changes in membrane potential, second messengers, 
and ligands to govern this described opening and closing process.  
Unlike pores and channels, carriers never present simultaneous access to both the intra- 
and extracellular environments. Instead, carrier-proteins must undergo a dynamic cycle of 
4
Figure 1.1 Diffusion across the plasma membrane. A lipid bilayer is shown providing 
a barrier between the extracellular environment (above) and intracellular space (below). 
The substrate, represented by the yellow circles, has a higher extracellular concentration, 
which creates a concentration gradient. Passive diffusion processes (simple or facilitated 
diffusion by pores, channels, and carriers) mediates substrate transport down its 
concentration gradient while active transport carriers use energy to transport substrate 
against its concentration gradient. The substrate represents a molecule that must cross the 
plasma membrane, and is not universally transported by all mechanisms. Small, 
uncharged, hydrophobic molecules can pass through the plasma membrane by simple 
diffusion. Larger, charged, and polar molecules require proteins to mediate passage into 
the cell. Protein channels and carriers are generally specific to one type of class of 
molecules. 
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conformational changes to facilitate translocation [2]. Carrier-mediated transport, 
therefore, is a saturable process, which limits the respective rate and quantity of 
molecules transported per event. Substrate binding within the transmembrane domain 
initiates cycling between binding site exposure to the inside or outside of the cell, thus 
marking the inception of the transport process. Cytoplasmic transporter domains, 
however, often control and regulate this process based upon interactions with intracellular 
factors, such as nucleotides.  
A second difference between pores and channels versus carriers is the driving force for 
solute movement. Pores and channels exclusively facilitate the passage of molecules 
down an electrochemical gradient without an additional energy source. Two factors 
contribute to regulating this passive transport process. First, the chemical potential 
difference is based upon the solute concentration gradient inside versus outside of the 
cell. Second, the electrical potential difference across the plasma membrane becomes a 
factor if the solute is charged. Together, the electrochemical potential difference 
determines net flux of a single solute into or out of a cell. Passive transporters generally 
catalyze uniport, a transport process that facilitates the uncoupled passage of a single 
substrate across the membrane.  
Carrier-proteins, such as GLUT1, mediate passive transport, but transporters are also 
capable of catalyzing active transport. In primary active transport, a solute is moved 
against its electrochemical gradient by utilizing the energy released by a coupled 
favorable process, such as ATP hydrolysis. In secondary active transport, energy 
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generated from the favorable movement of one solute down its electrochemical gradient 
is coupled to movement of another solute against its electrochemical gradient. Secondary 
active transporters generate the energy needed to mediate transport via antiport, where 
two substrates are transported in opposite directions, one into and one out of the cell, or 
via symport, where the coupled transport of two substrates proceeds in the same direction 
[5]. Active transport, regardless of the mechanism used to produce it, requires energy 
input to overcome the electrochemical gradient, thus providing the driving force for 
carrier-mediated net-solute flux. 
CARRIER-MEDIATED TRANSPORT PHYSIOLOGY 
The recent sequencing of the human genome indicates that at least 20% of identified 
proteins are polytopic integral membrane proteins and 3% are transport proteins [6-9]. 
The importance of carrier-mediated transport systems to cells and organisms is most 
evident when considering the pathophysiology of improperly functioning systems.  
Mutations within the type I facilitative glucose transport protein (GLUT1) impair glucose 
passage into the brain, a condition known as GLUT1-deficiency syndrome. These 
heterozygous mutations reduce glucose transport across the blood brain barrier by up to 
50%, which deprives neuronal cells of their primary energy source, causing seizures, 
developmental delay, and ataxia within affected patients [10]. The only known treatment 
for this disease is a high fat, low carbohydrate ketogenic diet. The Monocarboxylate 
Transporter (MCT1) is responsible for ketone delivery to the brain, thereby providing an 
alternative fuel source to glucose [11].  
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Similarly, in cystic fibrosis, a much more common and fatal hereditary disease, specific 
point mutations within the cystic fibrosis transmembrane conductance regulator protein 
(CFTR) cause improper folding of its transmembrane and cytosolic domains resulting in 
protein degradation [12]. In the absence of CFTR, negatively charged chloride ions can 
no longer cross the plasma membrane. Chloride accumulation outside of epithelial cells 
disrupts the intracellular electrochemical gradient resulting in the formation of thick, 
dehydrated mucus that blocks narrow passages within the lungs, pancreas, and intestines 
causing infection and organ damage.  
GLUT4 is the insulin-sensitive glucose transporter found within intracellular pools of 
heart, skeletal muscle, and adipose tissue. Upon insulin binding to its receptor, a complex 
signaling cascade results in GLUT4-vesicle translocation to the cell surface. This insulin-
sensitive response promotes a 10-20-fold increase above basal glucose transport levels, 
thereby controlling the postprandial rise in blood glucose concentration [13,14]. In 
patients suffering from Type II diabetes, insulin resistance causes higher than normal 
blood glucose levels. Unlike in type I diabetes, the Islets of Langerhans found in the 
pancreas still produce and release the insulin hormone, however, patients demonstrate 
resistance to insulin action, and the GLUT4-vesicle translocation response is stunted. 
Currently, GLUT4 and the insulin-signaling pathway are under extensive study to 
determine how insulin resistance develops, why it is linked with obesity, and how to 
overcome it. 
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Furthermore, integral membrane proteins such as drug receptors and transport proteins 
are increasingly being studied as targets for therapeutic agents. Chemotherapy agents are 
designed to diffuse or be transported across the plasma membrane of target cells, killing 
them and stopping further growth. Tumor cells that express the multidrug resistance 
transport proteins (MDR1, for example) are able to export these compounds from the cell 
rendering them ineffective as treatments. Mammalian MDR proteins are primary active 
transporters belonging to the ATP-binding cassette (ABC) Superfamily [15]. As the name 
implies, MDR proteins can transport multiple cytotoxic compounds with very little 
structural or charge similarity. Understanding the transport process from substrate 
recognition to conformational changes that mediate passage is crucial to improving drug 
treatment methods. 
Addictive drugs such as cocaine and heroin affect the ability to regulate neurotransmitter 
release or recycling by transport proteins. Cocaine specifically blocks and inhibits 
dopamine transporters, resulting in dopamine accumulation at the synapse, which 
stimulates pleasure [16,17]. Heroin, or its morphine metabolite, prevents the release of 
pain signals, subsequently enhancing the feeling of pleasure [18]. 
It is abundantly clear that transport proteins play a crucial role in ensuring cellular 
survival. Current studies focus upon the fundamental basis of how the structure-function 
relationship governs the role carrier-transport processes play in maintaining properly 
functioning biological processes. The findings of these works will lead to new and 
improved therapeutic strategies for the successful treatment of human disease. 
10
GLUCOSE METABOLISM 
Glucose is the primary metabolite utilized by living cells to produce energy. In fact, the 
brain requires continuous GLUT1-mediated sugar transport across the blood brain barrier 
(BBB). Neurons rely almost exclusively on glucose as the requisite energy source for 
maintaining communication and connection with the rest of the body [19]. Following 
digestion of dietary polysaccharides or hepatic metabolic processes, the circulatory 
system absorbs the produced glucose and delivers it to target cells. Various 
environmental factors, such as energy demand and oxygen availability determine how 
glucose is broken down. Glucose can be metabolized in rapid or efficient manners to 
produce ATP by anaerobic or aerobic glycolysis, respectively. Anaerobic metabolism 
produces the maximum amount of ATP in the shortest amount of time, providing the cell 
with sufficient energy for muscle contractions. This process is 100x faster than the 
slower, but more efficient aerobic glycolysis pathway that subjects pyruvate from the 
initial glycolysis reaction to the citric acid cycle and oxidative phosphorylation [20]. 
Aerobic glycolysis produces significant quantities of ATP per molecule of glucose by 
increasing the thermodynamic efficiency of the process at the expense of time. These two 
processes may be coupled in different cell types in the brain. According to the Astrocyte 
Neuron Lactate Shuttle (ANLS) hypothesis [21], astrocytes import glucose and process 
the glucose through lactate. The lactate is subsequently exported via the MCT transporter 
family into the interstitium, from which it is imported by neurons and processed 
aerobically. 
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GLUCOSE TRANSPORTERS 
Hexose metabolism is the primary source by which mammalian cells generate energy, but 
hydrophilic sugar molecules do not readily diffuse into the cell in a physiologically 
efficient manner. Glucose, therefore, must be transported across the cell membrane by 
carrier-proteins. Two different families of glucose transport proteins mediate sugar 
transport into the cell. Sodium/glucose cotransport proteins (SGLT) are expressed in the 
luminal membrane of absorptive tissue epithelial cells lining the small intestine and 
kidneys. These transporters use the electrochemical sodium gradient generated by the 
sodium-potassium ATPase pump to couple favorable sodium ion import with glucose 
uptake against its concentration gradient [22]. In contrast, the GLUT family of passive 
sugar transporters is distributed throughout all cell types in a tissue specific manner 
[22,23]. The facilitative glucose transporter family contains thirteen individual protein 
species named GLUT1-12 and HMIT (proton-coupled myo-inositol transporter). These 
proteins are subdivided into three classes based upon multiple sequence alignments. 
Within the entire family, the proteins display sequence identity ranging from 28 to 65% 
and share specific sugar transporter signature motifs [22,23].  
Class I isoforms of the facilitative glucose transporters, comprised of GLUT1 through 
GLUT4, have been studied most extensively in terms of their structure, function, 
substrate specificity, and tissue distribution. GLUT1 is the most ubiquitous of all glucose 
transporters, expressed in almost all cell types [24]. GLUT2 is found in the liver, kidney, 
intestine, and pancreatic islets and has a low affinity, but high capacity for dietary sugars 
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such as glucose, fructose and galactose [25]. In addition to being responsible for glucose 
transport from absorptive tissues into the bloodstream, GLUT2 also serves as a glucose 
sensing protein. Within the various tissue systems, it releases signals that regulate 
intestinal absorption, control insulin release, and trigger the transcription of glucose 
sensitive genes. GLUT3 primarily resides within sperm, platelets, the placenta, and the 
brain, specifically on the surface of neuronal cells, and has a characteristically high 
glucose affinity and high catalytic activity [19]. Finally, GLUT4 is the insulin sensitive 
glucose transporter found in heart, skeletal muscle, and adipose tissue.  
Classes II and III of the facilitative glucose transporters are less well understood than 
class I, and some of the members have only recently been identified by homology 
searches. Class II contains GLUT5, GLUT7, and GLUT11, which transport fructose as 
the primary substrate and GLUT9, a glucose transporter. Finally class III contains the 
remaining GLUT6, GLUT8, GLUT10, GLUT12, and HMIT, for which substrate 
specificity, trafficking, and potential role in diabetes have yet to be completely elucidated 
[22,23].  
This thesis specifically examines how the structural design of GLUT1 contributes to its 
physiological function. Furthermore, the similarities observed among polytopic integral 
membrane protein carriers will allow us to use GLUT1 as a model for studying other 
transport proteins. In this capacity, we address questions regarding the membrane 
transport process, structural organization of transport proteins within the plasma 
membrane, and provide new methods for the study of integral membrane proteins. 
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A MODEL TRANSPORT SYSTEM: THE HUMAN ERYTHROCYTE AND GLUT1  
The human erythrocyte serves as an ideal model system for studying transport. The red 
blood cell maintains homeostasis by using carrier-mediated transport to regulate proper 
pH, maintain a stable volume, and ensure proper gas-transport. Integral membrane 
proteins that complete these and other processes found within the red cell membrane 
include a Na+-K+ pump, a Ca2+-pump, an anion exchange protein, and the glucose 
transport protein GLUT1 [2,26].  
The mature, hemoglobin-containing erythrocyte is responsible for oxygen transport 
throughout the body [27]. During erythropoiesis, reticulocytes extrude all internal 
organelles, including the nucleus and DNA, such that only integral membrane proteins 
within the plasma membrane, the hemoglobin protein, and glycolytic enzymes remain in 
mature red blood cells. As a result, human red cells have a 120-day lifespan during which 
their biconcave shape and flexible nature, attributed to the cytoskeletal composition, 
allows them to circulate to all tissue systems within the body releasing hemoglobin bound 
oxygen to keep cells alive. In addition, since erythrocytes comprise 50% of the 
bloodstream, they effectively double the sugar carrying capacity of the blood using 
GLUT1-mediated transport of glucose to fill free space within the red cell. In this way, 
the red blood cells maximize the efficiency of the human circulatory system rapidly 
delivering and maintaining high levels of oxygen and sugar where they are needed most.  
In particular, the facilitative glucose transport protein GLUT1 expressed at the red blood 
cell surface provides an excellent cellular and protein model system for studying the 
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carrier-mediated transport process and mechanism. First, an established purification 
protocol has been developed that produces an ample amount of greater than 90% pure 
functional GLUT1 reconstituted in native erythrocyte lipids; 10 milligrams of GLUT1 is 
routinely purified from one unit of human blood [28]. Second, GLUT1 is membrane 
resident within the red blood cell plasma membrane. Unlike GLUT4, which must be 
trafficked to the plasma membrane by the insulin-signaling pathway, GLUT1 expressed 
in red blood cells serves as the paradigm example of carrier-mediated transport. Third, a 
large body of research exists describing GLUT1 substrate specificity, kinetics of 
transport, and tissue distribution, making it one of the most characterized eukaryotic 
transport proteins [14]. 
GLUT1 PHYSIOLOGY 
GLUT1, the most ubiquitous of all glucose transporters, is primarily expressed in red 
blood cells and the endothelial cells of the blood brain barrier (BBB) [24]. In addition, 
GLUT1 has been shown to be responsible for basal glucose transport in almost all other 
cell types including cardiomyocyte, muscle, and adipose tissue. Since glucose transport 
across the plasma membrane is the rate-limiting step of glycolysis and metabolism, 
GLUT1-mediated transport is vital to initiating energy production within these cells [29]. 
GLUT1 plays a fundamental role in delivering glucose to the brain to keep the central 
nervous system (CNS) functioning at maximum capacity. The BBB is made up of 
endothelial cells connected by tight junctions that effectively isolate the CNS from the 
rest of the extracellular environment found in the human body. In order to enter the CNS, 
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nutrients such as amino acids and glucose or drugs must pass through the transport 
systems expressed on both the luminal (blood-side) and abluminal (brain-side) 
membranes of the blood brain barrier [30]. In this way, the BBB and associated carrier-
proteins, such as GLUT1, serve to maintain homeostasis by regulating the import of 
required molecules and the export of unwanted drugs or secondary metabolites [19,30]. 
Within the endothelial cells of the BBB, GLUT1 is expressed at high levels. In this way, 
it catalyzes the rapid transport of glucose from the bloodstream, across the plasma 
membrane of the endothelial cells, and through the BBB into the interstitial fluid of the 
CNS [19,31]. Once in the CNS, glucose can be transported into neurons by the high-
affinity GLUT3 isoform, which is expressed at the neuronal plasma membrane. Since the 
brain cannot store glucose, the transfer across the BBB into the CNS must be rapid and 
efficient to keep the brain running at an optimized level.  
By governing GLUT1 expression levels at the plasma membrane, cells regulate glucose 
uptake rates to directly control metabolism. GLUT1 overexpression has been detected in 
many cancers including hepatic, pancreatic, breast, renal, brain, ovarian, lung, and 
cervical carcinomas [32]. The upregulation of high affinity GLUT1 results in increased 
glucose transport and energy generation from increased glycolytic flux. This increased 
energy generation enhances the biosynthesis of nucleotides, phospholipids, and other 
components necessary for new cell development [32]. GLUT1-mediated transport, 
therefore, supports angiogenesis and rapid cell division resulting in the propagation of 
cancer cells. 
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IMPORTANCE OF THE CARRIER-PROTEIN STRUCTURE-FUNCTION RELATIONSHIP 
Understanding the relationship by which the structure of a particular protein enables its 
subsequent function has long dominated the transporter research field. The most vexing 
question: how does the structure of membrane spanning amphipathic proteins catalyze 
substrate specific translocation across the plasma membrane? For GLUT1, early clues 
were provided by glucose transport kinetic studies performed by Widdas, Jung, and 
colleagues that established the carrier-mediated transport hypothesis [5,33-39]. Over the 
next thirty years, researchers intensively studied transport structure-function relationships 
using traditional techniques such as ligand binding and kinetic transport studies, 
computer simulations, peptide mapping, glycosylation and cysteine scanning 
mutagenesis, and hydropathy analysis [24,40-51]. These methods encompassed the fields 
of biochemistry, molecular biology, and bioinformatics and provided the raw data to 
develop, revise, refute, and explain the transport process. 
Following the crystallization of the KcsA potassium channel in 1998 [52], researchers 
succeeded in crystallizing the first transport protein when Toyoshima et al. published the 
structure of the P-type ATPase Superfamily calcium pump two years later [52,53]. 
Generally speaking, MFS transporters have proven refractory to crystallization because 
they are conformationally dynamic, exist in multiple states, are highly hydrophobic, and 
are difficult to overexpress in cellular systems [7]. In the last four years, however, the 
three-dimensional crystal structures for four MFS transport proteins have been obtained: 
oxalate transporter (OxlT; formate for oxalate; antiport; [5,34]), lactose permease (LacY; 
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galactoside/proton: symport; [33]), the glycerol-3-phosphate/phosphate antiporter (GlpT; 
phosphate for glycerol-3-phosphate: antiport; [35]), and an E. coli multidrug transporter 
(EmrD; proton for drugs that uncouple oxidative phosphorylation: antiport; [39]). The 
crystal structures reflect LacY and GlpT in an inward facing conformation (e1) and OxlT 
and EmrD in an intermediate or closed state (possibly the e2/e1 intermediate 
configuration). Although the sequence identity amongst these transporters is less than 
20%, they share a similar folding pattern and arrangement of transmembrane domains.  
Given that transporters are remarkably dynamic and undergo extensive conformational 
changes to catalyze substrate translocation, visualizing the static structure alone is not 
sufficient for answering all biological questions concerning the transport process. Crystal 
structures, however, do provide important information regarding the number of 
transmembrane helices, the helix packing motif, helical tilts, substrate binding sites, the 
flexibility or rigidity of peri- and cytoplasmic loops, and, in some instances, the breadth 
of different transporter conformations that exist in the presence or absence of substrates, 
inhibitors, or modulators. Additionally, crystal structures and subsequent homology 
modeling provide opportunity for the development of specific hypotheses that can be 
subject to experimental testing. Combining traditional biochemical techniques with three-
dimensional crystallography will produce the largest data set for analysis in terms of 
understanding the structure-function relationship that governs membrane transport 
proteins.  
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MAJOR FACILITATOR SUPERFAMILY 
Members of the Major Facilitator Superfamily (MFS) of transport proteins are 
ubiquitously expressed across all three domains of living organisms: Archaea, Bacteria, 
and Eukaryota. These proteins are responsible for the passive or secondary active 
transport of simple sugars, complex oligosaccharides, drugs, amino acids, ions, 
neurotransmitters, nucleosides, and other molecules catalyzing substrate translocation via 
uniport, antiport, or symport [54]. As an integral membrane protein responsible for 
facilitating sugar flux across cell membranes via uniport, GLUT1 belongs to the Major 
Facilitator Superfamily (MFS) of transport proteins [55]. Bioinformatics tools, such as 
sequence alignments and hydropathy plots, indicate that MFS proteins likely share very 
similar secondary structure properties, the majority of which contain 12 membrane 
spanning α-helices with the amino and carboxy termini exposed to the cytoplasm. MFS 
transport proteins average 400 to 600 amino acids in length and have two six-helix halves 
connected by a large intracellular loop (see the putative GLUT1 topography in Figure 
1.2) [6,33,35,56]. Although the two bundles display apparent structural symmetry, the 
sequence identity is quite low.  
The crystal structures reveal that these four distinct MFS transport proteins share several 
structural features. The N- and C-terminal halves display a striking pseudo two-fold 
symmetry in helical arrangement, tilt, and organization within the lipid membrane, 
consistent with the gene duplication hypothesis [57]. Within the plasma membrane, each 
adjacent helix is inserted into the membrane in the opposite direction of its partner. For 
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Figure 1.2 GLUT1 primary amino acid sequence and putative membrane topology 
from GlpT homology based structure [64]. Several key properties should be noted. 
Group 1 TMs are highlighted in pink. Group 2 and Group 3 TMs are highlighted in blue 
and green respectively. Some helices that span the bilayer extend beyond the boundaries 
of the bilayer (shown by horizontal lines). The bilayer-embedded region of each 
membrane spanning helix (TMs 1 through 12) comprise amino acids 17 - 39, 64 - 86, 93 - 
112, 120 - 141, 157 - 178, 187 - 207, 267 - 291, 305 - 325, 335 - 356, 362 - 385, 401 - 
421 and 431 - 452 respectively. GLUT1 is heterogeneously glycosylated at Asn45. TMs 
6 and 7 are linked by a large cytoplasmic loop (L6-7). The N- and C-termini are exposed 
to cytoplasm. Several conserved residues and signature sequences found among GLUT 
proteins are also noted. Conserved glycine, tryptophan, and tyrosine residues are boxed. 
Numerous symmetrical sequence motifs are shown using colored filled circles RXGRR 
(red), EX6R (olive), and PESPR/PETKGR (sky blue). Signature motifs found in most 
GLUT proteins that surprisingly do not confer substrate specificity include the QLS and 
STSIF sequences (orange) as well as a conserved proline-rich region thought to impart 
conformational flexibility on the molecule (yellow).  
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example, the N-terminal regions of helices 1 and 7 are oriented toward the cytoplasm 
while the C-terminal region faces the periplasm. Conversely, the N-terminal halves of 
helices 2 and 8 are oriented toward the periplasmic face whereas the C-terminal halves 
interface with the cytoplasm. The crystallized MFS structures suggest that the TM helices 
can be separated into three groups based upon their helix packing arrangements and 
associations with the lipid bilayer. Group 1, comprised of α-helices 1, 4, 7, and 10 and 
Group 2, composed of α-helices 2, 5, 8, and 11 appear to contribute to the aqueous pore. 
Group 3 transmembrane domains, including α-helices 3, 6, 9, and 12 serve as the 
scaffolding helices, which provide support for the eight substrate translocation cavity 
helices. Figure 1.3 shows the crystallized GlpT structure and illustrates the emergent 
MFS transport protein helix-packing model. 
Helical orientation can be described by studying the arrangement of each helix within the 
LacY and GlpT crystal structures that represent the endofacial e1 conformation. The 
group 1 TM domains form the most interior region of the aqueous translocation pathway 
[35]. TM1 and TM7 are inserted into the membrane from the cytoplasm and approach as 
they tilt toward each other until they come within close contact in the middle of the 
bundle formed by exofacial hemi-leaflet domains of TM2-TM5-TM-8-TM11. Helices 4 
and 10 are on opposite sides of the narrow cavity and do not come close to contacting one 
another. Group 2 TM domains form the outer portion of the cavity [35]. The N- and C-
terminal pairs are tilted at a 20° angle from the membrane normal, but in opposite 
directions, thus displaying a square peak-like orientation within the membrane, and 
presenting an opening within the cytoplasm. The placement and orientation of 
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Figure 1.3 MFS crystal structure and helix packing model. (A) The three-dimensional 
model of GLUT1 α-helix arrangement within the membrane as presented by Salas-
Burgos et al [64]. The GLUT1 primary sequence was homology modeled using the GlpT 
crystal structure template. (B) The putative MFS helix packing arrangement viewed from 
the cytoplasmic surface. TMs are colored and numbered as in Figure 1.2. The internal 
symmetry between N- and C-terminal halves of GLUT1 is evident from the helical tilts 
and may have resulted from a gene-duplication event. Adapted from [33,35]. 
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transmembrane group 3 helices with respect to the transport pore represent a striking 
synonymous characteristic amongst the four crystallized transporters [5,33-35,39]. Each 
of these helices faces away from the internal pore structure, is completely embedded 
within the lipid bilayer, and presents absolutely no side chain accessibility to solvent. 
These qualities explain why group 3 helices serve as such an effective support system for 
the eight cavity-forming helices.  
The shortest three helices, TM3, TM6, and TM9, define the boundaries of the membrane 
bilayer, indicating which protein domains are embedded within the plasma membrane 
[35]. As a result, in the e1 conformation, the majority of the periplasmic loops do not 
protrude very far from the membrane surface. In contrast, however, many of the α-
helices and the large intracellular loops and C-terminus protrude into the cytoplasm, 
away from the plasma membrane. Loop 6-7, which connects the amino and carboxy-
terminal halves of the protein, appears to be a long, flexible structure with minimal 
helical secondary structure [35]. 
THE GLUT1 STRUCTURE-FUNCTION RELATIONSHIP 
Researchers have employed a vast range of biochemical and biophysical techniques to 
understand the molecular basis of GLUT1 function. Over 50 years ago, several 
researchers studying the absorption of glucose in the intestine, its entry into erythrocytes, 
and its transfer from mother to fetus using sheep placenta found that glucose 
accumulation data could not be modeled by simple diffusion kinetics [58,59]. Widdas 
observed, rather, that sugar transport displayed saturation kinetics, i.e. a finite number of 
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carriers present themselves for sugar transport, and that this process could be modeled by 
the Michaelis-Menten equation routinely used to characterize enzyme activity [38]. 
Widdas further determined that the carrier was glucose specific, was presented at the cell 
surface, and likely exhibited a wide range of tissue distributions.  
The fluid-mosaic model was developed twenty years later and it described the plasma 
membrane as a discontinuous lipid bilayer with transmembrane spanning proteins 
embedded within it. Jung and colleagues provided strong evidence that membrane bound 
erythrocyte proteins catalyzed glucose transport into red blood cells. Jung showed that 
lysed and resealed erythrocyte ghosts, lacking internal cellular components, retained the 
glucose transport properties of red blood cells [37]. Additionally, transport capability was 
not observed when erythrocyte lipids alone were reconstituted into resealed bilayers [36]. 
Taking the observations of Widdas, Jung, and Singer together, researchers hypothesized 
that glucose transport in these systems was a saturable passive transport process mediated 
by substrate specific integral membrane proteins [14].  
Mueckler and colleagues first cloned GLUT1 from HepG2 cells in 1985, over thirty years 
after Widdas initially hypothesized that a glucose carrier protein existed [24]. The 
primary sequence contains 492 amino acid residues with a calculated molecular weight of 
54,117 Daltons. GLUT1 contains a single, heterologous, N-linked glycosylation site 
(NQT) at asparagine 45, which causes the protein to resolve as a broad, diffuse band 
when visualized by gel electrophoresis. The amino acid sequence indicates that over 60% 
of the residues are hydrophobic in nature. Fourier transform infrared spectroscopy studies 
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of proteolyzed, membrane-retained GLUT1 indicate a predominance of α-helices in the 
transmembrane region [60]. Circular dichroism and polarized Fourier transform studies 
confirmed this result and showed that the transmembrane α-helices are generally 
organized in an orientation perpendicular to the lipid bilayer [61,62]. 
Hydropathy plot predictions, N-linked glycosylation mutagenesis, and homology 
modeling simulations indicate that GLUT1 is comprised of 12 α-helical transmembrane 
spanning domains embedded within the lipid bilayer (Figure 1.2) [24,45,63,64]. 
Consistent with the organization for MFS transport proteins, proteolysis and antibody 
binding studies have revealed that the N and C-termini are cytoplasmic. A large 
intracellular loop between transmembrane domains 6 and 7 links the seemingly 
symmetric N- and C-terminal halves of the protein, an arrangement thought to have 
resulted from a gene duplication of the 6 transmembrane domain precursor [57]. The 
external loop connecting TMs 1 and 2, containing the N-linked glycosylation site, the 
large intracellular loop, and the C-terminal are the largest, most flexible non-membrane 
embedded protein segments. Additionally, covalent labeling with membrane-impermeant 
probes has shown that lysine 300 between TMs 7 and 8 and cysteine 429 between TMs 
11 and 12 are exposed to the interstitium adding further evidence for the proposed 
topographical arrangement of this membrane spanning transport protein [61,65,66]. 
Currently, a high-resolution three-dimensional GLUT1 crystal structure does not exist. 
Salas-Burgos et al. and Holyoake et al. have recently modeled the GLUT1 helix packing 
arrangement using the alignment from fellow MFS transport protein GlpT [63,64]. This 
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helix-packing model is consistent with hydrogen-deuterium exchange studies showing 
that approximately 80% of GLUT1 amide protons freely exchange with a deuterated 
aqueous environment, indicating that a majority of the protein is exposed to solvent [67].  
Mueckler and colleagues have studied virtually all of the GLUT1 TM helices to further 
understand the three-dimensional structure and helix packing arrangement of GLUT1. 
This method systematically scans through each proposed TM and adds back single 
cysteine mutations to a cysteine-less construct expressed in a Xenopus laevis oocyte 
expression system. The mutant protein is then assayed for p-chloromercuribenzene 
sulfonate (pCMBS) sensitivity by monitoring glucose transport rates compared to the 
cysteine-less mutant. Since pCMBS is a membrane impermeant cysteine reactive probe, 
it is proposed that transport inhibition in the presence of pCMBS is due to the exposure of 
the mutated residue to the aqueous environment, and by extension, said residue is 
predicted to line the permeation pathway. TM domains 1, 2, 5, 7, 8, 10, 11, and 12 have 
been found to contain residues that are pCMBS sensitive [48,68-74], while mutations 
within TMs 3 and 4 seemingly do not affect transport rates in the presence of pCMBS 
[49,50]. TMs 6 and 9 have yet to be studied via this technique. The observations are 
consistent with the proposed MFS helix-packing model, with the exception of TMs 4 
(pCMBS-insensitive) and 12 (pCMBS-sensitive). 
Bioinformatics analyses and sequence alignments of all facilitative glucose transport 
family members have revealed multiple signature sequences and invariable residues 
highly conserved among each GLUT family member (Figure 1.2) [23,61]. Although 
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many of these residues and signature sequences are required for transporter function, 
their respective contribution to substrate specificity is ambiguous at best. First, GLUT1 
contains two conserved tyrosine and tryptophan residues that fall within helix pairs 4 and 
7 and 6 and 11 respectively. Of these four conserved residues, W412 has proven to be 
functionally important for transport activity and ligand binding. Second, seven conserved 
glycine residues can be found within the membrane embedded region and are proposed to 
maintain the structural flexibility of these respective transmembrane α-helices [23]. The 
location of the conserved glycine residues is particularly interesting because they 
illustrate the trend of symmetrically conserved areas of the primary structure. Six of these 
residues are found in TM helices 1, 2, and 4, which correspond to TMs 7, 8, and 10 
according to the gene duplication hypothesis [56].  
Third, two even more striking displays of symmetry in the primary structure can be found 
in transporter signature motifs located at the cytoplasm-lipid bilayer interface at 
corresponding locations on the N- and C-terminal halves of the protein. Both the RXGRR 
and EX6R motifs are highly charged and are found in the intracellular loops connecting 
TMs 2-3 and 8-9 and TMs 4-5 and 10-11, respectively. Mutational analysis has shown 
the RXGRR motif to play a pivotal role in anchoring and properly orienting the protein 
within the lipid bilayer [75]. Additionally, the presence of numerous conserved charged 
residues at the meeting point between the lipid bilayer and intra- or extracellular space 
may also play a role in substrate induced conformational changes [75]. Finally, the most 
N-terminal residues of L6-7 and the cytoplasm exposed C-terminus contain GLUT family 
conserved PESPR and PETKGR motifs, respectively.  
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A characteristic sequence motif found within TM10, which includes W388, is both 
proline and glycine rich (GPGPIPW). Mutational studies indicate that although the 
individual residues do not appear to be crucial in maintaining transport activity, the side 
chains likely confer conformational flexibility to the transporter, facilitating the 
isomerization between the e2 (exofacial) and e1 (endofacial) orientations [76]. The QLS 
(QQLSG) and STSIF (YSTSIF) motifs found in TM7 and L7-8, respectively were 
initially characterized as glucose specificity sequences. [23,61,76-78]. When GLUT 
family members in addition to GLUT1-4 were found, however, this idea became less 
likely. The HMIT protein, which does not transport glucose, possesses the conserved 
QLS motif. Furthermore GLUT8 displays glucose specificity, however, it lacks the 
STSIF motif. It therefore appears that these conserved and symmetric residues play key 
roles in maintaining transport ability, transmembrane integrity, and in facilitating the 
required conformational changes, but do not confer substrate specificity [23].  
In the absence of a GLUT1 crystal structure, affinity-labeling and mutagenesis 
experiments have provided significant information regarding how GLUT1 structure 
relates to its function. These experiments used two well know endofacial transport 
inhibitors, cytochalasin B (CCB) and forskolin, to identify cytoplasmic regions of the 
protein critical for both substrate and inhibitor binding. CCB and forskolin are both 
inhibitors of glucose binding and transport, with CCB serving as a competitive inhibitor 
that binds at the glucose-binding site [61]. Regions of the protein affinity labeled by these 
two molecules correspond to the cytoplasmic loop that links TMs 10 and 11 as well as the 
endofacial halves of these two transmembrane domains. Within TM10, W388 has been 
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directly identified in forming one of the bonds with the forskolin molecule. When both 
W388 (of TM10) and W412 (of TM11) are mutated, the CCB binding and glucose 
transport capability are absolutely abolished [79]. The sequence alignments, 
identification of signature motifs, affinity-labeling observations, and mutagenesis studies 
have clearly implicated that the cytoplasmic portions of TMs 10 and 11 including the 
linker region are highly dynamic. Given how important these regions are in mediating 
CCB and forskolin binding, this region clearly plays a vital role in establishing a 
cytoplasmic glucose-binding pocket.  
The final structural characteristic that contributes to GLUT1 function is its oligomeric 
state. Like other MFS transporters, GLUT1 is active as a functional monomer. Kinetic 
observations measured in erythrocytes, however, are inconsistent with a physiologically 
relevant monomeric carrier. Rather, these studies suggest that GLUT1 is a complex 
oligomer, either a dimer or a tetramer in the plasma membrane. Carruthers et al. have 
measured the hydrodynamic radii of GLUT1 molecules in proteoliposomes and examined 
freeze-fractured electron microscope images to conclude that the functional transporter 
exists as a homotetramer [80]. Exposure to a reducing environment, however, supports 
the dimeric form. The tetramer is assembled as a dimer of dimers. Each monomeric 
subunit can transport glucose independently, but this arrangement pairs the two subunits 
in an obligate, anti-parallel fashion, such that as one subunit isomerizes from the e2 
conformation to the e1, its partner isomerizes in the opposite direction, regardless as to 
whether substrate has bound to both subunits [81]. This arrangement supports the 
simultaneous presentation of import and export sites within the complete oligomer.  
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KINETICS-DERIVED GLUT1 TRANSPORT MODEL 
Since we currently lack a GLUT1 crystal structure, the majority of transport models 
describing GLUT1 behavior have been developed using kinetic measurements. Widdas 
and Naftalin used these data to develop the two most predominant models that explain 
carrier-mediated transport: the alternating conformer model and the fixed-site carrier 
model.  
Widdas initially proposed the mobile carrier hypothesis where a glucose specific 
molecule bound glucose on one side of the membrane, moved across the lipid bilayer, 
and subsequently deposited the translocated glucose molecule on the other side of the 
membrane [38]. Although this model would prove incorrect, the glucose transport protein 
does not physically shuttle from one side of the membrane to the other, it spawned the 
alternating conformer model, see Figure 1.4. Here, the single GLUT1 transport subunits 
alternately present sugar import (e1) and export sites (e2). Glucose binding to the e1 site 
catalyzes a conformational change that results in its translocation across the plasma 
membrane. Multiple rounds of transport proceed by reconversion of the e1 conformation 
to the e2 arrangement either by simple isomerization or substrate binding and 
translocation. At any one time, however, the GLUT1 monomer presents only one site, 
either e1 or e2 [14]. 
Conversely, the fixed-site carrier model predicts that ligands bind the e2 and e1 sites 
simultaneously, see Figure 1.5 [14,82]. Here, the transporter exists as an oligomer within 
the membrane where one subunit presents an import site and the other an export site. 
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Figure 1.4 The simple carrier model. (A) King-Altman diagram showing the GLUT1 
carrier in either the e1 (inward facing) or e2 (outward facing) state. The carrier can either 
bind to extracellular sugar (e2.S2) or intracellular sugar (e1.S1). As described, the simple 
carrier model indicates that the transporter can only be bound to one molecule at a time. 
k0, k-0, k1, k-1, b-1, and b-2 are the first-order rate constants describing the rates of 
conformational changes or sugar dissociation. b1 and b2 are second order rate constants 
describing the rate of carrier interaction with S1 and S2, respectively [43]. (B) Graphical 
representation of the sugar transport process through a single GLUT1 subunit. Glucose 
binds to the e2 orientation, the transporter-sugar complex converts to the e1 conformation 
as the sugar is translocated across the cell membrane, the sugar is released into the cell, 
and finally the carrier relaxes or is converted back to the e2 conformation for another 
round of transport.  
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Figure 1.5 The fixed-site carrier model. (A) King-Altman diagram shows the carrier 
simultaneously presenting the e2 and e1 sugar binding sites. The carrier can be 
complexed with extracellular sugar (e.S2), intracellular sugar (e.S1), or both sugars 
(S2.e.S1). α represents the cooperativity constant for when the carrier is occupied at both 
binding sites. K1 and K2 are the dissociation constants between the sugar and the carrier 
[43]. (B) Graphical representation of the sugar transport process showing the movement 
of each subunit within a GLUT1 tetramer. The steps of this process (sugar binding, 
translocation, and release) are the same as described for the simple-carrier hypothesis. 
When one subunit undergoes a conformational change (e2→e1) its partner undergoes the 
reverse conformational change. In this way, the tetramer serves as a dimer of dimers 
paired in an obligate antiparallel arrangement that works in concert to catalyze glucose 
transport [86]. 
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Carruthers et al. observed that the rate of CCB binding to the endofacial e2 binding site 
was affected by the presence of exofacial e1-site-reactive sugars [83]. This observation is 
consistent with a hypothesis that predicts the simultaneous presentation of import and 
export sites and it resulted in a revised transport model. When sugar binds to an e2 site, it 
undergoes a conformational change resulting in sugar transport to the cytoplasm. At the 
same time, the other subunit, either with or without substrate bound, converts from the e1 
to e2 orientation. In this way, the two subunits present an obligate antiparallel 
arrangement, and account for the simultaneous presentation of the e2 and e1 sites across a 
dimeric subunit [81]. 
The recent MFS transporters crystal structures are strongly supportive of the biochemical 
evidence suggesting that the transport process is catalyzed by an individual transporter 
protein subunit [33,35]. Many transporters are believed to function as complex oligomers, 
however, and communication between the subunits confounds our understanding of the 
true transport mechanism. In fact, kinetic studies measuring glucose transport in red cells 
suggest that GLUT1 displays a higher order tetrameric structure within the cell 
membrane. Glucose transport regulation by intracellular nucleotides is dependent upon 
GLUT1 oligomeric state and it appears as if intramolecular disulfide bonds are 
responsible for this tertiary structure [28,81,84-86].  
Respecting the complexity of GLUT1 oligomeric structure, the examination of glucose 
translocation through a single, independent subunit is most useful in our efforts to 
illustrate how each domain and the total protein mediate transport. The simple carrier 
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hypothesis, therefore, appears to adequately describe individual subunit conformational 
changes. Specifically, a substrate recognizes and binds to a carrier protein oriented 
outside of the cell (e2→eS2). This binding results in a conformational change where the 
substrate becomes completely occluded within the transport protein in the form e(S) 
[5,87]. Another conformational change results in the exposure and release of the substrate 
into the cytoplasm of the cell (eS1→e1). The external facing conformation is then 
regenerated for another round of transport via the following mechanism: (e1→e( )→e2).  
HOW MFS STRUCTURE-FUNCTION RELATIONSHIPS COMPARE TO OTHER TRANSPORTERS 
In addition to MFS transporters, members from five additional families and superfamilies 
have recently been crystallized: 1.) P-type ATPase (H+-ATPase and Ca2+-ATPase) 
[53,88-90]; 2.) ATP Binding Cassette (ABC) Transporter (BtuCD and Sav1866) [91-95]; 
3.) Monovalent Cation/Proton Antiporter (CPA) (Na+/H+ Antiporter) [96]; 4.) Resistance-
Nodulation-Cell Division (RND) (AcrB) [97-99]; 5.) Mitochondrial Carrier (MCF) 
(ADP/ATP Carrier) [100].  
This literature review provides a structural basis for carrier-mediated transport 
mechanisms employed by transmembrane proteins. Thus far, we have focused 
predominantly on the structure-function relationship governing GLUT1 and fellow MFS 
transporters. It is interesting to note that many other transporters utilize the cytoplasmic 
domains to coordinate the conformational changes facilitating substrate translocation. 
Furthermore, ATP hydrolysis by the cytoplasmic domains of carriers is frequently 
exploited to power the transport machinery. In this regard, the transmembrane regions 
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appear to merely provide the transport pathway, but the regulatory factors are 
intracellular and not embedded in the plasma membrane. Carrier helix packing models, 
numbers of helices, helical tilts and interactions, propensity for and dependence upon 
homo- and hetero-oligomerization in structural and or functional mechanisms differ to 
varying degrees for passive, primary, or secondary active transporters [81]. Even though 
each transporter shares a common goal - the transport of substrate across the plasma 
membrane - the mechanisms employed to accomplish this objective differ greatly. We 
will review each mechanism, therefore, by focusing on how these processes compare and 
contrast to the MFS carrier-mediated transport phenomenon.  
P-TYPE ATPASE AND ABC SUPERFAMILIES 
Proteins belonging to the P-type ATPase and ABC superfamilies are integral membrane 
proteins in which a large portion of the primary structure resides in the cytoplasm. The 
majority of MFS transporter structure is typically embedded within the membrane 
bilayer. P-type ATPase proteins are primary active cation transporters, which create an 
electrochemical gradient inside the cell that helps to maintain intracellular pH and 
membrane potential by providing energy for nutrient uptake and ion exchange by 
secondary active transporters. ATP Binding Cassette (ABC) Transporters catalyze the 
unidirectional transport of substrates (such as drugs, vitamins, and waste products) across 
the membrane bilayer [93]. Recent crystallizations of the Ca2+-ATPase [53,88-90], the 
Sav1866 homodimer (each subunit contains a transmembrane and nucleotide binding 
domain (TMD; NBD) [91]), and the BtuCD heterotetramer (comprised of TMD and NBD 
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homodimers) [92,94,95]have provided a better understanding of how the membrane-
bound and cytoplasmic domains interact to catalyze transport.  
Ca2+-ATPase transporters have four major domains: an actuator (A; L2-3), nucleotide 
binding (N), and phosphorylation (P; L4-5) domains found in the cytoplasm and a 
transmembrane domain (M) containing ten α-helices embedded in the lipid bilayer. The 
two calcium ion-binding sites are formed by transmembrane helices M4, M5, M6, and 
M8 [88]. This packing model does not appear to display the structural symmetry 
observed for MFS carriers. ATP binding causes the N- and P-domains to approach and 
thereby produces profound conformational changes within cytoplasmic domains resulting 
in a more tightly packed overall structure. Consequently, the A-domain tilts causing the 
M-domain, to respond by occluding calcium ions within the transmembrane region.  
ABC transporters are comprised of two domains: the membrane embedded 
transmembrane domain (TMD) and the cytoplasmic nucleotide binding domain (NBD). 
The transmembrane domain subunits (TMD) reside within the lipid bilayer, contain 6-10 
α-helices each, form a water-filled cavity, link to the NBD at the lipid-cytoplasm 
interface, and create the ligand binding site [93]. The recent Sav1866 structure even 
indicates that the TMD regions from each subunit physically intertwine. TM1-2 of one 
subunit and TM3-6 of the corresponding subunit form the two sides of the open 
conformation [91]. The dimeric nucleotide binding domain (NBD) is highly conserved. 
While the coupling of ATP hydrolysis to transport is similar across the superfamily, 
TMD regions vary in sequence composition, likely contributing to a wide-range of 
40
substrate specificity [93]. Although substrate binding initiates the transport cycle, ATP 
hydrolysis, catalyzed by isomerization between the open and closed conformations of 
each NBD, provides the requisite free energy for TMD conformational changes and 
subsequent substrate translocation.  
The transport cycle of each transporter superfamily follows a modified Albers-Post 
derived e2→e1 series of conformational changes resembling those utilized by MFS 
transporters. The requirement for nucleotide binding, autophosphorylation, and 
subsequent dephosphorylation (P-type ATPase) or nucleotide binding and ATP 
hydrolysis (ABC transporters) to catalyze cycling between the e2 and e1 conformations 
differs from the passive or secondary active MFS transporters. With the primary active 
carriers, ATP binding, rather than substrate interaction appears to choreograph TM 
helical movements that result in substrate translocation. This role explains the importance 
of the large cytoplasmic domains of primary active carriers, which distinguishes them 
from MFS transporters, which typically only have a relatively small cytoplasmic loop 
connecting TMs 6 and 7. P-type ATPase transporters transport cations both into and out 
from the cell, and in fact, cation binding is required for cycling between the e2 and e1 
conformations [88,89,101]. MFS and P-type ATPase transporters share this substrate-
induced reconversion cycling mechanism. This is not found in ABC transporters, which 
display only a unidirectional substrate transport pathway. Here, reconversion from trans 
to cis conformations following substrate release is dependent upon ATP hydrolysis, not 
substrate binding [93].  
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MONOVALENT CATION/PROTON ANTIPORTERS 
Monovalent Cation/Proton Antiporters (CPA) regulate, cation/proton concentrations, cell 
volume. The recently crystallized sodium proton antiporter NhaA of Escherichia coli 
appears to function as an intracellular pH sensor [96]. NhaA exists as a homodimer 
within the lipid bilayer, however, like many MFS transporters, the monomer serves as the 
functional unit. Like MFS transport proteins, NhaA contains twelve membrane embedded 
helices with the N- and C-termini oriented towards the cytoplasm. The organization and 
packing of these TM helices, however, are very different from those of MFS transporters 
and the secondary structures of TMs IV and XI are quite unique.  
The TM region is organized into two tightly packed domains; domain A contains two 
oppositely oriented but structurally similar helix bundles and domain B contains 1 linear 
bundle. Helices IV and XI, which are oppositely oriented within the membrane, are 
especially noteworthy as they comprise a short helix, an unstructured chain, and another 
short helix; the helices are denoted as c or p, based upon proximity to the cytoplasm or 
periplasm, respectively. Two groups of TM helices, one containing TMIVc and the other 
TMXIp, form two distinct pockets facing the cytoplasm and interstitium, respectively. 
The extended chains of TM domains IV and XI block the link between the two pores.  
This organization of helices and evidence for two incomplete pores, (envisioned as e1 
and e2 oriented binding sites) plays a significant role in the functional mechanism 
employed by NhaA. Na+/H+ exchange is predicted to occur via an alternating access 
mechanism. Based upon the crystal structure, the authors suggest that a pH regulated 
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movement of the unstructured chains of TM domains IV and XI controls the accessibility 
of the binding pore to the intra- or extracellular environment [96]. Unlike the MFS 
transporters, the functional mechanism for NhaA only requires small conformational 
changes within a limited portion of the TM region, especially helices IV and XI. This 
functional mechanism may explain why NhaA [102] has a turnover number 
approximately 50-100 fold higher than LacY [103], the ADP/ATP antiporter [104], or 
GlpT [105]. 
MITOCHONDRIAL CARRIER PROTEINS 
A family of mitochondrial carrier proteins (MCF) transports nucleotides, phosphates, and 
other metabolites across the mitochondrial membrane. One such member of the MCF is 
the ADP/ATP antiporter, which imports spent ADP into the mitochondrial matrix and 
exports resynthesized ATP to the cytoplasm. The carrier has only six transmembrane α-
helical domains, organized as three dual-helix repeats. All of the helices are tilted, with 
the odd helices demonstrating a kink to the arrangement caused by an internal proline 
residue [100]. Within the crystal structure, the helices form a cavity accessible to the 
interstitium. The helices are connected to one another by short internal α-helical stretches 
and external loops. The cavity within the transmembrane region is quite hydrophilic in 
nature. The design, degree of secondary structure, and helical arrangement of the 
transport pore are quite different than those observed in MFS transporters. The difference 
in structure, beginning with oligomeric state likely explains why the transport process 
varies significantly.  
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Unlike MFS transporters where the monomer dominates as the common functional 
subunit, the functional ADP/ATP carrier is a dimer. The subunit adopting an external 
conformation will bind ADP and the subunit adopting an internal conformation will bind 
ATP. Both binding sites must be occupied for the antiport cycle to be completed [100]. It 
is likely that the relative orientation of the subunit to the mitochondrial membrane 
determines its conformation and confers specificity for the correct substrate (ADP when 
facing the outside and ATP when facing the inside). The kinked helices likely play a role 
in opening the channel that permits substrate transfer, and the tilt degree may play a role 
in exposing specific regions within the cavities to confer higher affinity toward one of the 
two nucleotides [100]. 
RESISTANCE-NODULATION-CELL DIVISION 
The Resistance-Nodulation-Cell Division (RND) family of transporters exports numerous 
anionic, cationic, zwitterionic, and neutral toxic compounds from the periplasm of Gram-
negative bacteria, thus granting multidrug resistance to the cells with high levels of RND 
protein expression. ArcB, a multidrug resistance transporter in Escherichia coli, is a 
member of the RND family. ArcB requires cooperation with TolC, an outer membrane 
channel, and ArcA, a membrane fusion protein to export molecules from the cell. The 
transporter itself is a functional trimer and each multi-domain subunit is referred to as a 
protomer. The protomer contains three major domains: the transmembrane domain, the 
porter domain, and the TolC docking domain. ArcB has been crystallized with each 
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protomer subunit in either the access, binding, or extrusion states of the transport 
mechanism [97-99].  
The drug export mechanism displays little similarity with MFS or other transporter 
proteins. The porter domain of ArcB is located at the interface between the inner 
membrane and the periplasm. This domain undergoes the major substrate-induced 
conformational changes that extrude toxic drugs from the periplasm into the TolC 
channel, which exports them across the outer membrane and into extracellular space. The 
transport mechanism provides useful information regarding alternative ways to export 
drugs from cells and the breadth of conformational changes that can accomplish this 
process [97,99]. First, in the access stage, a periplasmic drug enters an open vestibule, 
that has restricted access to the binding site. Following an enlargement of the binding 
site, the drugs enter and bind within a large binding pocket. The exit site is blocked by 
the inclined central helix from the adjacent protomer, which is in the extrusion state. 
Finally, the access and binding vestibule is closed, the occluding helices are inclined 
away, and the substrate is pushed up, out of the binding pocket to TolC, rotating the 
protomer back to the access state, therefore readying for another round of transport. Each 
protomer is always in one of the three states and the rotation from access to binding to 
extrusion state is controlled by proton translocation that occurs in an entirely different 
domain within the transmembrane region. Unlike crystallized LacY and GlpT, the proton 
translocation pathway is completely separate and independent from the substrate pathway 
[97]. 
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OVERALL CONCLUSIONS AND RESEARCH PURPOSE 
Carrier-mediated transport and the proteins that catalyze these reactions play an 
important physiological role in sustaining total body and cellular homeostasis. Using 
GLUT1 as a model transport system, the goals of this thesis focus on examining the 
integral membrane protein structure-function relationship. In particular, this work will 
investigate the glucose transport mechanism, the structural arrangement and dynamics of 
the 12 GLUT1 membrane-spanning α-helices, and the molecular mechanism for glucose 
transport regulation by ATP. 
With regard to the glucose transport mechanism, we ask how does GLUT1 catalyze sugar 
translocation? Our goal is to further dissect the mechanism by which glucose is 
transported into or out of the cell. In particular, we would like to answer the following 
questions: How many glucose transport steps are required? Is each step protein–
mediated? What kinetic constraints govern each step? How do regulatory agents such as 
ATP modulate each step? Using rapid kinetics studies, we were able to examine the 
series of conformational changes required for GLUT1 catalysis of a complete glucose 
transport cycle. These experiments isolated a previously unidentified rapid transport step. 
A number of experimental results are presented to support our proposal that the rapid step 
represents the intermediate step between the e2 to e1 uptake cycling event. Recent 
crystallographic evidence showing MFS transporters statically trapped in this 
arrangement have since been observed for OxlT and EmrD [5,39,87]. 
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In light of the recent three-dimensional structures obtained for MFS transport proteins 
LacY, GlpT, OxlT, and EmrD, does the organization of GLUT1 α-helices within the lipid 
bilayer share a common fold or present a different and unique arrangement? Homology 
modeling has become a popular technique in creating structural models for proteins that 
continue to prove refractory to crystallization. Recent publications have used sequence 
alignment and homology threading to identify conserved residues within secondary active 
MFS transporters (LacY template) and homology-modeled GLUT1 using the GlpT 
structure as the template [7,63,64]. While both GlpT and GLUT1 belong to the MFS 
classification, GlpT is an antiporter that transports phosphate molecules, whereas GLUT1 
is a uniporter that transports glucose molecules. Homology modeling, therefore, is an a 
priori exercise rather than an analysis supported by direct experimental evidence.  
In order to test our hypothesis, we developed a novel mass spectrometry approach to 
resolve individual GLUT1 peptides encompassing all protein domains. Mass 
spectrometry of integral membrane proteins has been notoriously difficult [106,107]. 
Despite comprising greater than 20% of the proteins encoded by the human genome, 
integral membrane proteins are continually underrepresented in proteomics studies. The 
hydrophobic nature of the transmembrane domains, tendency of these peptides to 
aggregate during HPLC separation, presence of reactive reduced cysteine residues, and 
contamination by more soluble proteins in cellular samples contribute to this difficulty 
[107]. Furthermore, few mass spectrometry studies exist that exclusively focus on the 
structure-function relationship of single integral membrane proteins [108-113].  
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The development of this technique and the observed findings provide powerful insight 
into the GLUT1 structure-function relationship and will lay the groundwork for future 
studies examining this association. We therefore subjected native GLUT1 
proteoliposomes to site-specific proteolytic digests and covalent modification with water-
soluble probes for two reasons: first, to map the surface accessibility of GLUT1 domains 
and second, to study conformational dynamics and differential labeling in the presence of 
substrates, inhibitors, and modulators. Our findings directly support the hypothesis that 
GLUT1 shares the consensus MFS helix packing arrangement, implicate two 
transmembrane α-helices and the cytoplasmic regions in conformational dynamics, and 
support the existence of an aqueous accessible glucose translocation pore.  
To further assess the arrangement of GLUT1 α-helices, we ask how sulfhydryl chemistry 
controls the native oligomeric structure and organization of GLUT1 within the lipid 
bilayer? The structure-function relationship for GLUT1-mediated transport has been 
thoroughly examined in two different systems. In human erythrocytes, a large body of 
biophysical and biochemical data describes GLUT1 transport kinetics, oligomeric state, 
and allosteric regulation [14,42,43,81,86,114]. GLUT1 expressed in a Xenopus oocyte 
system, however, has been employed in studies that examine the function and orientation 
of transmembrane helices [40,44,48-51]. The Xenopus expression system, however, does 
not display the same kinetic sensitivity to reductant (i.e. the breaking of potential 
disulfide bridges that cause an observed reduction in transport rates) or oligomerization 
properties observed for GLUT1 natively expressed in erythrocytes, CHO, HEK, and COS 
cells [86]. In particular, we wanted to analyze how sulfhydryl chemistry controls native 
48
oligomeric structure and GLUT1 organization within the membrane. We examined the 
reductant sensitivity of cysteine residue accessibility to alkylating agents. After observing 
that deglycosylated GLUT1 resolves anomalously by gel electrophoresis, we show that 
GLUT1 cysteine residues are differentially alkylated in the presence of reductant. Thiol 
chemistry and disulfide formation, therefore, likely affect GLUT1 structure.  
In summary, the data and analysis presented here will address questions regarding how 
the structural organization of GLUT1 within the plasma membrane contributes to the 
carrier-mediated transport process. In addition to furthering our understanding as to how 
GLUT1 functions on the molecular level, the methods developed in the process of 
obtaining these results can be broadly applied to studying the structure-function 
relationship in other integral membrane proteins.  
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CHAPTER II 
 
 QUENCH FLOW ANALYSIS REVEALS MULTIPLE PHASES OF GLUT1-
MEDIATED SUGAR TRANSPORT 
 
This chapter was published in the journal Biochemistry in 2005, and can be found using 
the following reference: 
 
Blodgett DM, Carruthers A (2005) Quench-flow analysis reveals multiple phases of 
GluT1-mediated sugar transport. Biochemistry 44: 2650-2660. 
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Medicine: 
 
Blodgett DM, Carruthers A (2004) Conventional transport assays underestimate sugar 
transport rates in human red cells. Blood Cells Mol Dis 32: 401-407. 
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ABSTRACT 
Standard models for carrier-mediated nonelectrolyte transport across cell membranes do 
not explain sugar uptake by human red blood cells. Most measurements of red cell sugar 
transport have been made over intervals of 10 seconds or greater, a range which may be 
too long to measure transport accurately. In the present study, we examine the time 
course of sugar uptake over intervals as short as 5 milliseconds to periods as long as 8 
hours. Using conditions where transport by a uniform population of cells is expected to 
be monophasic (use of subsaturating concentrations of a non-metabolizable but 
transported sugar, 3-O-methylglucose), our studies demonstrate that red cell sugar uptake 
is comprised of three sequential, protein-mediated events (rapid, fast and slow). The 
rapid phase is more strongly temperature-dependent than the fast and slow phases. All 
three phases are inhibited by extracellular (maltose or phloretin) or intracellular 
(cytochalasin B) sugar transport inhibitors. The rate constant for the rapid phase of 
uptake is independent of 3-O-methylglucose concentration. The magnitude (moles of 
sugar associated with cells) of the rapid phase increases in a saturable manner with [3-O-
methylglucose], similar to both the amount of sugar retained by red cell membrane 
proteins upon addition of cytochalasin B and phloretin and the D-glucose inhibitable 
cytochalasin B binding capacity of red cell membranes. These data support a transport 
mechanism in which newly bound sugars are transiently sequestered within the 
translocation pathway where they become inaccessible to extra- and intracellular water. 
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INTRODUCTION 
A family of glucose transport proteins catalyzes the stereoselective, bidirectional, passive 
transport of sugar molecules across the cell membrane. One member of this family, 
GLUT1, mediates sugar transport across the human erythrocyte membrane [115]. 
Although extensively studied, the molecular mechanism of GLUT1-mediated sugar 
transport is unknown. In the absence of stable GLUT1-substrate intermediates for 
structural analysis, researchers have used biochemical and biophysical approaches to 
investigate transport. Their results suggest three possible transport mechanisms. The 
transporter may function as a simple, alternating carrier, sequentially presenting sugar 
import (e2) and export (e1) sites [2,38,41,116]. During uptake, extracellular sugar binding 
to the e2 site catalyzes a conformational change (e2→e1) that releases bound sugar into 
cytosol and exposes an e1 site. The e2 conformer is regenerated for additional cycles of 
sugar import via the inverse (e1→e2) conformational change resulting from either the 
binding and rapid export of intracellular sugar or from a slow, sugar independent relaxation 
to the initial state. An alternative hypothesis describes a simultaneous-carrier mechanism, 
where the transporter molecule simultaneously exhibits import and export configurations 
[117-119]. In this model, the transporter is proposed to be a complex of four GLUT1 
proteins in which each subunit (GLUT1 protein) functions as a simple, alternating carrier. 
An obligate functional relationship between subunits is proposed to limit the 
conformational freedom of subunits within the transport complex. At any instant, 
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therefore, two subunits must exist as e2 conformers while the remaining two subunits 
must present e1 conformers [84]. A third model suggests that GLUT1-mediated sugar 
transport is inconsistent with the predictions of either of the preceding mechanisms. 
Imported sugars are proposed to interact with noncatalytic binding sites associated with 
the carrier or with internal red cell components [117,120,121]. This compromises the 
accuracy of transport determinations because intracellular [sugar]total > intracellular 
[sugar]free.  
The recent crystallization of lactose permease (LacY) in the e1 (export) configuration 
provides a clearer picture of a carrier substrate binding site [33]. Although not strictly a 
passive sugar carrier, this proton-disaccharide symporter is capable of passive transport in 
the absence of an electrochemical gradient for proton driven sugar transport [122]. LacY 
is also a member of the wider Major Facilitator Superfamily (MFS) of transporters that 
includes the GLUT family of carriers [23,57]. The LacY e1 crystal structure is 
characterized by a large internal hydrophilic cavity (25 Å by 15 Å) extending from the 
cytosol to deep within the core of the membrane-embedded portion of the carrier. The 
volume of the cavity is approximately 1.5 x 10-24 L – a space large enough to contain as 
many as 3 - 5 hydrated glucose molecules assuming a self-diffusion coefficient of glucose 
of 4 x 10-6 cm2.s-1 at 20°C [123]. It is proposed that following substrate binding to e1, the 
cavity closes to engulf the bound sugar molecule and then opens at the opposite or trans-
side of the membrane to form a similar outward facing cavity into which the bound 
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substrate can dissociate and subsequently diffuse into the interstitium [33]. The e1 
structure of a second MFS transporter – the bacterial glycerol-3-phosphate/Pi antiporter 
(GlpT) – provides additional support for the alternating conformer transport mechanism 
in prokaryotes [35,124]. The process by which the substrate binding event promotes 
conformational changes that result in substrate translocation is unknown [33,35,124] and 
e2 or intermediate forms of LacY and GlpT are unavailable for more detailed analysis. 
While the alternating conformer model for carrier mediated transport gains strong support 
from the LacY and GlpT structures, it is also evident that this model does not 
quantitatively describe the sugar transport properties of human red blood cells [43,125]. 
Transport measurements obtained by conventional bench-top procedures indicate that the 
Haldane requirements for a passive transport mechanism (Vmax/Km(app)) ratios for 
exchange and net entry and exit of sugars must be equal) are not satisfied [43,125-127]. 
More rapid sampling procedures (resolution less than 1 second) obtained by quench flow 
appear to result in transport parameters that satisfy the Haldane requirements [116]. This 
suggests that red cell sugar transport is very fast and requires rapid sampling procedures 
for accurate determination of initial rates. However, these more rigorously determined 
Michaelis and velocity parameters fail to predict the kinetics of red cell sugar transport 
over physiological time intervals (seconds to minutes; [43,125,128-130]). 
The present study was conducted to examine the kinetics of sugar uptake by human red 
cells over intervals ranging from milliseconds to hours. To achieve this, we used a rapid 
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quench flow device (which provides subsecond temporal resolution) in conjunction with 
reduced reaction temperature to study the earliest events associated with glucose 
transport. These studies provide evidence for at least three phases of protein-mediated 
glucose translocation into the red cell, provide “Vmax and Km” parameters for transport 
obtained during each of these phases, and suggest that it is possible to isolate an 
intermediate GLUT1 form, e(S), that bridges the e⋅S2→e⋅S1 transition. 
MATERIALS AND METHODS 
Materials [3H]-3-O-Methylglucose and [3H]-cytochalasin B were purchased from 
Amersham Biosciences (Piscataway, NJ); [3H]-L-Glucose was purchased from Sigma-
Aldrich. Rabbit antisera against amino acid residues 480-492 of the GLUT1 carboxy 
terminus (C-Ab) were prepared as described in and obtained from Animal Pharm Services, 
Inc. (Healdsburg, CA) [85]. Goat Anti-Rabbit (GAR) horseradish peroxidase (HRP) 
conjugate was purchased from Bio-Rad Laboratories (Hercules, CA). Washed red blood 
cells and whole blood stored in CPDII AS-1 preservative solution were obtained from 
Biological Specialties Corporation (Colmar, PA). All other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO) unless otherwise noted. 
Solutions KCl saline (kaline) consisted of 150mM KCl, 6mM MgCl2, 5mM HEPES, 
and 4mM EGTA, pH 7.4. Ice-cold lysis medium contained 10 mM Tris – HCl and 1 mM 
EGTA, pH 7.4. Stopper solution consisted of ice-cold kaline, 10 µM cytochalasin B 
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(CCB) and 100 µM phloretin; RQF stopper solution contained ice-cold kaline, 20 µM 
CCB, and 200 µM phloretin. Phosphate buffer saline (PB) consisted of 145 mM NaCl 
and 20 mM sodium phosphate. Sample buffer (2x) contained 125 mM Tris – HCl, pH 
6.8, 4% SDS, 20% glycerol, and 50 mM DTT. 
Red Blood Cell Preparation Red cells were isolated from whole human blood by repeated 
wash/centrifugation cycles. One volume of whole blood was mixed with 20 volumes of 
ice-cold kaline and centrifuged at 5,443 x g for 10 minutes at 4°C. The serum and white 
buffy coat were aspirated and the cycle repeated until the supernatant was clear and the 
buffy coat was no longer visible. When depletion of endogenous intracellular sugar was 
required, cells were resuspended in 20 volumes of kaline and incubated for 30 minutes at 
37°C.  
Red Cell Ghost Preparation Washed red cells were mixed with 50 volumes of ice-cold 
hypotonic lysis buffer, and the suspension gently stirred for 10 minutes at 4°C. Red cell 
membranes were harvested by centrifugation at 18,566 x g for 15 minutes, followed by 
two additional washes in lysis buffer and centrifugation steps. Membranes were resealed 
in 20 volumes of kaline medium for 30 minutes at 37°C, containing or lacking 4 mM ATP, 
pH 7.4. Resealed ghosts were harvested using the same centrifugation settings, and stored 
on ice for no more than 24 hours.  
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Red cell integral membrane proteins (IMPs) Peripheral proteins were displaced from red 
cell membranes by exposing unsealed erythrocyte ghosts to 2 mM EDTA, 15.4 mM 
NaOH, pH 12 at a concentration of 0.8 mg protein/mL for 10 minutes at 4°C. Membranes 
were collected by centrifugation at 18,566 x g for 20 minutes at 4°C. The pH of the 
membrane suspension was restored by 3 wash/centrifugation cycles in 5 volumes of Tris 
– HCl medium. Final protein concentration of the membrane suspension was adjusted to 
2 mg/mL in Tris – HCl and membranes were stored at -20°C (prior to use within 24 hr) or 
at -80°C (for longer storage intervals).  
Bench-top Sugar Transport Measurements The time course of [3H]-3-O-methylglucose 
([3H]-3MG) uptake by red cells and red cell ghosts was measured at 4°, 12°, and 20°C as 
described previously [131]. Briefly, 50 or 100 µL of cells or ghosts were exposed to 
unlabeled sugar with trace amounts of [3H]-labeled sugar. Uptake was allowed to proceed 
over intervals as short as 10 seconds to equilibrium intervals of up to 8 hours (at 4°C, 
with high concentrations of cold sugar). The addition of 10 volumes of ice-cold stopper 
solution to the reaction suspension was used to quench the transport reaction. Cells were 
pelleted by a one-minute centrifugation (Fisher-Scientific, Model 235C microcentrifuge; 
14,000 x g), washed for a second time in stopper solution, and pelleted again via a second 
one-minute spin. The contents of the isolated cells were released upon addition of 1 mL 
3% perchloric acid (PCA), clarified by centrifugation, and two 400 µL aliquots of 
57
supernatant were transferred to scintillation vials, mixed with scintillation fluid, and 
counted in a Beckman Scintillation Spectrophotometer (LS6500).  
Rapid Quench Flow Sugar Transport Measurements The time course of [3H]-3-O-
methylglucose ([3H]-3MG) uptake by red cells and red cell ghosts was measured at 4° 
and 20°C by the RQF-63 Rapid Quench Flow system (Hi-Tech Scientific), as described 
previously [132]. Briefly, this instrument permits precise control of the processes of 
reagent mixing (radiolabeled sugar and cells), delay (reagents sit in a reaction loop, where 
the length of the loop and reactant flow rate determine the total reaction time), and 
quenching (addition of stopper solution) to complete an uptake assay. Stopper solution 
was maintained at 4°C for all uptake experiments at all temperatures. The reaction sample 
is collected manually in 1 mL of stopper solution and processed as in conventional 
transport assays. The RQF was calibrated for temporal accuracy by monitoring the 
alkaline hydrolysis of dinitrophenolacetate (DNPA), a reaction that forms dinitrophenol 
and acetate. Using HCl (1 M) as the stopper solution, and DNPA (88 µM) and NaOH 
(0.5 M) as the reactants, half-lives of 38.5 ± 3.9 milliseconds and 178 ± 9 milliseconds 
were obtained for DNPA hydrolysis at 22°C and 4°C respectively. These results are 
consistent with an Ea (activation energy) for DNPA hydrolysis of 14.7 kcal/mol/K and 
extrapolate to the expected t1/2 for DNPA hydrolysis at 25°C of 25 msec [133]. 
Equilibrium Sugar Spaces Washed red blood cells and resealed ghosts were incubated 
with 50 µM 3MG, with trace radiolabel for 2 hours at 4°C, at which point equilibrium 
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3MG distribution was reached. Incubation time was increased up to eight hours when 
3MG stock concentrations exceeded 10 mM. The reaction was quenched and the samples 
processed as described for conventional transport assays.  
Fractional equilibration at each time point (FEt) was calculated using the following 
equation:  
! 
FEt =
dpmt
dpmequilibrium
 
where dpmt represents disintegrations per minute (amount of [3H]-3MG) at time t, and 
dpmequilibrium describes disintegrations per minute (amount of [3H]-3MG) when the 
reaction has attained equilibrium. This calculation normalizes results for variations in cell 
dilutions and radioisotope specific activity across multiple experiments.  
Sugar occlusion Washed red blood cells were lysed in the presence or absence of 4 mM 
MgATP. Cells were then incubated at 4°C in lysis medium with 50 µM 3MG plus trace 
radiolabel for sufficient time (> 2 hr) to ensure equilibrium 3MG binding with GLUT1. 
Reactions were stopped by addition of 50 volumes of ice-cold stopper and processed as 
per usual methods. In lysed ghost experiments, the reaction was stopped with lysis 
buffer containing or lacking 10 µM CCB and 100 µM phloretin. In experiments using 
IMPs, kaline buffer replaced lysis buffer and contained no inhibitors, CCB (10 µM), 
phloretin (100 µM) or CCB plus phloretin. IMPs were subject to trypsin digestion at a 
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1:30 trypsin:protein ratio for 15 minutes at 37°C, as described previously [134]. 
Proteolysis was stopped by addition of a complete EDTA-free protease inhibitor cocktail 
(Roche). Parallel null digestions received equivalent volumes of trypsin-free kaline and 
protease inhibitor. 
Equilibrium Cytochalasin B Binding CCB binding to red cells and stripped ghosts was 
measured as described previously [43]. Briefly, 50 µL of cells were mixed with 50 µL of 
radiolabeled CCB, in the presence of increasing concentrations of unlabeled CCB. Two 10 
µL aliquots were removed for counting (totals). The suspension was incubated with 
rotation at 4°C for 30 minutes by which time equilibrium binding was achieved. The 
suspension was centrifuged for one minute, and two 10 µL aliquots of the supernatant 
were removed for counting (free) counts. Bound CCB is computed as total counts less 
free counts. Cytochalasin D (10 µM) was included in all solutions to inhibit CCB binding 
to non-GLUT1 sites.  
Analytical Procedures Protein concentrations were determined by the Pierce BCA 
procedure. Enzyme-linked immunosorbent assays (ELISA) confirmed that membrane 
suspensions contained equivalent amounts of GLUT1. C-Ab and goat anti-rabbit HRP 
conjugate antibodies served as the primary and secondary antibodies, respectively. ELISA 
reactions were developed with Pierce 1-Step ATBS developing solution and analyzed by 
using a Bio-Rad Laboratories Benchmark Microplate Reader. SDS-slab (10%) PAGE and 
Western blot analysis of proteins using C-Ab of membrane proteins were performed as 
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described previously [135]. Red cell counts were obtained by using a standard curve of 
cell suspension hemoglobin absorbance at 417 nm versus manual cell counts obtained 
using a hemocytometer. ATP was measured in neutralized perchloric acid extracts of cells 
and red cell ghosts using a luciferin-luciferase assay kit purchased from Molecular Probes 
(Eugene, OR). 
Calculation of Transport Constants Radiolabeled sugar uptake by cells and ghosts (time-
course data) were fitted to a three-compartment (phase) equation:  
  
! 
St = Cr(1" e
"kr t ) + Cf (1" e
"k f t ) + Cs(1" e
"ks t )  
where St = sugar associated with the cells at time t and Cr, Cf, and Cs represent equilibrium 
sugar spaces associated with rapid, fast and slow cell compartments or transport phases  
respectively, and kr, kf, and ks are first-order rate constants describing the rate of 
equilibration of rapid, fast and slow compartments/phases respectively. Vmax and Km(app) 
for 3MG uptake were computed using direct, nonlinear regression analysis of the sugar 
concentration dependence of 3MG uptake assuming simple Michaelis-Menten kinetics. 
Arrhenius plots (ln k versus 1/T) were fitted by linear regression using the equation: 
! 
lnk
n
= lnA +
E
a
RT
 
where kn is the rate constant for rapid, fast or slow phases of uptake, A is the Arrhenius 
constant, R is the gas constant (1.987 cal. K-1 mole-1), Ea is the activation energy (kcal K-1 
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mole-1). The slope (Ea/R) is obtained by linear regression analysis. The software program 
KaleidaGraph (version 3.6, Synergy Software) was used to plot all data and compute best 
fit parameters for each curve fit. 
RESULTS 
Time Course of 3MG Uptake 3MG uptake by red blood cells has been reported to be a 
biphasic process [121]. With the extended temporal resolution provided by the RQF, it is 
now evident that curve fitting with a two exponent equation does not adequately describe 
the most rapid transport process. The time course of 3MG uptake by erythrocytes at 
22°C (0.01 to 3600 seconds) is best described by a three exponent fit (Figure 2.1). This 
analysis describes net transport as the sum of either three parallel or three sequential 
processes. These processes are the rapid filling of a small compartment, a fast filling of a 
large compartment, and the slow filling of a large compartment.  
The temperature dependence of 3MG net import by erythrocytes is summarized in 
Figure 2.2. The size of each compartment and the corresponding rates of compartment 
filling are significantly affected by reduced temperature. The rapid process is inhibited by 
50-fold upon lowering temperature from 22° to 4°C, whereas the relative size of the slow 
process is increased with decreasing temperature. Only conventional assays could be 
performed at 12°C because the RQF was not easily adjusted to this temperature. 
Arrhenius analysis of the temperature dependence of the rate of each process is presented 
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Figure 2.1 3-O-methylglucose uptake by human erythrocytes at 22°C. Ordinate: 3MG 
uptake reported as fractional equilibration. Abscissa: time in seconds. The dashed and 
solid curves were computed by nonlinear regression and represent the time course of net 
3MG uptake assuming that transport consists of a double or triple exponential process, 
respectively. The two exponent fit fails to account for the rapid phase. The following 
constants were obtained: for the double exponential: Cr = 0.58; kr = 0.17 sec-1; Cf = 0.42; 
kf = 0.0008 sec-1; Constants describing the triple exponential are: Cr = 0.13; kr = 22.6 sec-
1; Cf = 0.50; kf = 0.086 sec-1; Cs = 0.37; ks = 0.0007 sec-1. Each data point represents the 
mean of triplicate measurements made in three separate experiments. 
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Figure 2.2 Temperature dependence of 3-O-methylglucose uptake by human 
erythrocytes: at 4°C (), 12°C (), and 22°C (), respectively. Ordinate: 3MG uptake 
reported as fractional equilibrium. Abscissa: time in seconds. Uptake at 4°C and 22°C are 
fit with a three exponent curve, the 12°C data do not include the rapid (earliest) phase of 
3MG uptake data. All data are superimposed on a background of 0.02. Each point 
represents the mean of three independent experiments. The following rate constants were 
obtained: 4°C: Cr = 0.01; kr = 0.277 sec-1; Cf = 0.248; kf = 0.0147 sec-1; Cs = 0.742; ks = 
0.000236 sec-1; 12°C: Cr = 0.03§; kr = 6.8 sec-1§; Cf = 0.502; kf = 0.0675 sec-1; Cs = 0.468; 
ks = 0.00121 sec-1; 22°C: Cr = 0.03; kr = 38.76 sec-1; Cf = 0.562; kf = 0.115 sec-1; Cs = 
0.408; ks = 0.000687 sec-1. (§Represents values estimated from Arrhenius plot, not 
obtained directly.) 
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in Figure 2.3. Rapid, fast, and slow phases are characterized by activation energies of 44.6 
(two temperature points only), 20.9 ± 5.9, and 20.8 ± 6.7 kcal.mole-1 respectively. By 
comparison, EA for the simple self-diffusion of glucose in aqueous solution is 5.1 
kcal.mole-1 [123]. This suggests that neither the rapid, fast or slow processes are 
diffusion-limited reactions. 
Time Course of 3MG Uptake in the Presence of Inhibitors Cytochalasin B interacts with 
the sugar exit site of GLUT1 serving as a competitive inhibitor of sugar exit, and as a 
noncompetitive inhibitor of sugar uptake [136,137]. Extracellular maltose is not 
transported by GLUT1, but interacts with the glucose import site to competitively inhibit 
sugar uptake [136]. The time course of 3MG uptake by red blood cells at 4°C is severely 
inhibited in the presence of 50 µM CCB (Figure 2.4A) and 50 mM maltose (Figure 2.4B). 
These results indicate that all three transport phases are subject to inhibition by specific 
inhibitors of carrier (protein)-mediated sugar transport. This result is expected if uptake 
were described by three, independent (parallel), carrier-mediated processes. This result 
would also be produced if net transport were described by three sequential (dependent) 
processes in which all three processes are carrier-mediated and inhibited by CCB. This 
result is not expected if only the first or second phases of three sequential processes are 
inhibited. Here only the inhibited phases should show reduced rates of progression. 
Monophasic 3MG uptake by red cells in the presence of CCB also suggest that the 
population of cells employed in these studies is uniform with respect to surface 
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Figure 2.3 Arrhenius plot examining temperature dependence of 3-O-methylglucose 
uptake rates. Ordinate: natural log of rate constants from figure 2.2. Abscissa: 
1/Temperature as K-1. The straight lines drawn through the points were computed by 
linear regression. The activation energies of each of the three phases are obtained from 
the slope of each plot as described in Materials and Methods: rapid (): 44.6 kcal 
kcal.mole-1, fast (): 20.9±5.9 kcal.mole-1, and slow (): 20.8±6.7 kcal.mole-1, 
respectively. Data are also shown for red blood cell ghosts lacking (small , small , 
and small ) or containing 4 mM ATP during resealing (small , small , and small ). 
Ghost data summarize rate constants for rapid (squares), fast (triangles) and slow (circles) 
phases of uptake. 
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Figure 2.4 A 3-O-methylglucose uptake by human erythrocytes in the presence of 
transport inhibitors: (A) Cytochalasin B at 4°C. Ordinate: 3MG uptake reported as 
fractional equilibrium. Abscissa: time in seconds. Control uptake () in the absence of 
CCB differs greatly from uptake where the red cells and 3MG were previously exposed 
to 50 µM CCB (). At all measured time points, a substantially higher fractional 
equilibrium is reached when uptake is uninhibited. The curves drawn though the points 
have the following constants: control Cr = 0.05; kr = 5 sec-1; Cf  = 0.45, kf = 0.014 sec-1; 
Cs = 0.5, ks = 11.8 x10-5 sec-1, R2 = 0.997; CCB Cs = 1; ks = 0.0002 sec-1; background = 
0.02, R2 = 0.567. (B) 3-O-methylglucose uptake by human erythrocytes in the presence 
of competing sugar maltose at 4°C. Control uptake () proceeds more rapidly than 
uptake in the presence of 50mM () maltose. The curves drawn though the points have 
the following constants: control Cr = 0.05; kr = 2 sec-1; Cf = 0.35, kf =0.009 sec-1; Cs =0.6, 
ks = 7.3 x10-5 sec-1, R2 = 0.989; 50 mM Maltose Cr = 0.035; kr = 1 sec-1; Cf = 0.45, kf 
=0.0054 sec-1; Cs =0.515, ks = 7.0x10-5 sec-1, R2 = 0.991. 
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area:volume ratio. The rate constant, k, for trans-bilayer diffusion of a molecule into a cell 
of radius r is directly proportional to the product PA where P is the permeability 
coefficient (cm.s-1) for transbilayer diffusion of the molecule and A is the surface 
area:volume ratio (cm-1) of the cell [2]. Assuming P is constant for all red cell-derived, 
membrane bound vesicles, k is directly proportional to A. For a spherical body, the 
surface area: volume ratio, A = 3/r (red cells are biconcave disks but membrane vesicles 
formed from red cells are predominantly spherical [138,139]). Thus for rapid, fast and 
slow rate constants of 69.7, 0.13 and 0.0021 per sec (22ºC, Table 2.1), the relative A 
values are 3.4 x 103, 66 and 1 respectively. If the slowest phase corresponds to the radius 
of an erythrocyte (3.5 µm), the rapid and fast phases would correspond to uptake by 
cells with radii of 0.1 nm and 45.7 nm respectively. Thus a mixture of three cell 
populations of these sizes is also expected to display rapid, fast and slow phases of 
transmembrane sugar diffusion. 
Time Course of 3MG Uptake in resealed, hypotonically lysed cells At 22ºC, the slowest 
phase of net sugar uptake is 32,000-fold slower than the most rapid phase of uptake. 
This raises the interesting possibility that the slow phase of sugar import may reflect 
some process other than sugar release into cytosolic water. 3MG, like D-glucose, can 
non-enzymatically glycate cellular proteins [140]. The slow phase may therefore 
represent 3MG interaction with cellular proteins to form glycated proteins or to form 
noncovalent precursors to glycated proteins [140]. If 3MG interaction with cytosolic 
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Legend to Table 2.1 Kinetics of 3MG uptake in red cells and red cell ghosts. aThe 
time course of 50 µM 3MG uptake was measured in red cells and red cells ghosts 
containing or lacking 4 mM exogenous MgATP. Uptake data were analyzed assuming 3 
phases of uptake – rapid, fast and slow (see Figures 2.1, 2.2 and 2.5). bk is the first-order 
rate constant describing the rate of compartment filling (per sec). cC is the compartment 
size as a fraction of the total cellular 3MG space. dExperiments made at 12ºC did not 
permit determination of the kinetics of filling of the rapid compartment. These numbers 
were obtained by extrapolation from Arrhenius analysis of the temperature dependence of 
transport (see Figure 2.3). eThese analyses were made before we recognized that uptake 
was consistent with a three compartment model. Time points were not obtained over a 
sufficiently broad time-range to accurately determine ks and Cs. The data are therefore 
analyzed assuming only two components of uptake – rapid and fast. These data represent 
the mean ± SEM of at least 3 separate determinations made in triplicate. 
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Table 2.1 3MG uptake kinetics in red cells and ghosts 
  
aCompartment 
  Rapid Fast Slow 
Cells Temperature ºC bkrapid cCrapid bkfast cCfast bkslow cCslow 
  s-1 fraction s-1 fraction s-1 fraction 
        
Intact Cells 4 0.94 0.036 0.013 0.27 0.00020 0.71 
  ± ± ± ± ± ± 
  0.26 0.006 0.001 0.03 0.00003 0.02 
        
 12 d6.76 0.03 0.067 0.502 0.0011 0.468 
    ± ± ± ± 
    0.001 0.016 0.0001 0.016 
        
 22 69.7 0.037 0.13 0.51 0.0021 0.45 
  ± ± ± ± ± ± 
  17.5 0.004 0.01 0.08 0.0015 0.09 
        
Ghosts + ATP 4 2.73 0.071 0.0183 0.594 0.0004 0.335 
  ± ± ± ± ± ± 
  0.77 0.016 0.009 0.030 0.0001 0.046 
        
 22 e56.83 e0.058 e0.050 e0.942   
  ± ± ±    
  26.16 0.026 0.012    
        
Ghosts 0 ATP 4 3.02 0.122 0.008 0.3913 0.0003 0.4867 
  ± ± ± ± ± ± 
  1.47 0.013 0.0023 0.022 0.00004 0.035 
        
 22 e82.80 e0.043 e0.069 e0.958   
  ± ± ±    
    25.96 0.017 0.017       
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proteins accounts for the slow phase of net uptake, the use of resealed erythrocyte ghosts 
which lack more than 90% of cytosolic proteins should diminish this phase of transport. 
The kinetics of 3MG net uptake by resealed red blood ghosts at 4ºC are not significantly 
different from those observed in intact cells (Table 2.1, Figure 2.5). This observation 
refutes the hypothesis that the slow phase of uptake results from 3MG interaction with 
cytosolic proteins. Sugar that is transported into the cell is also fully recoverable during 
sugar export [121,141] indicating that 3MG does not form a covalent complex with 
cellular molecules. 
Experiments at 22ºC were performed before it was recognized that three phases of uptake 
exist. These data were analyzed assuming two phases of uptake and, because insufficient 
time points were collected at longer times (200 – 10,000 sec), the data do not permit 
accurate determination of constants for filling of the slow compartment. Compartment 
size and rates of compartment filling in red cell ghosts lacking exogenous ATP at 4ºC are 
not significantly different from those measured in intact red cells. The intact cells used in 
these specific measurements had been stored at 4ºC for a prolonged period (>14 days) 
suggesting that they may have become metabolically depleted. Exogenous, intracellular 
ATP (4 mM) increases the size of the fast compartment at the expense of the slow 
compartment in resealed cells (Figure 2.5). Analysis of cellular ATP content indicates that 
ATP-free ghosts are nominally ATP-free while intact cells contain significantly lower 
ATP levels (0.7 mM) than do ghosts containing exogenous ATP (3.8 mM). These data 
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Figure 2.5 3-O-methylglucose uptake at 4°C by human erythrocyte ghosts 
containing () or lacking () 4 mM ATP respectively. Ordinate: 3MG uptake 
reported as fractional equilibrium. Abscissa: time in seconds. Uptake is fitted with a three 
exponent curve. The following rate constants were obtained from averages of three 
independent experiments: 4 mM ATP (dotted curve): Cr = 0.01; kr = 0.277 sec-1; Cf = 
0.248; kf = 0.0147 sec-1; Cs = 0.742; ks = 0.000236 sec-1; 0 ATP (dashed curve): Cr = 
0.03§; kr = 13.1 sec-1§; Cf = 0.502; kf = 0.0675 sec-1; Cs = 0.468; ks = 0.00121 sec-1. The 
time course of 3MG uptake in red cells at 4ºC (Figure 2.2) is also shown for comparison 
(solid line). 
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strongly suggest that prolonged cold storage of human blood results in significant 
depletion of intracellular ATP levels. 
The temperature dependence (4 and 22°C) of 3MG net import by resealed erythrocyte 
ghosts is summarized in Figure 2.3 and Table 2.1. The rapid process (kr) is 
indistinguishable from that of intact red cells. The fast process in ghosts appears to have 
somewhat reduced (2-fold) temperature sensitivity relative to the fast process in intact 
cells. This is manifest as indistinguishable kf in cells and ghosts at 4ºC but slightly lower 
kf in ghosts at 22ºC. At 4ºC, the slow processes (ks) in intact cells and red cell ghosts are 
indistinguishable. 
Concentration-Dependence of Sugar Uptake  Vmax and Km(app) parameters for sugar 
uptake are, in principle, computed by using initial rates of net sugar transport. RBC 3MG 
uptake at 4°C was measured during rapid (0.125 min), fast (0.5 min) and slow (30 min) 
phases of uptake (Figure 2.6). Vmax and Km(app) values computed for uptake during the 
rapid transport phase are 42.6 ± 4.2 mmol/L cell water/min and 26.5 ± 4.1 mM, 
respectively. Vmax and Km(app) for uptake during the fast phase are 2.5 ± 0.6 mmol/L cell 
water/min and 27.5 ± 10.7 mM respectively. Vmax and Km(app) for uptake during the slow 
transport phase are 1.97 ± 1.01 mmol/L cell water/min and 148.2 ± 84.5 mM, 
respectively. Vmax for sugar uptake is approximately 15-fold greater when computed using 
rapid time points rather than fast incubation intervals. Km(app) values are similar when 
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Figure 2.6 [3MG]-dependence on Vmax and Km in human erythrocytes at 4°C. 
Ordinate: Uptake rate of 3MG (moles L-1 minutes-1). Abscissa: 3MG concentration in 
uptake solution, measured in mM concentration units. 3MG uptake rates were measured 
at three time points corresponding to rapid (0.125 min), fast (0.5 min) and slow (30 min) 
phases of sugar transport. The transport parameters at each time point are reported as 
follows: rapid phase (): Vmax = 40.3 ± 16.0 mmol/L cell water/min, Km = 22.6 ± 10  
mM, R2 = 0.998; fast phase (): Vmax = 2.4 ± 0.5 mmol/L cell water/min, Km = 22.7 ± 
6.2 mM, R2 = 0.982; slow phase (∆): Vmax = 1.33 ± 0.02 mmol/L cell water/min, Km = 
94.2 ± 4.5 mM, R2 = 0.997. 
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measured during rapid and fast phases and 6-fold higher when measured during the slow 
phase. 
3MG Concentration-Dependence of kr Figure 2.7 summarizes the [3MG] dependence of 
kr and Cr. kr is independent of [3MG] but the size of the rapid compartment (Cr) 
increases in a saturable manner with [3MG]. The maximal size of Cr is 1.94 nmol/mg 
membrane protein and the compartment is 50% filled at 340 µM 3MG. 
Is Sugar occluded by GLUT1? Previous equilibrium sugar binding experiments have 
demonstrated that 2 mol 3MG are bound per mol GLUT1 [131]. Only one of these sites 
is inhibited by CCB. In the present study, we considered the possibility that the rapid 
phase of net sugar uptake corresponds to CCB and phloretin-dependent sugar-occlusion 
within the translocation pathway. If correct, occlusion may be measurable in lysed 
(unsealed) ghosts and in IMPs as the ability of membranes to retain sugar following 
removal of unbound sugar by multiple ice-cold washes in the presence of the transport 
inhibitors CCB and phloretin. 
Ghosts lysed in the presence of Mg or MgATP and incubated in lysis medium containing 
3MG, retain more sugar upon washing in sugar-free stopper solution than do ghosts lysed 
in the absence of MgATP. MgATP containing ghosts, however, characteristically display 
higher absorbance at 417 nm and higher total protein amounts, despite ELISA analysis 
confirmation that all cells contain the same amount of GLUT1. It is possible, therefore, 
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Figure 2.7 [3MG]-dependence of kr and Cr at 4°C. 3MG (50, 125, 250 and 625 µM) 
uptake was measured during the first 2 seconds following mixing. kr and Cr were 
computed by nonlinear regression and are plotted as a function of [3MG]. A Dependence 
of kr on 3MG. Ordinate: kr, per sec; Abscissa: [3MG] in µM. The results of two or more 
separate experiments made in triplicate are shown as mean ± SEM. The straight line 
drawn through the points was computed by nonlinear regression (assuming kr = intercept 
+ constant* [3MG]) and weighted by the SEM of each data point. The results were: 
Intercept = (0.90 ± 0.12) per sec, constant = (0.00014 ± 0.00036) per µM per sec, R2 = 
0.074. B Dependence of Cr on 3MG. Ordinate: [3MG] per pmol 3MG retained per 100 
µg membrane protein (µM 3MG 100 µg membrane protein /pmol 3MG retained); 
Abscissa: [3MG] in µM. This is a Hanes-Woolf analysis of 3MG retention by red cell 
IMPs. The results of two or more separate experiments made in triplicate are shown as 
mean ± SEM. The straight line drawn through the points was computed by nonlinear 
regression (assuming Cr = intercept + constant X [3MG]). The results are: Intercept = 
(1.74 ± 0.34) µM 3MG 100 µg membrane protein /pmol 3MG retained, constant = 
(0.0051 ± 0.0009)  µM 3MG 100 µg protein per pmol 3MG retained, R2 = 0.953. 
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that this effect is due to decreased lysis efficiency in the presence of MgATP. To avoid 
this pitfall, sugar occlusion experiments were repeated using IMPs. These membranes are 
enriched in GLUT1 content, are osmotically inactive and both cytosolic and extracellular 
GLUT1 domains are quantitatively accessible to peptide-directed IgGs [84,142]. This 
confirms that IMPs do not form sealed proteoliposomes under these conditions. As with 
ghost membranes, the presence of transport inhibitors in the wash solution promotes 
sugar retention by IMPs (Figure 2.8). 
GLUT1 digestion by intracellular trypsin is known to inhibit red cell sugar transport 
[143]. We hypothesized that trypsin would also inhibit 3MG occlusion by RBC IMPs due 
to proteolytic modification of sugar and inhibitor binding sites. 3MG retention at 4°C by 
native and trypsinized IMPs are not significantly different (Figure 2.8A). CCB binding 
by IMPs is not significantly altered by trypsinization (control: Bmax = 0.72 ± 0.19 
nmol/mg membrane protein, Kd(app) = 72 ± 30 nM; trypsin: Bmax = 1.01 ± 0.25 nmol/mg 
membrane protein, Kd(app) = 177 ± 55 nM). A second round of exposure of control and 
trypsin treated IMPs to conditions that disrupt salt-bridges (alkaline wash medium) does 
not significantly diminish CCB binding to IMPs. Immunoblot analysis of IMPs using 
GLUT1 carboxy-terminal peptide-directed Abs (C-Abs) confirms that trypsin 
quantitatively cleaves GLUT1 carboxy-terminal domains (not shown). 
Sugar retention appears to be enhanced by stopper solutions in trypsinized cells versus 
control cells. Retention measurements made using radiolabeled L-glucose (a nonreactive 
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Figure 2.8 3MG Sugar Retention. (A) 3-O-methylglucose retention by red cell integral 
membrane proteins at 4°C after arresting equilibrium reactions (50 µM 3MG or 50 µM L-
glucose plus 100 µg IMPs) with buffer or buffer plus transport inhibitors. Ordinate: sugar 
retention measured in mol sugar per 100 µg membrane protein. Abscissa: equilibrium 
transport reaction stop conditions. In control non-trypsin treated cells (solid bar), 
stopping the reaction with complete CCB/Phloretin quench solution, results in the 
statistically significant increase of 3.3 pmol 3MG retained versus stopping the reaction 
with kaline buffer. In trypsin-treated IMPs (dashed bar), stopping the reaction with 
complete quench, CCB, and phloretin, results in the statistically significant increase of 
4.4, 2.3, and 3.3 pmol of 3MG retained versus stopping the reaction with kaline buffer. 
Trypsinized membranes retain 3MG more effectively than do control membranes. L-
Glucose retention ± quench (CCB and phloretin) were not significantly different from 
3MG in the absence of quench. B. Quantitative comparison of 50 µM 3-O-methylglucose 
uptake by red cells and retention by red cell integral membrane proteins at 4°C. Ordinate: 
sugar uptake by red cells or retention measured in mol sugar per 100 µg membrane 
protein. Abscissa: time in minutes. The open circles show the time course of 3MG uptake 
by cells. The curve drawn through the points is a single exponential with the following 
constants: Cr = (22.6 ± 8) pmol/100 µg protein; kr = 0.5 ± 0.2 per sec. The open bar 
represents the equilibrium (±SEM) 3MG retention space of IMPs when quenched with 
CCB and phloretin. The filled bar represents the equilibrium (±SEM) 3MG retention 
space of IMPs when quenched with inhibitor-free buffer. 
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substrate) indicate no enhancement of sugar retention in the presence of CCB and 
phloretin. L-glucose retention by IMPs is quantitatively indistinguishable from 3MG 
retention in the absence of CCB and phloretin (Figure 2.8A). These observations suggest 
that CCB and phloretin-dependent 3MG retention is a GLUT1-mediated event. Figure 
2.8B compares the amount of 3MG retained by IMPs (± quench) to the rapid time course 
of 50 µM 3MG uptake by red cells at 4°C. 
DISCUSSION 
The Three Sequential Phases of Glucose Transport The experiments presented in this 
study indicate that monosaccharide import by erythrocytes is comprised of at least three 
phases. Multiphasic uptake is consistent with two possibilities. 1) There are three 
distinct populations of red cells characterized by different sizes or by different GLUT1 
content. 2) There is a single cell population containing three serial compartments through 
which a sugar molecule must pass to equilibrate with total cellular space. 
Several observations argue against the first hypothesis. These include: 1) Rejection of 
multiple cell sizes by the observation of monophasic 3MG uptake in cells when transport 
is inhibited by CCB (Figure 2.4A and [121]); 2) The extreme range of cell sizes (0.1 nm -
3.5 µm radii, see Results) that would be necessary to explain the findings. 3) Monophasic 
sugar exit from red cells over time courses corresponding to the fast and slow phases of 
uptake [[121,144,145]; Leitch and Carruthers, unpublished]. The latter observation 
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excludes the possibility that some red cells possess greater sugar transport capacity than 
other cells in the same population. We therefore conclude that the three phases of 
protein-mediated sugar import correspond to three processes that occur sequentially. 
What are the Three Measurable Glucose Transport Phases? Rapid, fast, and slow phases 
of 3MG uptake by red cells are retained in red cell ghosts. This indicates that all three 
phases are associated with the red cell membrane and are independent of sugar interaction 
with cytoplasmic proteins. This does not exclude the possibility that 3MG interacts with 
other membrane associated proteins following release from the glucose transporter. 
The rapid phase The 3MG uptake experiments presented in Figures 2.2 and 2.3 show 
that all phases of sugar translocation are temperature-sensitive. The high activation energy 
of the rapid phase indicates that this phase presents the greatest energy barrier to sugar 
import. Each transport phase is inhibited by specific inhibitors of GLUT1-mediated sugar 
transport. This result is expected if transport proceeds through serial steps and all three 
steps are sensitive to inhibitor. The CCB and phloretin-dependent 3MG space 
“occluded” in or retained by unsealed red cell ghosts and by integral membrane protein 
suspensions is quantitatively most similar to the smallest and most rapid phase of sugar 
uptake by cells. The sugar concentration dependence of the size of this phase indicates 
simple, saturable kinetics with a 3MG capacity of 1.94 nmol/mg membrane protein and 
Kd(app) = 340 µM. This sugar binding capacity is indistinguishable from the sugar-
inhibitable CCB binding capacity of human red cells (0.9 - 1.5 nmol/mg membrane protein 
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[131,146]) but is somewhat greater than the measured 3MG retention of red cell 
membrane integral membrane proteins at 50 µM 3MG (see Figure 2.8B). 
The time-course of the rapid phase of 50 µM 3MG uptake at 4°C extrapolates to an 
equilibrium 3MG space of 22.6 ± 8.1 pmol 3MG per 100 µg membrane protein. The 
quench-dependent 3MG retention space of IMPs at 50 µM 3MG is 3.2 ± 1.3 pmol per 
100 µg protein. Assuming the relative GLUT1 content of IMPs is 1.67-fold greater than 
that of intact red cell membranes and that the rapid phase of uptake and 3MG retention 
by membranes represent the same process, this represents a retention efficiency of 10%. 
Low efficiency sugar retention could result from two factors: 1) In red cell experiments, 
sugar associated with the rapid phase of uptake is released into the wash-inaccessible, 
intracellular water whereas in experiments with IMPs, the water content of the entire 
suspension is exchanged during washes; 2) The transient nature of carrier interaction with 
the quenching agents (CCB and phloretin) may lead to loss of carrier-sequestered sugars. 
CCB has an average dwell time on the e1 site of approximately 1 sec at 4-10°C (1/koff; 
[83,147]). While equivalent data do not exist for phloretin interaction with the e2 site, 
Ki(app) for phloretin inhibition of GLUT1 is approximately 10-fold greater than Ki(app)  for 
CCB inhibition of transport [136] suggesting that koff for phloretin dissociation from the 
e2.phloretin complex may be even greater than koff for CCB dissociation from e1.CCB. 
The lifetime of the rapid phase of 3MG import (0.3 - 1 second at 4°C) is similar to the 
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CCB dwell time on the carrier. It is probable, therefore, that a significant fraction of the 
sequestered 3MG is lost during multiple washes in the presence of CCB and phloretin. 
kr is independent of [3MG] (Figure 2.7A) suggesting that this step does not represent the 
second order process of sugar binding to GLUT1 in which kr would be expected increase 
linearly with [3MG] [83]. We therefore propose that the rapid phase represents a 
conformational change subsequent to and promoted by 3MG binding to e2. This 
conclusion is also supported by estimates of the second order encounter rate constant for 
3MG interaction with GLUT1 if the rapid phase of import were to represent the second-
order reaction between 3MG and GLUT1. If this were true, the pseudo-first order rate 
constant (kr) for this interaction at fixed [GLUT1] is given [83] by  
kr = koff + ke [3MG] 
where the rate constants koff  and ke describe the reaction: 
GluT1 + 3MG GluT1.3MG
ke
koff  
ke is therefore obtained as: 
! 
ke =
kr " koff
[3MG]
 
koff for simple carrier-mediated transport is estimated [2] as  
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! 
koff =
V
max
exchange
[GLUT1]
 
where 
! 
V
max
exchange  is the Vmax for unidirectional sugar fluxes when [3MG]i = [3MG]o. 
Previous measurements of  
! 
V
max
exchange  permit calculation of koff as 40 s-1 at 4ºC and 275 s-1 
at 22ºC [43]. Measurements of kr reported here are 1 s-1 at 4ºC and 70 s-1 at 22ºC (Table 
2.1). According to this analysis, ke would have a negative value if kr represents the second 
order interaction between 3MG and GLUT1. This is a physical impossibility. The 
pseudo first order rate constant describing 3MG interaction with GLUT1 must be at least 
4 to 40-fold greater than the first-order rate constants measured for the rapid phase of 
transport. 
We suggest that the occluded 3MG space and the rapid phase of 3MG uptake by cells 
represent sugar occlusion within the sugar translocation pathway. The occluded 3MG 
space cannot be the previously reported ATP-dependent 3MG binding to GLUT1 [131] 
because that reaction is inhibited by CCB and phloretin, is rapidly reversible and bound 
3MG would therefore be lost during multiple washes to remove unbound sugars. 
The fast and slow phases The fast and slow phases have lower temperature sensitivities 
than the rapid phase of net import. The activation energy for GLUT1-mediated glucose 
transport in reconstituted proteoliposomes ranges between 5.1 and 23.7 kcal.mole-1 
(specific values are lipid composition-dependent; [148]). In human red cells, the 
activation energy for glucose transport is 18.4 kcal.mole-1 [149,150]. This latter value 
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was obtained by measuring transport over intervals that correspond to the fast phase 
reported in the present study where EA is 20.9±5.9 kcal.mole-1. 
Previous studies from this laboratory have demonstrated the existence of a cytosolic 
3MG occlusion mechanism in which an additional sugar binding site within the glucose 
transporter is exposed upon GLUT1 interaction with ATP [131]. We propose that this 
binding phenomenon is associated with the fast phase of transport reported in the present 
study because 3MG equilibrium binding to the cytosolic site and the fractional size of the 
fast phase of 3MG uptake by red cells and red cell ghosts are both increased by 
cytoplasmic ATP (see Figure 2.5, Table 2.1 and [131]). We propose that the slow phase 
of net sugar import corresponds to release of bound sugar from the GLUT1 cytoplasmic 
sugar binding site into bulk cytosol. It is also possible that the slow phase represents 
noncovalent 3MG interactions with red blood cell membrane proteins. Interactions with 
bulk cytosolic proteins are ruled out because the kinetics of slow compartment filling and 
the relative sizes of fast and slow compartments are retained in red cell ghosts. 
Model for Glucose Transport Resolution of the crystal structures of E. coli LacY and 
GlpT transport proteins in the e1 (inward-facing) conformation has prompted the 
development of a model for lactose-proton symport [33,35]. The model is a physical 
reinterpretation of the theoretical simple carrier, as proposed by Stein [2]. The 
monomeric transporter first presents an import (e2) site. Upon lactose and proton binding, 
LacY undergoes a conformational change to the export (e1) configuration where sugar 
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and proton are subsequently released. This mechanism presumes an intermediate 
conformation between e2 and e1 isomers in which the bound substrates are transiently 
sequestered within the closed translocation pathway and are neither accessible to 
interstitium nor cytosol. This translocation intermediate may resemble the occluded K 
and Na states of the Na,K-ATPase (an e1e2ATPase) in which Na-dependent, ATP-
hydrolysis and K-binding induced dephosphorylation promote conformational changes 
that temporarily occlude bound substrate from the aqueous milieu [151,152]. 
As with these preceding transport systems, the glucose transporter undergoes an 
analogous e2↔e1 conformational change. This change, however, does not require ATP 
hydrolysis and can occur (although more slowly) in the absence of bound substrate. Sugar 
transport through a GLUT1 subunit may proceed as follows (see Figure 2.9): 1) sugar 
binds to the e2 or external configuration to form eS2; 2) this event promotes a 
conformational change forming the translocation intermediate e(S); 3) when the 
transporter proceeds through e(S) to the eS1 state, the sugar dissociates into an internal 
cavity formed by GLUT1 cytosolic domains where it may bind to an ATP-dependent, 
noncatalytic sugar binding site and thus remain within the confines of the protein; 4) the 
sugar is released from the noncatalytic binding site back into the internal cavity or is 
released directly from eS1 into the cavity from which it diffuses (slowly in the presence 
of ATP) into bulk cytosol. We propose that the present study has examined phases two, 
three, and four while phase one, the initial binding step, is refractory to the specific 
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Figure 2.9 A King-Altman scheme for sugar transport. The transporter, e, can exist in 
only one of 3 states in the absence of substrate (S) and ligands (I). e1 is the inward 
configuration of the carrier that presents a sugar binding site to cytosol. e2 is the outward 
configuration of the carrier that presents a sugar binding site to interstitium. The carrier 
isomerizes between e1 and e2 states via the e( ) conformer. The e( ) conformer can bind 
extracellular (I2) and intracellular (I1) inhibitors simultaneously. e2 can interact only 
with extracellular inhibitor I2 or extracellular sugar S2. e1 can interact only with 
intracellular inhibitor I1 or intracellular sugar S1. eS1 isomerizes to eS2 via the occluded 
e(S) complex in which the sugar is trapped within the translocation pathway. As with e( ), 
e(S) can interact with I1 and I2 simultaneously. 
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techniques of measurement used. It should be noted that this hypothesis predicts that 
ATP removal (e.g. formation of ghosts ± ATPi) should reduce the size of the fast 
compartment (Cf) and increase the rate of release of sugar from the fast to slow 
compartments (reduce ks). The former prediction is observed (Figure 2.5 and Table 2.1) 
but the latter is not – in part, perhaps due to lack of precision in data. Future studies 
must address this prediction more closely. 
If the rapid phase does indeed represent the formation of an e(S) state in which the sugar 
is occluded within the sugar transport pathway, this would mean that e(S) is capable of 
binding CCB and/or phloretin/extracellular maltose simultaneously. Indeed it is possible 
to measure e(S) only in the presence of these inhibitors. A fundamental tenet of the 
simple carrier hypothesis is that CCB and maltose cannot bind to a carrier that contains a 
complexed transport substrate [118]. However, we do know that GLUT1 does react 
simultaneously with CCB and phloretin [118]. If the simple carrier hypothesis is correct, 
the ability of e(S) to bind phloretin and CCB would explain the experimental 
observations. A recent theoretical model of GLUT1 structure [64] suggests that 
intracellular CCB and extracellular phloretin docking sites may be simultaneously 
presented by each GLUT1 subunit. A second possibility is that in multimeric GLUT1, 
3MG can be occluded within one subunit while the second subunit is locked into a dead-
end conformation with CCB or phloretin. This hypothesis suggests a molar stoichiometry 
of 1 mol CCB bound per mol e(S) - an assertion consistent with the results of this study. 
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It would be interesting to determine the effects of intracellular sugar on all three phases of 
unidirectional sugar uptake. Under infinite-trans uptake conditions (intracellular 
unlabelled [sugar] is high, extracellular radiolabeled sugar levels are varied), the simple 
carrier hypothesis predicts that more e2 sites are available for interaction with 
extracellular sugar (S1 drives the carrier back to e2 via the eS1→e(S)→eS2 export 
translocation pathway which is faster than the e1→e( )→e2 relaxation pathway; Figure 
2.9). The simple carrier hypothesis, therefore, predicts that S1 will increase the amount of 
e(S) but not the rate of e(S) formation. The tetramer model predicts that the amount of 
e(S) formed is independent of S1 but that the rate of formation is increased by S1 due to 
allosteric interactions between subunits. In two exploratory experiments measuring 
uptake of 50 µM 3MG in intact cells, we observe that 1 mM unlabelled intracellular 
3MG increases Crapid from 0.031±0.009 to 0.060±0.013 while krapid is unchanged (68 ± 11 
per sec). This suggests that the former rather than the latter model may be more 
consistent with the data. kfast was also increased from 0.043 ± 0.004 to 0.100 ± 0.008 per 
sec by 3MGi. This result is expected for simple competitive inhibition of a binding 
process (kobs = koff + kon([3MGi] + [14C-3MGi]) and is consistent with the hypothesis 
that imported radiolabeled extracellular sugar and unlabelled intracellular sugar compete 
for binding at a GLUT1 cytoplasmic site. More detailed analyses must be performed to 
confirm these findings and to examine the effects of intracellular ATP on these processes. 
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Compartment Sizes Most of the experiments reported in the present study were carried 
out at [3MG] = 50 µM. It is useful to consider the compartment sizes that would result 
if the proposed transport mechanism were correct. The starting assumptions are as 
follows: 1) The free water space of a red cell is 60 fL [121]; 2) The GLUT1 content of a 
red cell is 600,000 copies per cell [131]; 3) Kd(app) for 3MG binding to e2 is 340 µM 
(Figure 2.7B); 4) The number of ATP-dependent, noncatalytic 3MG binding sites in the 
“cage” is n; 5) Kd(app) for 3MG binding to these noncatalytic sites is extremely low and 
the sites are always occupied (1 molecule in the LacY e1 cavity (1.5 x 10-24 L; [33,35]) 
would produce a [3MG] of 1.1 M). With these starting assumptions, the relative amounts 
of cellular 3MG in the forms of e(S) (rapid compartment), eScage (fast compartment) and 
cell water (slow compartment) at equilibrium are 3.5 : 24.1 :  72.4 (when n = 1); 2.8 : 38.9 
: 58.3 (when n = 2) and 2.3 : 48.8 : 48.8  (when n = 3). These numbers are generally 
consistent with the available data and suggest that n lies between 2 and 3. The LacY e1 
cavity is large enough to hold as many as 3-5 hydrated glucose molecules [33]. The slow 
rate of loss of sugar from the cage to cytosol may reflect the very significant probability 
of re-association of sugar in the cage with the noncatalytic binding sites. As [3MG] is 
increased, the relative contribution of Crapid and Cfast to total cellular 3MG space should 
fall significantly. This has been observed previously [121]. 
 
 
98
CONCLUSIONS  
The present study demonstrates that the time-course of 3MG uptake at 4-22°C by 
human red blood cells is comprised of 3 sequential phases - rapid, fast and slow. Each 
phase is inhibited by carrier-mediated glucose transport inhibitors. The rapid phase is 
more strongly temperature dependent than the fast and slow phases. The rapid phase 
does not represent the reaction between sugar and carrier to form a carrier-sugar complex. 
Rather, it may represent the subsequent conversion of the carrier-substrate complex to 
the intermediate form e(S) where the bound sugar is occluded within the translocation 
pathway. This occluded form of carrier can be isolated (with 10% efficiency) in the 
presence of transport inhibitors thus rendering the occluded sugar inaccessible to 
interstitium and cytosol. 
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CHAPTER III 
 
 HUMAN ERYTHROCYTE GLUCOSE TRANSPORT PROTEIN 
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ABSTRACT 
We present a study that examines whether the emergent bacterial MFS helical folding 
pattern adequately describes the structural organization of the mammalian facilitative 
glucose transporter GLUT1. Proteolytic enzymes trypsin and α-chymotrypsin and lysine 
specific covalent probes were used to examine GLUT1 membrane topology and 
accessibility of transmembrane α-helices to solvent. Peptide fragments were 
characterized by release into aqueous solvent or retention within the membrane following 
proteolysis and incubation with ligands. Unique elution conditions for each 
transmembrane α-helix provided relative hydrophobicity values. Putative pore-forming 
α-helices (1, 2, 4, 5, 7, 8, 10, and 11) are accessible to proteolysis and release peptide 
fragments into the aqueous solvent. The remaining α-helices (3, 6, 9, and 12) are 
completely resistant to proteolysis and do not interact with the aqueous environment. The 
lipid-embedded α-helices are significantly more hydrophobic than the pore lining α-
helices. Transmembrane domain 1 is released from the membrane following trypsin 
proteolysis and cytochalasin B binding to the transporter promotes transmembrane 
domain 8 release into the aqueous environment. These results confirm that amphipathic 
α-helices line the translocation pore and promote interactions with the aqueous 
environment and substrate. The relative aqueous accessibility of each α-helix is 
fundamental to glucose-induced GLUT1 conformational changes and glucose 
translocation. 
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INTRODUCTION 
Major Facilitator Superfamily (MFS) transport proteins mediate passive and secondary 
active transmembrane transport of nutrients, drugs, amino acids, ions, neurotransmitters, 
and other molecules in organisms spanning bacteria to eukaryotes [56]. Of the more than 
1,000 proteins belonging to the MFS classification, the facilitative glucose transporter 
family (GLUT1-12 and HMIT) is responsible for monosaccharide uniport [22,23]. GLUT 
proteins are expressed in a tissue- and organ-system specific manner allowing them to 
meet the metabolic needs of each cell type. For example, GLUT2 is found in the liver 
[25], GLUT3 is expressed in neuronal cells [19], and insulin-sensitive GLUT4 is found in 
muscle and adipose tissue [13]. GLUT1 is found in many tissues throughout the body but 
is expressed most highly in the circulatory system [23,153] and at blood-tissue barriers 
[31,154]. Glucose transfer at the blood-brain barrier (an epithelium comprising capillary 
endothelial cells connected by tight junctions) is mediated by GLUT1, which catalyzes 
transcellular glucose transport. 
Mueckler et al. cloned GLUT1 from HepG2 cells in 1985 [24], more than thirty years 
after Widdas initially hypothesized that a glucose carrier protein existed [38]. GLUT1 
primary sequence contains 492 amino acids, has a molecular weight of 54,117 Daltons, 
and contains a single, heterologous, exofacial N-linked glycosylation site (NQT) at 
asparagine 45. GLUT1 sequence indicates that over 60% of the residues are hydrophobic 
and Fourier transform infrared spectroscopy studies show that GLUT1 peptides retained 
by membranes following proteolysis are predominantly α-helical in nature [60]. 
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Hydropathy analysis [155], scanning glycosylation mutagenesis [45], proteolysis, 
antibody binding, and covalent modification studies indicate that GLUT1 contains 12 
transmembrane (TM) α-helices, intracellular N- and C-termini, and a series of extra- and 
intracellular loops that connect each TM domain [61]. Amphipathic α-helices are 
proposed to form an aqueous translocation pathway through which glucose crosses the 
plasma membrane and enters the cell [64,74]. 
The structural basis of stereoselective substrate translocation across the plasma 
membrane, as reviewed by Dahl et al., has been greatly aided by the recent low and high-
resolution crystal structures of membrane transport proteins [156]. Of particular interest 
are the structures solved for the lactose permease ((LacY [33]); a galactoside/proton 
symporter), the glycerol-3-phosphate antiporter (GlpT [35]) and a multidrug transporter 
(EmrD; proton/drug antiporter [39]) - each protein being native to and crystallized from 
Escherichia coli. An electronic density map for the oxalate transporter (OxlT; 
formate/oxalate antiporter [34]) of Oxalobacter formigens is also available. Although 
there is little sequence similarity between these four structures, they demonstrate a 
common folding pattern and helix arrangement that may be characteristic of all MFS 
transport proteins.  
Mammalian membrane transporters, such as GLUT1, remain refractory to three-
dimensional crystallization. The flexible, dynamic, and amphipathic nature of 
mammalian membrane carrier proteins, coupled with their low expression in vivo 
contribute to this complexity [7,156]. Transporter proteins with unsolved structures can 
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be homology modeled using the template provided by a crystallized homolog [156]. 
Models change as new and more homologous crystal structures are solved. In the past, 
GLUT proteins have been modeled using aquaporin [157], MscL, OxlT [158], and LacY 
[159] templates and low resolution modeling programs [160]. These attempts, however, 
have required manual manipulation and fitting to account for the differences between 
template and GLUT1 sequence alignments, number of transmembrane domains, and 
native folds.  
Salas-Burgos et al. and Holyoake et al. have recently developed a three-dimensional 
GLUT1 model using the GlpT template [63,64]. This model fits GLUT1 to the emergent 
MFS helical fold and uses biochemical data to support the helix packing arrangement. 
Mueckler and colleagues have employed cysteine-scanning mutagenesis in a Xenopus 
laevis expression system to systematically examine the accessibility of each TM helix in 
accordance with this model [40,48-50,68-70,72,74]. There are, of course, striking 
differences between the GlpT template and the GLUT1 modeling target. GlpT is a 
secondary active phosphate antiporter, while GLUT1 is a passive glucose uniporter. GlpT 
and GLUT1 share less than 20% sequence similarity, and often times the larger extra- 
and intracellular loops found in mammalian proteins can complicate sequence alignment 
[156]. The most practical use of homology modeling, therefore, lies in cues it provides 
for devising further biochemical experiments to assess and examine the protein structure-
function relationship. 
104
We present a study that examines the accessibility of transmembrane α-helices within the 
native, membrane-resident GLUT1 protein using reverse phase high performance liquid 
chromatography in-line with electrospray ionization mass spectrometry (RP-HPLC-ESI-
MS/MS). We characterize the relative accessibility of TM helices 1-12 to proteolytic 
digestion by water-soluble enzymes trypsin and α-chymotrypsin. We assess lysine 
residue topology by analysis of accessibility to covalent modification. We examine how 
proteolysis affects peptide partitioning between the aqueous environment and membrane 
bilayer, and we identify a TM α-helix that is released from the lipid bilayer in response to 
incubation with a transport inhibitor. We calculate the relative hydrophobicity of 
individual TM α-helices based upon their unique RP-HPLC elution profile. These results 
provide new insights into the physical properties of GLUT1 transmembrane α-helices 
and how they contribute to glucose transport function. 
MATERIALS AND METHODS 
Materials Fresh, de-identified human blood was purchased from Biological Specialties 
Corporation (Colmar, PA). Protein assays, Pro Blue coomassie stain, Sulfo-NHS-LC-
Biotin and Supersignal chemiluminescence kits were from Pierce (Rockford, IL). 
Glycerol-free endoglycosidase peptide-N-glycosidase F (PNGaseF) was purchased from 
New England Biolabs (Ipswich, MA). Nitrocellulose and Immobilon-P were purchased 
from Fisher Scientific (Hampton, NH). Purified rabbit IgGs raised against a synthetic 
cytoplasmic carboxyl-terminal peptide of human GLUT1 (C-Ab, residues 480-492) were 
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obtained from Animal Pharm Services, Inc. (Healdsburg, CA). All other reagents were 
purchased from Sigma-Aldrich (St. Louis, MO).  
Solutions Saline consisted of 150 mM NaCl, 10 mM Tris-HCL, and 0.5 mM EDTA, pH 
7.4. Lysis medium contained 10 mM Tris-HCl and 0.2 mM EDTA, pH 7.2. Stripping 
solution contained 2 mM EDTA, 15.2 mM NaOH, pH 12. Tris medium contained 50 mM 
Tris-HCL, pH 7.4. Kaline consisted of 150 mM KCl, 5 mM HEPES, 4 mM EGTA, and 5 
mM MgCl2. Phosphate-buffered saline containing Tween (PBS-T) comprised 140 mM 
NaCl, 10 mM Na2HPO4, 3.4 mM KCl, 1.84 mM KH2PO4, 0.1% Tween, pH 7.3. 
Human erythrocyte membranes and glucose transport protein Glucose transporter and 
endogenous lipids were purified from human erythrocyte membranes in the absence of 
reductant as described previously [84,161]. This produces osmotically inactive, unsealed 
GLUT1 proteoliposomes [83], which contain (by protein mass) 90% GLUT1, 8% RhD 
protein, 2% nucleoside transporter (ENT1) and have a lipid:total protein mass ratio of 1:1 
[86]. 
GLUT1 Deglycosylation GLUT1 (50 µL 1 mg GLUT1/mL in kaline buffer) was 
incubated with 3 µL (1,500 activity units) PNGaseF for 1 hr at 37ºC.  
Gel Electrophoresis and Western Blotting GLUT1 protein was resolved on 8% 
polyacrylamide gels as described by Laemmli [162]. Immunoblot analysis using C-Ab (at 
1:10,000 dilution) was as previously described [86]. 
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GLUT1 covalent modification GLUT1 (25-100 µg) was incubated with freshly dissolved 
EZ-Link-Sulfo-NHS-LC-Biotin (10 mM; pH 7.4, 4ºC) at GLUT1:covalent probe molar 
ratios ranging from 1:0.2 to 1:2,000 for 1 minute to 1,800 minutes. Reactions were 
quenched with 50 mM TrisHCl or glycine and membranes were sedimented and washed 
several times with additional quench. The final pellet was resuspended in appropriate 
media for follow-up analysis (PBS, 2% Triton-X-100 in PBS, or Kaline for ELISA, solid 
state precipitation ELISA, and digestion/HPLC ESI-MS, respectively). 
ELISA Assays Biotin incorporation was quantitated using enzyme-linked immunosorbent 
assays (ELISA). Since GLUT1 purification results in 10% protein contamination, 
GLUT1 was immuno-absorbed onto 96-well polystyrene plates pre-coated with C-Ab 
(200 µL of a 1:5,000 dilution for 300 minutes at 37°C, followed by a blocking step with 
3% bovine serum albumin for 120 minutes at 37°C). Following biotinylation, labeled 
GLUT1 proteoliposomes were solubilized in 2% Triton X-100 in PBS (60 minutes at 
4°C). Solubilized GLUT1 (200 µL per well, in triplicate) was added to the plate, 
incubated for 2 hr at 4ºC then washed and blocked in 3% BSA (+2% Triton-X-100). 
Horseradish peroxidase (HRP) conjugated streptavidin (1 µg/mL; 1 hour; 20°C) served as 
the reporting probe with product development measured as absorbance at 415 nm using a 
Benchmark Microplate Reader (BioRad). 
Preparation of Tryptic and α-Chymotryptic Digested GLUT1 Peptides Unmodified or 
pretreated GLUT1 reconstituted into proteoliposomes and resuspended in Kaline (0.5 
mg/mL, 55 µL total reaction volume) was digested with trypsin or α-chymotrypsin at a 
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1:10 ratio (proteolytic enzyme:GLUT1, by mass) for 0 to 2 hours at 30°C. Peptides were 
either subjected to HPLC-ESI-MS/MS immediately or processed further. The digested 
sample was separated into aqueous and membrane fractions by centrifugation for 30 
minutes at 4°C in Beckman Air-Driven Ultracentrifuge (≈ 200,000 x g). The supernatant 
was collected and subjected to HPLC-ESI-MS/MS or stored at -20°C to prevent further 
proteolytic digestion. The membrane fraction (trypsin-digested GLUT1 pellet) was 
resuspended in kaline buffer plus ligands (0.2% DMSO, 10 µM CCB or CCD, or 50 mM 
D-glucose or maltose) and subjected to a second round of sedimentation and aqueous 
fraction isolation for storage at -20°C or direct processing by HPLC-ESI-MS/MS.  
HPLC Separation of GLUT1 Peptides Peptides were subjected to HPLC separation prior 
to in-line electrospray ionization mass spectrometry. The digested mixture (25 µg 
GLUT1 in 50 µL kaline) was resolved by reverse phase chromatography [111] using a 
polystyrene divinylbenzene copolymer column (5 µm, 300 Å, 150 x 2.1 mm; PLRP-S, 
Polymer Labs (Amherst, MA)) at 40°C. Peptides were eluted using one of two gradients 
with different rates of conversion from solvent A (5% 1:1 (v/v) acetonitrile:isopropanol 
(ACN:IPA) in HPLC Grade water) to solvent B (1:1 (v/v) ACN/IPA); both solvents 
contained 0.1% formic acid 0.01% trifluoroacetic acid (TFA) [108,111]. Resolution of 
supernatant fractions was achieved by using: 15 minute equilibration in 98% solvent A 
and 2% solvent B followed by raising the percentage of solvent B to 10% over 3 minutes, 
45% over 37 minutes, and 95% over 2 minutes, where it was held for 10 minutes prior to 
re-equilibration. Flow rate was 200 µL/min. The gradient for resolution of membrane 
fraction peptides required longer exposure to organic solvents: after 15 minutes of 
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exposure to 95% solvent A and 5% solvent B, the percentage of solvent B was raised to 
20% over 4 minutes, 95% over 56 minutes, where it was subsequently held for 10 
minutes prior to re-equilibration. Gradients were controlled with Janeiro II software and a 
Rheos 2000 micro LC/MS pump (Flux Instruments AG Basel, Switzerland) when using 
the Thermo-Fisher LCQ ESI-MS and using the X-Calibur control software and Thermo-
Fisher surveyor MS pump when using an LTQ ESI-MS. 
Electrospray Ionization Mass Spectrometry ESI-MS analysis was performed using either 
a Thermo Fisher LCQ or LTQ electrospray ionization mass spectrometer. Operational 
parameters include positive ion mode, spray voltage, 4.5 kV; capillary temperature, 
225°C; scan range m/z 400-2,000. The linear ion trap measures the m/z ratio of each 
peptide (creating an MS spectrum), and ions exceeding the threshold intensity are 
isolated. MS/MS fragments of isolated peptide species were produced in the ion trap by 
collision induced dissociation (CID) with inert helium gas at 35 V. Acquisition methods 
were created using X-Calibur (version 1.2). MS/MS spectra were identified using the 
Bioworks Sequest version 3.2 database search program against the human red blood cell 
proteome database compiled by Kakhniashvili et al. [27]. 
RESULTS 
All experiments were performed using purified GLUT1 proteoliposomes reconstituted 
with co-purified, native erythrocyte lipids. These proteoliposomes are unsealed and 
simultaneously expose endo- and exofacial GLUT1 domains to exogenous ligands, 
proteolytic enzymes, and antibodies [83,147]. All RP-HPLC-ESI-MS/MS results were 
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obtained following a two hour digestion (30°C) of GLUT1 proteoliposomes with either 
trypsin or α-chymotrypsin at a 1:10 enzyme to protein ratio (by mass). The entire sample 
of digested GLUT1 peptides was subjected to chromatography and mass spectrometry to 
identify all amino acid residues accessible to proteolytic enzymes. The digested sample 
was sedimented to separate membrane-associated peptides from peptides released into the 
aqueous environment (supernatant fraction). Resuspension of the membrane-associated 
region with GLUT1 ligands followed by a second round of sedimentation permits 
analysis of the released peptides that respond to GLUT1-ligand interactions. As our 
frame of reference, GLUT1 residues comprising individual transmembrane α-helices, 
intra- and extracellular loops, and the N- and C-termini were assigned using the 
homology model developed by Salas-Burgos et al. in which the GLUT1 primary 
sequence was threaded through the GlpT crystal structure template (Figure 3.1A) [64]. 
This model establishes three groups of transmembrane α-helices organized by putative 
location and function: those forming the aqueous translocation pathway (Group 1 (TMs 
1, 4, 7, and 10) and Group 2 (TMs 2, 5, 8, and 11)) or those comprising the membrane-
embedded scaffolding region (Group 3 (TMs 3, 6, 9, and 12); Figure 3.1B) [33,35].  
GLUT1 Accessibility to Proteolytic Enzymes GLUT1 contains 16 lysine and 20 arginine 
residues that are potential TPCK-trypsin proteolysis sites [155]. These residues are 
systematically spread throughout the protein within proposed intra- and extracellular 
loops, the N- and C-termini, and at the membrane-solvent interface as shown by the 
putative topology. Our findings indicate that 33 sites are accessible to trypsin cleavage 
110
Figure 3.1 Putative GLUT1 topology and MFS helix-packing model. (A) Putative 
GLUT1 topology adapted from the GlpT homology based structure [64]. Several key 
properties should be noted. Group 1 TMs are highlighted in pink. Group 2 and Group 3 
TMs are highlighted in blue and green respectively. Some helices that span the bilayer 
extend beyond the boundaries of the bilayer (shown by horizontal lines). The bilayer-
embedded region of each membrane spanning helix (TMs 1 through 12) comprise amino 
acids 17-39, 64-86, 93-112, 120-141, 157-178, 187-207, 267-291, 305-325, 335-356, 
362-385, 401-421 and 431-452 respectively. GLUT1 is heterogeneously glycosylated at 
Asn45. TMs 6 and 7 are linked by a large cytoplasmic loop (L6-7). The N- and C-termini 
are exposed to cytoplasm. (B) Putative helix packing arrangement viewed from the 
cytoplasmic surface. TMs are numbered and colored as in Figure 3.1A. The internal 
symmetry between N- and C-terminal halves of GLUT1 is evident from the helical tilts 
and may have resulted from a gene-duplication event [56]. Adapted from [33,35]. 
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(Figure 3.2A). Only R153 and K183, flanking TM5 and K451 at the C-terminal end of 
TM12 are inaccessible to trypsin digestion.  
α-Chymotrypsin is a less specific protease, which we observe cleaves GLUT1, on a 
consistent and reproducible basis (as judged by the quality of MS/MS spectra), at the C-
terminal end of phenylalanine, tyrosine, tryptophan, as well as leucine, alanine, 
methionine, and glutamic acid. These amino acid residues are found both in putative 
aqueous-accessible domains and in membrane-embedded protein domains. Although 
each putative transmembrane domain presents a minimum of 5 potential α-chymotrypsin 
cleavage sites, we detected variable levels of proteolysis (Figure 3.2B). All group 1 and 2 
α-helices display at least one amino acid residue that is accessible to cleavage by α-
chymotrypsin, whereas group 3 helices are completely resistant to proteolytic digestion. 
Table 3.1 summarizes the results of GLUT1 proteolysis by α-helix classification and 
protein region. Overall, group 1 and group 2 α-helices demonstrate greater susceptibility 
to cleavage than group 3 α-helices (41% and 34% versus 2%, respectively). Group 1 
TMs display the highest number of physically cleaved sites compared to group 2 and 
group 3 α-helices (15 to 10 to 1, respectively). The N- and C-termini, L1-2, and L6-7, 
which according to the model represent the largest regions of unstructured and flexible 
protein, are twice as susceptible to cleavage than the shorter loop regions [35]. Putative 
extra-membranous regions are two times more accessible to proteolysis than the 
membrane-embedded TM domains. Overall, 36% of all potential GLUT1 α-
chymotrypsin cleavage sites are observed as actual sites with this reaction protocol. 
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Figure 3.2 Topology representation of sites accessible to proteolytic enzymes. 
Proteoliposome resident GLUT1 was digested with proteolytic enzymes (either trypsin or 
α-chymotrypsin) prior to separation and analysis by RP-HPLC and ESI-MS/MS. Peptides 
containing cleavage sites indicated in each graphic (adapted from the membrane topology 
model presented in Figure 3.1A) were positively identified by MS/MS. (A) GLUT1 
contains 36 potential trypsin cleavage sites (16 lysine residues, 20 arginine residues) 
within its primary structure. 33 of the 36 potential sites are cleaved by trypsin. ✩ 
indicates cleaved lysine residues,  represents inaccessible lysine residues,  indicates 
cleaved arginine residues, and  demonstrates intact arginine residues. R400 (grey ) is 
flanked by proline residues at its N- and C-termini and therefore is not a trypsin cleavage 
site. (B) GLUT1 contains 197 potential α-chymotrypsin cleavage sites (F, Y, W, L, M, A, 
E as identified in our MS/MS analyses) within its primary structure. ✩ indicates that 52 
of these residues are accessible to proteolytic cleavage. Potential α-chymotrypsin 
cleavage sites appear in all TM domains, though no sites in TM α-helices 3, 6, 9, or 12 
are accessible to α-chymotrypsin. Individual peptides and cleavage sites are listed in 
Appendix 1; Table A1.1. 
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Legend to Table 3.1 Analysis of GLUT1 accessibility to proteolytic digestion by 
trypsin and α-chymotrypsin. The columns show the potential number of cleavage sites 
(TOTAL Sites), the number detected as susceptible to proteolysis (# Cleaved), and the 
percent accessibility of the region to proteolysis. Regions are delineated as: 1.) 
individual, membrane-embedded α-helices; 2.) helical grouping arrangements; 3.) loop, 
tail, and regions not embedded within the membrane; 4.) a summation of the individual 
membrane-embedded α-helices versus those regions not embedded within the membrane; 
5.) the proteolytic susceptibility of the entire transport structure. A graphical 
representation is presented in Figure 3.3. 
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Region TOTAL Sites # Cleaved % Cleaved % Cleaved # Cleaved TOTAL Sites Region
TM1 7 4 57% 60% 6 10 TM7
TM2 9 4 44% 40% 2 5 TM8
TM3 13 1 8% 0% 0 12 TM9
TM4 9 4 44% 9% 1 11 TM10
TM5 7 2 29% 25% 2 8 TM11
TM6 9 0 0% 0% 0 12 TM12
Group 1 37 15 41%
Group 2 29 10 34%
Group 3 46 1 2%
N-Term 10 5 50%
L1-2 10 7 70%
L6-7 37 24 65%
C-Term 19 10 53%
Total 76 46 61%
Others 46 13 28%
Membrane 112 26 23%
Extramembrane 122 59 48%
GLUT1 TOTAL 234 85 36%
Table 3.1
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Figure 3.3 Accessibility of each bilayer-embedded TM helix. The X-axis shows each 
α-helix arranged according to its respective group classification (Group 1 includes TMs 
1, 4, 7, 10). The Y-axis shows the fraction of potential proteolytic cleavage sites (trypsin 
or α-chymotrypsin) cleaved by proteolytic digestion for each α-helix.  
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Figure 3.3 represents these data graphically as the fractional proteolytic accessibility of 
each membrane-embedded α-helix according to group assignment. Group 1 and group 2 
α-helices demonstrate similar accessibilities, however, the relative proteolysis patterns 
are distinct. TMs 1 and 7, which are characterized as helical symmetry pairs [56], 
demonstrate more than 50% accessibility to protease. TMs 4 and 10, also characterized as 
corresponding helices in the N- and C-terminal halves of the protein, do not share the 
same accessibility. Group 2 partners 2/8 and 5/11 as well as group 3 partners 3/9 and 6/12 
demonstrate similar, but group specific, proteolysis patterns.  
GLUT1 Peptide Partitioning Behavior Following proteolytic digestion, GLUT1 peptides 
may be separated into aqueous- or membrane-associated fractions. Trypsin digestion 
releases the N- and C-termini, a portion of L1-2, and L6-7 in its entirety into the aqueous 
fraction. The L1-2 peptide is only detected following complete deglycosylation of 
GLUT1 catalyzed by PNGaseF. Full-length TM1, cleaved at intracellular R11 and 
extracellular K38 is also detected in the aqueous fraction (Figure 3.4A).  
α-Chymotrypsin digestion releases a similar pattern of extra-membranous regions into 
the aqueous fraction including the N- and C-termini, a portion of L7-8, and L1-2, L6-7, 
and L10-11 in their entirety. The isolated aqueous fraction also contains TM1 in its 
entirety as well as outside facing portions of TM4, TM7, and TM8, inside facing peptides 
assigned to TM10 and TM11, and multiple faces of TM2 (Figure 3.4B).  
When trypsin digestion was conducted in the presence of 10 µM cytochalasin B (CCB), a 
transport inhibitor that binds to the inward facing e1 GLUT1 conformation [136], TM8 
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Figure 3.4 GLUT1 peptides released into the aqueous environment. Proteoliposome-
resident GLUT1 was digested by protease (trypsin or α-chymotrypsin), sedimented by 
high-speed centrifugation and the aqueous fraction collected and subjected to separation 
and analysis by RP-HPLC and ESI-MS/MS. (A) & (B) Peptides were positively 
identified using Bioworks Sequest version 3.2 database search program. Using the 
GLUT1 membrane topology map (from Figure 3.1A), those domains colored in black are 
detected in the aqueous fraction. (A) Trypsin digestion releases the N-terminus, TM1 in 
its entirety (cut at R11 and K38), a portion of L1-2, all of L6-7, and the C-terminus. If the 
digest occurs in the presence of 10 µM CCB or if the sedimented pellet is resuspended in 
10µM CCB, TM8 (cleaved at K300 and R330) is released from the lipid region and is 
soluble in the aqueous fraction (area defined by the arrows). (B) α-chymotrypsin released 
fragments include the N-terminus, TM1, L1-2, portions of TM2, TM4, all of L6-7, 
portions of TM7, TM8, TM10, L10-11, TM11, and the C-terminus. The individual 
peptides are listed in Appendix 1; Table A1.2. 
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Figure 3.5 MS/MS spectrum CCB-released TM8. The TM8 peptide is released upon 
CCB addition to GLUT1 during or following trypsin digestion. The amino acid sequence 
is K(300).AGVQQPVYATIGSGIVNTAFTVVSLFVVER(330).A, which corresponds to 
a portion of L7-8 and TM8 near the membrane/cytoplasm interface as predicted by the 
GlpT-homology model. The peptide elutes from the RP-HPLC column at 42.73 minutes, 
which corresponds to 43% organic solvent. The indicated y- (read C- to N-terminus, 
shown in blue) and b- (read N- to C-terminus, shown in red) ion series positively confirm 
the identity of this peptide with Sequest scoring parameters: XCorr: 5.53, Peptide 
Probability: 7.43 x 10-8, ΔCn: 0.75, Preliminary Score: 1471.6. 
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(cleaved after residues K300 and R330) is released into the aqueous fraction (Figure 3.5). 
The same CCB-specific response is observed when the trypsin-digested membrane-
associated fraction is resuspended with CCB containing buffer. Resuspension of the 
membrane-associated fraction in medium containing cytochalasin D, DMSO, D-glucose, 
or maltose does not release TM8 or other trypsin-derived peptides. 
Covalent Modification of GLUT1 Lysine Residues In order to further investigate 
GLUT1 membrane topography and assignment of amino acid residues, we examined the 
accessibility of all 16 lysine residues to covalent modification by an aqueous soluble 
Sulfo-NHS-LC-Biotin probe. The reactive NHS ester specifically interacts with the 
primary amine on the lysine side chain forming a covalent amide bond that withstands 
MS/MS ionization. The GLUT1 modification reaction displays a pseudo-first-order rate 
constant that increases linearly with [Sulfo-NHS-LC-Biotin] (Figures 3.6A, 3.6B). The 
extent of modification saturates at probe to protein ratios above 200:1, and is half-
maximal at a probe to protein ratio of (15.5 ± 3.2):1 (Figure 3.6B). CCB binding to 
GLUT1 proteoliposomes is competitively inhibited by GLUT1 biotinylation with half-
maximal inhibition observed at a probe to protein ratio of 43 ± 17:1 (Figure 3.6C). 
Hence, ligand binding is not significantly altered at probe to protein ratios of less than 
20:1 where 2.4 moles of probe incorporated per mole of GLUT1. At 20:1 and 200:1 
probe to protein, all cytoplasmic lysine residues in L6-7 and the C-terminus are equally 
accessible (Figure 3.7). We identified modified GLUT1 peptides by accounting for a 
possible 339.16 Da adduct to lysine residues using the Sequest analysis program. 
Comparing the MS/MS spectra between unmodified (Figure 3.8A) and modified (Figure 
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Figure 3.6 Kinetics of GLUT1 modification. (A) Time course of GLUT1 labeling at 
20ºC, pH 7.4 by sulfo-NHS-LC-biotin. Each data point represents the mean ± SEM of at 
least 4 separate measurements. The curves drawn through the points were computed 
using the Levenberg-Marquardt algorithm assuming a first order process described by: 
labeling = B0+B∞(1-e-k.t). (B) The results of Figure 3.6A were re-plotted as rate of 
GLUT1 modification versus [probe to protein molar ratio] or as equilibrium extent of 
GLUT1 labeling by biotin versus [probe to protein molar ratio]. The curves drawn 
through the points were computed using the Levenberg-Marquardt algorithm. The rate of 
labeling equation is described by: rate = (2.92 x 10-6 ± 0.30 x 10-6)x + (0.0021 ± 0.0003 
min-1), R2 = 0.984. The extent of labeling was calculated using a modified Michaelis 
Menten equation: Bmax = (1.70 ± 0.06) and K½ = (15.5 ± 3.2):1 , χ2 = 1.9 x 10-2. (C) 
Effect of GLUT1 modification on GLUT1 CCB binding. Ordinate: Biotinylated GLUT1 
CCB binding capacity () or Kd(app) () relative to untreated GLUT1; Abscissa: NHS-
LC-biotin:GLUT1 molar ratio. Results are shown as mean ± SEM of 3 separate 
experiments in which CCB binding was measured over the [CCB] range of 0.05 to 25 µM 
in quadruplicate. Control GLUT1 is characterized by Bmax (capacity) and Kd(app) of 0.45 
± 0.01 mol CCB/mol GLUT1 and 265 ± 16 nM respectively. The straight line drawn 
through the Kd(app) data was computed by linear regression and extrapolates to a probe to 
protein molar ratio of 43 ± 17. 
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A
B C
2000x
200x
20x
2x
0.2x
B0 B∞ k (min
-1) χ2
0.45 ± 0.09 1.6 ± 0.1 0.008 ± 0.002 0.065
0.24 ± 0.08 1.69 ± 0.002 0.0021 ± 0.0005 0.086
0.04 ± 0.04 0.93 ± 0.02 0.0026 ± 0.0003 0.0006
0.020 ± 0.005 0.20 ± 0.01 0.0016 ± 0.0003 0.0003
0.008 ± 0.001 0.027 ± 0.002 0.0025 ± 0.0006 0.00002
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Figure 3.7 Which GLUT1 cytoplasmic domains are most accessible to lysine-
reactive probes? Proteoliposome-resident GLUT1 was biotinylated by exposure to probe 
to protein molar ratios of 2, 20 or 200 for 1,000 min at 4ºC then treated with trypsin for 2 
hr. Peptides retained within the lipid bilayer were removed by high speed sedimentation. 
Peptides (those released into the aqueous medium) were subjected to separation and 
analysis by RP-HPLC and ESI-MS/MS. This chart indicates the extent of biotinylation of 
L6-7 and CT peptides. L6-7 is divided into 3 domains - residues 224-232 (red bars), 
residues 233-249 (white bars) and residues 254-264 (light gray bars). The C-terminus 
(CT) domain comprises residues 469-492 (blue bars). Ordinate: fraction of pooled, 
biotinylated L6-7 & CT peptides observed as a biotinylated subdomain peptide. Abscissa: 
probe to protein molar ratio. Indicated above the bar chart is the percentage of total 
peptide (biotinylated and non biotinylated peptide ions) observed as biotinylated peptide. 
The extent of modification increases with probe to protein ratio. 
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Figure 3.8 MS/MS spectra of GLUT1 peptide modified by Sulfo-NHS-LC-Biotin. 
Lysine accessibility to an aqueous probe was monitored using Sulfo-NHS-LC-Biotin. 
The reactive NHS ester covalently modifies lysine side chain primary amines resulting in 
a net covalent mass addition of 339.16 Da, which are detected by Sequest analysis 
software. (A): MS/MS spectrum of a GLUT1 peptide cleaved by trypsin at arginine 232 
and arginine 249 with amino acid sequence R(232).GTADVTHDLQEMKEESR(249).Q 
corresponding to a portion of L6-7. The peptide eluted from the RP-HPLC column at 
10.47 minutes, which corresponds to a 26% organic solvent. The y- and b-ion series (blue 
and red respectively) confirm the identity of this unmodified peptide: with Sequest 
scoring parameters of XCorr: 4.636, Peptide Probability: 3.4 x 10-9, ΔCn: 0.740, 
Preliminary Score: 1975.5. (B): The same peptide as in (A), except modified at K245 by 
Sulfo-NHS-LC-Biotin. The modification can first be observed at y5 and b13, which show 
a 339.16 Da adduct to the lysine residue. All sequential ions in each series also represent 
this mass adduct. The modified peptide eluted from the RP-HPLC column at 19.64 
minutes into the gradient, which corresponds to a 31% organic solvent. The MS/MS 
spectrum and the Sequest scoring parameters confirm its identification: XCorr: 4.652, 
Peptide Probability: 5 x 10-9, ΔCn: 0.615, Preliminary Score: 1235.2. 
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3.8B) GLUT1 peptides containing K245 shows the m/z ratio difference in the b- and y-
ion series peaks that correspond to unmodified and modified lysine residues. 
Table 3.2 summarizes the putative location, susceptibility to trypsin proteolysis, and 
accessibility to covalent modification of GLUT1 lysine residues. The localization of 
lysine residues to the putative intra- and extracellular loops as well as at the membrane-
aqueous interface made them ideal for assessing membrane topography. Of the 16 lysine 
residues, 14 residues are detected as actual tryptic cleavage sites. Only K183 and K451 
are not detected as cleavage sites producing trypsin-specific GLUT1 peptides. Of the 14 
trypsin accessible lysine residues, 12 are covalently modified by the Sulfo-NHS-LC-
Biotin probe. K114 and K117 of extracellular L3-4 and K456 at the C-terminal end of 
TM12 are not detected as labeled amino acids. This could mean that these sites are not 
modified or that modification blocks trypsin cleavage and subsequently prevents 
production and detection of these peptides by MS/MS.  
Relative TM Hydrophobicity Calculations The reverse phase HPLC and ESI-MS/MS 
data analysis method provides the elution conditions and amino acid sequence of each 
GLUT1 peptide produced by proteolytic digestion. Using the sequence specific retention 
(SSR) calculator developed by the Manitoba Center for Proteomics [163], we compared 
the organic composition of the elution profile for each peptide (experimental peptide 
hydrophobicity) with the value obtained from entering the amino acid sequence into the 
SSR calculator (theoretical peptide hydrophobicity).  
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Legend to Table 3.2 GLUT1 Lysine Accessibility. GLUT1 lysine residues (column 1), 
their location within GLUT1 putative domains (column 2), their propensity to 
biotinylation by Sulfo-NHS-LC-biotin as detected by MS/MS (column 3) and their 
propensity to cleavage by trypsin as detected by MS/MS (column 4). 
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Lysine Residue Putative Location Detected as Labeled Detected as Cleaved
K6 N-Terminus
2x 20x 200x
Yes
K7 TM1 Yes
K38 TM1 Yes
K114 TM3 Yes
K117 L3-4 Yes
K183 L5-6 No
K225 L6-7 Yes
K229 L6-7 Yes
K230 L6-7 Yes
K245 L6-7 Yes
K255 L6-7 Yes
K256 L6-7 Yes
K300 L7-8 Yes
K451 TM12 No
K456 C-Terminus Yes
K477 C-Terminus Yes
Table 3.2
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Figure 3.9 Relative TM domain hydrophobicity. Experimentally observed elution 
conditions were compared with the relative hydrophobicity as predicted by the Sequence 
Specific Retention (SSR) Calculator [163]. (A) Comparative analysis of how the 
predicted hydrophobicity corresponded to the actual measured elution conditions. 
Ordinate: the relative hydrophobicity of eluted peptides (Sequence Specific Retention 
score) calculated using the actual sequence and length of the eluted peptides. Abscissa: % 
Organic Solvent required for peptide elution. The straight line drawn through the points 
(y = 0.65x +12.62; R2=0.947) was computed by linear regression. (B) Relative theoretical 
hydrophobicity and order of elution for each membrane-embedded α-helix, L1-2, L6-7, 
and the C-terminus. The organic elution conditions (ordinate) were computed using the 
calculated, sequence-dependent SSR values. The SSR values (abscissa) were inserted into 
the standard curve obtained in (A). 
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We first established a standard curve that plotted the elution conditions for trypsin 
derived peptide fragments versus the calculated SSR values for the exact sequence of the 
eluted peptide (Figure 3.9A). This plot shows a significant correlation between 
experimental and theoretical peptide hydrophobicity values (R2 equals 0.94). We next 
used the standard curve and calculated SSR values to determine the experimental elution 
order for the membrane-embedded portion of each TM α-helix as described in the model 
presented by Salas-Burgos et al (Figure 3.9B). These results show that TM1 is the most 
hydrophilic and TM12 the most hydrophobic of all membrane-spanning domains. α-
helices belonging to groups 1 and 2 show comparable average hydrophobicity values, 
whereas group 3 α-helices are approximately 30% more hydrophobic. 
DISCUSSION 
The primary goal of this investigation was to experimentally unravel the structure of the 
mammalian facilitative glucose transporter GLUT1 from its innermost, aqueous, pore-
forming α-helices to its outermost, lipid-embedded, scaffolding α-helices. To this end, 
we employed in-line RP-HPLC-ESI-MS/MS analysis to examine membrane-resident 
GLUT1 accessibility to water-soluble probes such as proteolytic enzymes and small 
molecules. This approach directly addresses the accessibility of individual 
transmembrane α-helices to solvent, the relative solubility of GLUT1 peptides in aqueous 
versus membrane environments, and the experimental hydrophobicity of individual TM 
α-helices. Although we use the MFS-homology predictions for GLUT1 helix packing as 
a guide, we present several observations that are inconsistent with the putative α-helical 
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arrangement and identify domains that potentially mediate conformational changes 
contributing to GLUT1 function as a carrier-protein [64]. We will discuss these results 
individually and then show how they support a new GLUT1 structural model.  
Their positively charged nature suggests that lysine and arginine residues are located 
outside of the membrane [164]. Specific covalent modification of lysine side chains and 
the susceptibility of lysine and arginine residues to trypsin digestion address lysine and 
arginine topology relative to GLUT1 structure. Our results broadly support the modeling 
of lysine and arginine residues to either the intra- and extracellular regions corresponding 
to the N- and C-termini, loops connecting the TM α-helices, or the interface between the 
membrane-embedded protein and the aqueous environment. With the exception of three 
residues, we detect cleavage at all potential trypsin targets. All lysine residues detected as 
Sulfo-NHS-LC-Biotin reactive sites are also detected as cleavage sites. Additionally, 
lysine residues located in proposed intracellular L6-7 and the C-terminus (K225, K229, 
K230, K245, K255, K256, and K477) are equally accessible to covalent modification, 
which supports the depiction of these regions as unstructured and flexible within the 
cytoplasm [35]. R126 is the only potential trypsin cleavage site proposed to be located 
within the membrane bilayer. Despite this location, however, it is susceptible to 
proteolytic cleavage whereas putative loop residues R153, K183, and K451 are not 
detected as accessible sites. The locations of K183 (putative extracellular loop at the N-
terminal end of TM6) and K451 (C-terminal end of the TM12 α-helix) are consistent 
with the proposed membrane insertion of these two regions. 
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α-Chymotrypsin accessibility studies and the identification of peptide fragments released 
into aqueous medium offer additional support for the proposed GLUT1 membrane 
topology. Similar to our results with trypsin, the N- and C-termini, L1-2, L6-7, L10-11, 
and a portion of L7-8 are accessible to α-chymotrypsin and released into the aqueous 
fraction. This is consistent with proposed assignments of extra-membranous residues. 
Interestingly, however, numerous α-helical fragments dissociate from the membrane-
embedded region. Portions of TM2, TM4, TM7, TM8, TM10, and TM11 as well as TM1 
in its entirety (from trypsin) or as individual fragments (from α-chymotrypsin) are found 
in the aqueous fraction following proteolytic digestion. Fragments from TMs 3, 5, 6, 9, 
and 12, if they are detectable at all, are only observed in the membrane-associated 
fraction.  
Our results support the hypothesis that α-chymotrypsin-catalyzed proteolysis proceeds 
from the most aqueous portions of the protein toward more lipid-embedded regions. The 
loop and cytoplasmic terminal regions are highly accessible, as confirmed by lysine 
modification. We predict that α-chymotrypsin digestion and accessibility patterns reflect 
the extent to which each α-helix contributes to the aqueous translocation pore. TMs 1 and 
7, which display the highest number of cleaved sites and protease accessibility 
(comparable to the termini and long transmembrane loops) likely comprise the innermost, 
aqueous-exposed α-helices. Cleavage susceptibility gradually decreases across TMs 2, 4, 
and 8, followed by TMs 5, 11, and 10, indicating further distance from or diminished 
interaction with the aqueous environment. The inner GLUT1 α-helices, therefore, show 
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characteristic contributions to the aqueous translocation pathway. The outer group 3 α-
helices (3, 6, 9, and 12) are completely resistant to proteolysis (R93 in TM3 bridges the 
aqueous-lipid interface). Unlike their inner, pore-lining, variably accessible counterparts, 
these TMs are uniformly embedded within the membrane. According to the MFS model, 
they serve as scaffolding domains that keep the protein anchored within the membrane 
during conformational changes associated with transport. These observations are 
consistent with the model provided in Figure 3.1. 
The release of small peptides from inner transmembrane α-helices into the aqueous 
fraction confirms their amphipathic nature and ability to interact with the aqueous 
environment and substrate. These interactions are fundamental to glucose-induced 
GLUT1 conformational changes and glucose translocation. TM1 is released from the 
membrane following trypsin digestion in a substrate-independent fashion. Previous 
studies demonstrated that CCB binds to proteolyzed GLUT1 proteoliposomes [87]. We 
hypothesized, therefore, that ligands and substrates might promote GLUT1 
conformational changes that cause the release of additional transmembrane domains. 
Consistent with this proposal, we detect TM8 release from the membrane when 10 µM 
cytochalasin B is present during or following trypsin digestion of GLUT1 
proteoliposomes. This result is CCB-specific, as D-glucose, maltose, and additional 
buffers do not alter TM8 release. This suggests that CCB binding to membrane-
associated GLUT1 domains promotes a transporter conformational change. This could 
result from a physical interaction between TM8 and CCB or may be an indirect 
consequence of CCB binding to a distal region of the transporter. Peptide mapping 
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studies of CCB covalently photolabeled to GLUT1 indicate that TM10 forms a major site 
of GLUT1-CCB interaction [61].  
The release of TM8 from the membrane indicates that the TM regions undergo a 
significant reorientation during the conformational changes that lock the transporter in 
the e1 orientation. The respective ability of each TM to leave the membrane bilayer and 
interact stably with the aqueous environment upon polypeptide backbone cleavage 
highlights their potential involvement in carrier conformational changes and is consistent 
with the high activation energies required for glucose sequestration within a translocation 
intermediate [87]. Crystallized EmrD [39] and OxlT [5,34] structures also suggest 
sequestration of substrates within the translocation pathway. These observations differ 
markedly from the protease resistance displayed by the less conformationally active 
cation translocation pathway of K+-channels [52,165]. We propose that TMs 1 and 8 
serve as key, structurally dynamic TMs, which, through the adoption of hydrophobic or 
hydrophilic conformations, mediate conformational changes associated with uniport and 
exchange transport function. 
The close correspondence between calculated sequence specific retention (SSR; [163]) 
and the experimental elution profile of any given GLUT1 peptide from HPLC (Figure 
3.9A), allows us to predict the relative hydrophobicity and elution conditions of full-
length, membrane spanning α-helices (Figure 3.9B). In this work, we demonstrate that 
TM domains 1 and 8 are the most hydrophilic of all putative α-helices in terms of their 
minimally organic elution profile, favorable partitioning into the aqueous environment, 
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and low SSR score. Conversely, the group 3 α-helices are approximately 30% more 
hydrophobic than those associated with groups 1 and 2 and four of the six most 
hydrophobic TMs belong to group 3. This observation provides direct biochemical 
support for the idea that these TMs are completely embedded within the lipid bilayer and, 
therefore, are unlikely to present any interface with the aqueous environment.  
Mueckler et al. have employed a scanning cysteine accessibility method (SCAM) to show 
that GLUT1 α-helices are amphipathic in nature and vary in accessibility to aqueous 
solvent. With the exception of TM 4 [49] and TM12 [74], the examined TMs show 
characteristic accessibility predicted by the emergent MFS helix-packing model 
[40,48,50,68-70,72]. They also support the idea that each pore forming α-helix presents 
differential accessibility patterns specific to the e2 or e1 protein configuration. TM5 and 
TM10 may be the most interesting in our studies because of their unique interaction with 
the aqueous environment. TM5 displays the same number of susceptible cleavage sites 
(two) as its helix-symmetry partner TM11, but all peptides remain tightly associated with 
the membrane. Conversely, unlike its helix symmetry partner TM4, TM10 only presents 
one susceptible cleavage site to digestion, but the C-terminal portion of this TM is 
released from the membrane-associated region.  
We further note that the GlpT homology model does not account for the intramolecular 
disulfide bond proposed to link TMs 9 and 11 that promotes GLUT1 oligomerization 
observed in the plasma membrane [80,86]. As a result, it is likely that the MFS helix-
packing model represents transporter proteins in the monomeric state. Given that our 
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studies were conducted on native protein, in non-reducing conditions, a disulfide bond 
between TMs 9 and 11 would change the helical tilts and relative orientation within the 
bilayer. This interaction would likely sequester TM10 from the aqueous translocation 
pathway reducing its accessibility to proteolytic digestion (Figure 3.10). The overall lack 
of accessibility to aqueous solvent demonstrated by TMs 3, 6, 9, and 12 may permit these 
α-helices to form the oligomerization interface.  
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Figure 3.10 Model for GLUT1 α-helix packing arrangement. TMs are numbered as 
presented in Figure 3.1B and colored according to their fractional protease accessibility. 
TMs 1, 2, 4, 5, 7, 8, 10, and 11 are proposed to form the glucose translocation pathway 
with variable degrees of interaction with aqueous solvent. TMs 3, 6, 9, and 12, which 
present no fractional accessibility to protease nor release any peptides into the aqueous 
fraction are deeply embedded within the membrane and have no contact with the aqueous 
solvent. We propose that the proposed disulfide bond between C3477 and C421 (found in 
TM9 and TM11, respectively) causes TM10 to be sequestered from the translocation 
pathway, thus reducing its fractional accessibility to protease. 
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CHAPTER IV 
 
CYTOPLASMIC REGIONS ARE RESPONSIBLE FOR ATP MODULATION OF 
GLUT1-MEDIATED SUGAR TRANSPORT 
 
This chapter will be submitted as a manuscript in April of 2007. 
 
This work was supported by NIH grants DK 36081 and DK 44888 and by ADA grant ADA 
1-06-IN-04 (Gail Patrick Innovation Award supported by a generous gift from the Estate of 
Gail Patrick) 
 
Data presented in this chapter found in Figures 4.1, 4.2, 4.3, and 4.4 were collected and 
analyzed by Julie A. K. DeZutter, PhD. 
ABSTRACT 
Cytoplasmic ATP regulates GLUT1-mediated sugar transport by reducing Km and Vmax 
for net sugar import and Km for exchange transport. We undertook an investigation of the 
mechanism of GLUT1-regulation by ATP by identifying GLUT1 domains that undergo 
significant conformational change upon GLUT1-ATP interaction. ATP (but not GTP) 
affords GLUT1 protection against tryptic digestion. Immunoblot analysis shows peptides 
released from the GLUT1 N-terminus, L6-7, L7-8 and the GLUT1 C-terminus are 
degraded less completely when tryptic digestions are carried out in the presence of ATP. 
ELISA assays of antibody binding to full-length GLUT1 show reduced binding of IgGs 
directed against L7-8 or the GLUT1 C-terminus when binding is performed in the 
presence of ATP. C-terminal antibody binding to wild-type GLUT1 expressed in HEK 
cells is inhibited by ATP but binding to a GLUT1-GLUT4 chimera in which L6-7 of 
GLUT1 is substituted with L6-7 of GLUT4 is unaffected by ATP. Sulfo-NHS-LC-Biotin 
GLUT1 labeling decreases in the presence of ATP. ESI-MS/MS studies show that 
labeling of lysine residues 245, 255, 256, and 477 is inhibited in the presence of ATP, 
whereas lysine residues 225, 229, and 230 demonstrate no change in labeling efficiency. 
These data suggest that the GLUT1 C-terminus interacts with the C-terminal half of L6-7 
in an ATP-dependent manner, thereby reducing the efficiency of glucose transport. 
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INTRODUCTION 
Most eukaryotic cells import and export glucose via a saturable but passive transport 
process that, in the absence of sugar metabolism, leads to the equilibration of glucose 
between cell water and interstitium [2]. This sugar transport is catalyzed by a family of 
integral membrane proteins (GLUT1 - GLUT12 [115]) and is characterized by the 
catalytic mechanism of carrier-mediated, facilitated diffusion [2]. GLUT1 is expressed in 
most tissues but is especially abundant in erythrocytes [166], blood-tissue barriers (brain, 
retina, olfactory epithelium, inner ear, peripheral nerve and heart [167]), cardiomyocytes 
[168], vascular smooth muscle [167] and astrocytes [19]. While our studies specifically 
focus upon GLUT1 found in human erythrocyte, examining how GLUT1 catalyzes 
glucose transport and how this process is regulated should explain how this process is 
mediated and controlled at blood-tissue barriers. 
Glucose uptake is rate-limiting for glucose utilization in cells with low glucose transport 
capacity relative to high rates of sugar metabolism (e.g. smooth, striated and cardiac 
muscle, adipose, nucleated erythrocytes and certain cultured cell lines). These cells 
characteristically display acute sugar transport regulation in which net sugar uptake is 
rapidly stimulated when glucose utilization is increased [169-173]. Sugar transport in 
muscle, nucleated erythrocytes and cultured cells is stimulated 3 to 50-fold by cellular 
metabolic depletion [170,172-174] while insulin produces an 8 to 40-fold stimulation of 
sugar transport in muscle and fat [175,176]. Many cells respond acutely to stimuli by 
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increasing cell surface sugar transporter content [176] while others respond with 
increased GLUT intrinsic activity [174]. 
The field has long held that sugar transport regulation is unnecessary in cells where 
transport is faster than metabolism [14,177]. This conclusion is, however, based on the 
assumption that the target served by the sugar transport activity of a cell is the metabolic 
machinery of that transporting cell. Would this conclusion still hold if the target were 
downstream from the transporting cell? In the brain, for example, glucose utilization by 
astrocytes and neurons is fed by glucose transport across the blood brain barrier. This 
barrier comprises endothelial cells which account for only 0.1% of the mass of the brain 
[178] but which must transport sugar for a significantly greater mass of metabolically 
active cells. 
Several tissues are protected from direct access to serum-borne nutrients and electrolytes 
by blood-tissue barriers. The protected tissues include the brain, the retina, the olfactory 
epithelium, the inner ear, peripheral nerve and the heart [154,167]. The cells that form the 
blood-tissue barrier are normally endothelial cells sealed by tight junctions [154]. GLUT1 
is expressed at high levels in these endothelial cells and constitutes the major pathway for 
glucose movement across these barriers via transcellular transport [154]. Glucose 
transport into brain, peripheral nerve and retina is especially important because glucose 
stores in these tissues are very small relative to glucose demand [179]. 
Erythrocytes and endothelial cells rapidly equilibrate with glucose indicating that their 
capacity to metabolize glucose is significantly less than their glucose transport capacity 
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[180]. Endothelial cell GLUT1 is functionally analogous to human red cell GLUT1 in that 
it displays similar substrate affinities, trans-acceleration of transport, and inhibitor 
sensitivities [181]. Human red cell GLUT1 and human GLUT1 heterologously expressed 
in CHO cells and HEK cells respond acutely to ATP-depletion with enhanced glucose 
import capacity [85,119,131,182,183]. 
Glucose transport measurements in human erythrocyte ghosts do not display the same 
characteristic transport asymmetry parameters observed in native human red cells. The 
removal of ATP from the cytosol is responsible for promotion of transport symmetry. In 
fact, ATP lowers Km and Vmax for net sugar import and lowers Km for exchange transport 
in human red cells [114,184]. This transport modulation reflects a direct action of ATP on 
GLUT1 [185], is competitively inhibited by AMP and ADP, and does not involve ATP 
hydrolysis [131]. At low temperatures (4ºC) where transport in human red cells is most 
easily measured, GLUT1 asymmetry is at least 20-fold [184]. At physiological 
temperature, asymmetry falls to 1.4 to 2-fold [116]. Thus the loss of transport asymmetry 
in the absence of ATP increases sugar uptake capacity at 4°C and 37°C by 20- and by 1.4 
to 2-fold respectively. 
GLUT1 is a nucleotide binding protein that directly interacts with ATP [135]. Peptide 
mapping studies suggest that ATP binds to GLUT1 between amino acid residues 301 to 
364. This region comprises TM helices 8 and 9 and cytoplasmic loop 8-9. The primary 
sequence of this region displays 50% sequence identity with the ATP binding region of 
adenylate cyclase and further narrows the binding region to residues 332 to 343 [135]. 
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The likely nucleotide-binding pocket, therefore, minimally contains L8-9 and the 
cytoplasmic half of TM9, however, the modulation mechanism (in terms of primary 
sequence) is likely distal to the physical binding site.  
Our studies suggest that the GLUT1 C-terminus interacts with the cytoplasmic loop (L6-
7) in an ATP-dependent manner thereby reducing the efficiency of transport. The overall 
modulation of erythrocyte GLUT1 by ATP may reflect a fundamental mechanism for 
GLUT1 regulation in other tissues. This chapter examines the biochemical basis of 
GLUT1 regulation by ATP through analysis of ATP-sensitive GLUT1 subdomains.  
MATERIALS AND METHODS 
Limited Proteolytic Digestion of Purified GLUT1 10ug of purified GLUT1 was 
digested with a 20:1 (protein:enzyme) ratio of purified porcine trypsin (Princeton 
Separations) in 50 mM Tris-HCl (pH 7.5), 0.1% SDS, 5 mM MgCl2, 4mM ATP (pH 7.5). 
Digestions were performed at 4°C for 60 minutes, or the indicated time period. Reactions 
were immediately loaded onto 15% SDS-PAGE. 
Western Blotting Following SDS-PAGE, samples were transferred to nitrocellulose and 
blocked overnight in 25% nonfat dry milk/PBS/0.1%Tween-20. Primary antibody [C-Ab 
(1:15,000), L6-7-Ab (1:500), N-Ab (1:200), L2-3-Ab (1:200), L7-8-Ab (1:200)] was 
incubated in 3% nonfat dry milk/PBS/0.1% Tween-20 for 1 hour at room temperature. 
Blots were washed 3x with PBS/0.1% Tween-20. HRP conjugated goat anti-rabbit 
secondary antibody, diluted 1:5000, was incubated at room temperature for 1 hour. Blots 
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were washed 3x with PBS/0.1% Tween-20 followed by an additional 3 washes with 
PBS/0.2% Tween-20. Blots were developed using Pierce SuperSignal West Pico 
Chemiluminescent substrate and visualized by autoradiography. 
Differential Antibody binding:  ELISA 200 ng of purified GLUT1 in 1x PB buffer (20 
mM NaH2PO4, 145 mM NaCl) was adsorbed to an ELISA plate for 2 hours at 37°C. 
Plates were blocked with PB buffer/3% BSA for 2 hours at 37°C. Primary antibody [C-
Ab (1:15,000), L6-7-Ab (1:500), N-Ab (1:200), L2-3-Ab (1:200), L7-8-Ab (1:200)] was 
incubated in PB buffer/0.1% BSA for 2 hours. Plate was washed 5x with PB buffer. 
HRP-conjugated goat anti-rabbit secondary antibody, diluted 1:5000, was incubated for 1 
hour at 37°C. Plate was washed 5x with PB buffer. ELISA was developed using 100 µl of 
1-Step ABTS solution  (Pierce). Extent of antibody binding was measured by quantitating 
OD (415nm). 
Construction of GLUT1-L6-7-GLUT4 Chimera The human GLUT1chimera, which 
had the middle loop (L6-7) substituted with that from its counterpart from rat GLUT4, 
was constructed using a 6-step PCR protocol. In PCR 1A, a HindIII primer 
complimentary to the 5’ end of human GLUT1 and a reverse primer complimentary to 
nucleotides (600-619) of GLUT1 and (667-685) of GLUT4 was used to generate a 
fragment containing TM 1-6 (nucleotides 1-620) of GLUT1. In a separate reaction, 
PCR1B, primer (TGCATCGTGCTGCCCTTCTGTCCTGAGAGCCCCCGA) containing 
sequence complimentary to nucleotides (600-619) of GLUT1 and (667-685) of GLUT4 
(5’end of L6-7) and a reverse primer (containing a Not I restriction site) complimentary 
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to the 3’ end of GLUT4 was used to generate a fragment containing the middle loop and 
TM 7-12 (nucleotides 667-1531) of GLUT4. In PCR2, the HindIII primer complimentary 
to the 5’ end of human GLUT1 and the reverse primer (containing a Not I restriction site) 
complimentary to the 3’ end of GLUT4 were used along with the products from PCR1A 
and B to generate an intermediate chimera containing sequence from nucleotides (1-620) 
of GLUT1 and (667- 1531) of GLUT4. This intermediate chimera contained TM 1-6 of 
GLUT1 in frame with L6-7 and TM 7-12 of GLUT4. In PCR 3A, the HindIII primer 
complimentary to the 5’ end of human GLUT1 and a primer  
(CGCACCCAGGGGCAGCCTATCCTCATCGCTGTGGTC) complimentary to 
nucleotides (844-862) of GLUT4 and (815-829) of GLUT1 were used along with the 
product from PCR2 to generate a fragment containing TM 1-6 of GLUT1 (nucleotides 1-
619) in frame with L6-7 (nucleotides 667-862) of GLUT4. In PCR 3B, a primer 
(CGCACCCAGGGGCAGCCTATCCTCATCGCTGTGGTC) complimentary to 
nucleotides (844-862) of GLUT4 and nucleotides (815-829) of GLUT1 were used with 
wild type GLUT1 plasmid as a template to generate a fragment containing TM 7-12 
(nucleotides 815-1480) of GLUT1. In the final reaction, PCR 4, HindIII primer 
complimentary to the 5’ end of human GLUT1 and the NotI primer complimentary to the 
3’ end of GLUT1 were used with the products of PCR 3A and B as a template generating 
the final product which contained TM 1-6 (nucleotides1-619) of GLUT1, followed by 
L6-7 of GLUT4 (nucleotides 667-862), followed by TM 7-12 (nucleotides 815-1480) of 
GLUT1. This PCR product was digested with HindIII and NotI and ligated into the 
mammalian expression vector pcDNA 3.1+, cut with the same enzymes. Sequences were 
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confirmed and the GLUT1-L6-7-GLUT4 chimera was shown transport glucose into HEK 
cells with kinetics similar to that seen for wt GLUT1.  
Sulfo-NHS-LC-Biotin labeling, RP-HPLC, and ESI-MS/MS techniques are as described 
previously in Chapter III.  
RESULTS 
Purified human GLUT1 is reconstituted into unsealed proteoliposomes upon detergent 
removal [41,83,146] because the protein co-purifies with human red cell membrane 
lipids. If exogenous lipid is added to the protein/lipid/detergent mixture prior to detergent 
removal, the increased lipid:protein ratio causes sealed proteoliposomes, which contain 
GLUT1 in a random transmembrane orientation, to form [186-188]. These 
proteoliposomes are osmotically active and are suitable for sugar transport 
determinations. In the proteolysis and biotinylation experiments described below, we 
employed purified human GLUT1 in unsealed proteoliposomes to ensure that added 
reagent has access to both surfaces of the lipid bilayer and thus full access to exo- and 
endo-facial GLUT1 domains.  
Exposure of GLUT1 proteoliposomes to trypsin (62.5:1 by mass) at 37ºC results in the 
rapid loss of intact GLUT1 as judged by silver-stain detection of peptides resolved by 
10% SDS-PAGE (Figure 4.1A). The time course of GLUT1 proteolysis is biphasic, being 
characterized by a rapid burst phase of proteolysis in which approximately 30% of 
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Figure 4.1 GLUT1 digestion by trypsin at 37ºC. (A) GLUT1 (10 µg) was incubated 
with trypsin (0.16 µg) ± ATP (concentrations indicated) for 60 sec (panels (A) & (C)) or 
with 0 ATP, 4 mM ATP or 4 mM GTP for the times indicated (B). GLUT1 was separated 
from proteolytic fragments by SDS-PAGE and the fraction of intact GLUT1 remaining 
quantitated by densitometry of silver-stained gels. The curves drawn through the data 
points assume two exponential phases of proteolysis. The fast phase accounts for 33% of 
GLUT1 proteolysis and has a first order rate constant of 0.056 ± 0.009 per sec (control) 
or 0.046 ± 0.018 per sec (GTP). The slow phase accounts for 66% of GLUT1 digestion 
and has a first order rate constant of 0.00036 ± 0.00003 per sec (control) or 0.00026 ± 
0.00022 per sec (GTP). ATP reduces the magnitude of the fast phase to 22 ± 2% and 
slows the fast rate constant to 0.017 ± 0.003 per sec. Insufficient data exists to analyze 
slow phase kinetics in the presence of ATP. ATP protection of GLUT1 during fast phase 
proteolysis is half-maximal at 497 ± 148 µM ATP (panel C). 
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GLUT1 is hydrolyzed with a tau of 4.5 sec and the remaining intact GLUT1 is 
proteolyzed with a tau of 2500 sec (Figure 4.1B). 
Specificity of nucleotides We first wanted to determine if the presence of nucleotides 
affects GLUT1 proteolysis by trypsin. Addition of 4 mM GTP is without effect on the 
time-course of GLUT1 proteolysis by trypsin (Figure 4.1B), however when 4 mM ATP 
is present in the digestion, the size and rate of the proteolysis burst phase are 
significantly reduced (extent = 22%, tau = 56 sec) (Figure 4.1B). Like GTP, unreactive 
nucleotides AMP, ADP, and CTP also do not affect the rate of trypsin-catalyzed 
GLUT1 proteolysis. 
We further investigated ATP-suppression of GLUT1 trypsin digestion by measuring 
GLUT1 proteolysis at 60 seconds in the presence of increasing ATP concentrations. 
ATP inhibition of GLUT1 proteolysis shows a saturable dependence on [ATP] with 
50% suppression of proteolysis observed at 627 ± 268 µM ATP (Figure 4.1C).  
Immunoblot Analysis We also examined GLUT1 fragmentation patterns by immunoblot 
analysis of GLUT1 digests using GLUT1 peptide-directed IgGs. These included N-Ab 
(directed against GLUT1 amino acid 1-13), L6-7-Ab (directed against GLUT1 amino acid 
217-231), L7-8-Ab (directed against GLUT1 amino acid 299-311) and C-Ab (directed 
against GLUT1 amino acid 480-492). ATP (4 mM) reduces GLUT1 digestion efficiency 
(100:1 GLUT1:trypsin by mass; 20ºC; 30 min reaction) as detected by antibodies specific 
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to L7-8 and the C-terminus, see Figure 4.2A. Figure 4.2B aligns peptides with 
immunoblot analysis based upon peptide mass, location of trypsin-cleavage sites, and 
antibody reactivity to indicate potential assignments of ATP-protected peptides to 
GLUT1 sequence. To more closely examine the region specific concentration dependence 
of ATP-inhibition of trypsin-catalyzed GLUT1 proteolysis, we measured the retention 
of peptides recognized by carboxy terminal domain antibody (Figure 4.3). ATP-
suppression of C-terminal digestion is half-maximal at approximately 400 µM ATP.  
Analysis of full-length GLUT1 accessibility to peptide directed IgGs We next examined 
if ATP induced global conformational changes to GLUT1 by using ELISA to monitor 
peptide-directed IgG binding to membrane-resident GLUT1. GLUT1 proteoliposomes 
were adsorbed to ELISA wells then incubated ± ATP and peptide-directed IgGs. As 
reported previously [185], ATP inhibits C-Ab binding to GLUT1 proteoliposomes 
(Figure 4.4A). This is also observed with C-Ab binding to red cell membrane fragments 
(Figure 4.4B) and in membranes isolated from HEK cells exogenously expressing wild-
type human GLUT1 (Figure 4.4C). When HEK cells are transfected with a GLUT1-
GLUT4 chimera in which the GLUT1 large middle loop (L6-7) is replaced by equivalent 
GLUT4 sequence (G1L46-7G1C1), ATP-inhibition of C-Ab binding to the chimera is lost. 
Despite the loss of ATP-modulation, this chimera is expressed at the cell surface and 
transports 2-deoxy-D-glucose as efficiently as does wild-type GLUT1.  
We have also examined a wider array of peptide-directed IgG for ATP-inhibition of 
binding using this ELISA technique. Similar to the western blot analysis examining 
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Figure 4.2 Immunoblot analysis of trypsin digested GLUT1 ± 4 mM ATP. Purified 
GLUT1 was digested with limiting amounts of trypsin in the presence and absence of 
4mM ATP. The resulting peptides were analyzed by Western Blot analysis using a panel 
of antibodies directed against specific GLUT1 domains: N-Ab (GLUT1 residues 1 - 13; 
L6-7-Ab (GLUT1 residues 217-231); L7-8-Ab (GLUT1 residues 299-311) and C-Ab 
(GLUT1 residues 480-492). The upper panels show western analysis of tryptic digests. 
The key indicates the presence (+) or absence (-) of trypsin or ATP (4 mM). The bars to 
the left of each blot show the mobility of molecular weight standards (kDa). The arrows 
to the right of each blot indicate peptides whose intensity is greater when digests are 
carried out in the presence of ATP. The lower panel represents GLUT1 in linear form and 
the open boxes show the locations of N-Ab, L6-7-Ab, L7-8-Ab and C-Ab directed IgG 
binding domains. The arrows above linearized GLUT1 indicate GLUT1 tryptic cleavage 
sites determined by MS/MS analysis of GLUT1 tryptic digests. The panels below 
indicate putative assignments of ATP-sensitive GLUT1 peptides detected by peptide-
directed IgGs and their theoretical molecular weight (kDa). 
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Figure 4.3 [ATP] dose response to trypsin digestion. Purified GLUT1 was digested 
with limiting amounts of trypsin in the presence of increasing amounts of ATP. The 
resulting peptides were analyzed by Western Blot analysis (A) using C-Ab (GLUT1 
residues 480-492). The key indicates the concentration of ATP present during 
proteolysis. The lines to the left of the blot show the mobility of molecular weight 
standards (kDa). The arrows to the right of the blot indicate peptides (20 and 28 kDa) 
whose intensity was quantitated. (B) The relative intensities of 20 kDa (filled circles) and 
28 kDa (open circles) peptides as [ATP] is increased during proteolysis. Peptide 
intensity (volume) was quantitated by densitometric analysis using the Image J software 
package and plotted as a function of [ATP]. The curves drawn through the points were 
computed by nonlinear regression assuming that intensity increases with [ATP] in a 
simple, saturable fashion. 20 kDa and 28 kDa peptides are half-maximally protected by 
ATP at (366 ± 202) and (440 ± 211) µM, respectively. 
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Figure 4.4 Time course of C-Ab binding to ELISA dish-Immobilized GLUT1 
proteoliposomes: (A), red cell membranes (B), membranes from HEK cells expressing 
GLUT (C) and membranes from HEK cells expressing the GLUT1-GLUT4 chimera 
G1L46-7G1C1 in which GLUT1 L6-7 is substituted by GLUT4 L6-7 (D). In each panel, 
the extent of C-Ab binding is read as OD415 nm obtained upon addition of HRP substrate 
and using HRP-conjugated goat anti-rabbit IgG as the secondary antibody. The abscissa 
indicates the duration of C-Ab exposure to membranes prior to free C-Ab removal. Filled 
circles shown C-Ab binding in the presence of ATP (4 mM) and open circles show C-Ab 
binding in the absence of ATP. Results are shown as mean ± SEM of triplicate 
measurements. In all cases, results were analyzed assuming a single exponential phase of 
IgG binding described by Bmax(1-e-kt) where Bmax is equilibrium binding, k is the first order 
rate constant for binding and t is time. The following results were obtained:  A, 0 ATP, 
Bmax = 0.65  ± 0.012, k = 0.13 ± 0.06 per min; + ATP, Bmax = 0.46 ± 0.02, k = 0.12 ± 0.01 
per min. B, 0 ATP, Bmax = 0.84  ± 0.13, k = 0.10 ± 0.03 per min; + ATP, Bmax = 0.49 ± 
0.05, k = 0.17 ± 0.05 per min. C, 0 ATP, Bmax = 0.67  ± 0.02, k = 0.11 ± 0.01 per min; + 
ATP, Bmax = 0.47 ± 0.03, k = 0.11 ± 0.01 per min. D, 0 ATP, Bmax = 0.63  ± 0.02, k = 0.14 
± 0.05 per min; + ATP, Bmax = 0.56 ± 0.04, k = 0.12 ± 0.01 per min. 
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trypsin-derived peptides, ATP does not affect binding of L2-3-Ab or L6-7-Ab to 
membrane-resident GLUT1. ATP does, however, reduce L7-8-Ab and C-Ab binding to 
full-length GLUT1 proteoliposomes. N-Ab and L8-Ab do not bind appreciably to native 
GLUT1 structure.  
Analysis of GLUT1 biotinylation We have previously used ESI-MS/MS to show that 
biotin-conjugated N-hydroxysuccinimide esters (Sulfo-NHS-LC-Biotin) react with at 
least 12 of the 16 GLUT1 lysine side chains to form a covalent, MS/MS stable amide 
bond (see Chapter III). This probe is particularly useful for detecting differential side 
chain accessibility on both the global (western blot or ELISA using streptavidin-HRP) 
and local (MS/MS identifying the modified lysine) levels. In this study, monitoring 
GLUT1 labeling by these techniques provides the most specific method (in addition to 
the aforementioned observations from immunoblot and ELISA techniques) for probing 
the conformational dynamics displayed by GLUT1 in response to ATP modulation of 
glucose transport. 
GLUT1 proteoliposomes were incubated at 4°C for 30 minutes with ATP (or control 
buffer environment) prior to adding a 20-fold molar excess of Sulfo-NHS-LC-Biotin to 
begin GLUT1 labeling. The reaction was quenched by exposure to 100 mM glycine, 
which neutralized remaining probe. Figure 4.5A shows the time course of GLUT1 
labeling in the presence of 4 mM ATP. Compared to reaction conditions lacking 
nucleotide or containing non-inhibitory AMP (4 mM), the inclusion of ATP reduces total 
modification by approximately 40% (inset), without slowing the reaction rate.  
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By examining the extent of Sulfo-NHS-LC-Biotin incorporation in the presence of 
increasing ATP concentrations, we calculated the 
! 
K
i
ATP  for ATP-inhibition of GLUT1 
biotinylation to be 2.0 mM, (Figure 4.5B). AMP (0 to 4 mM) does not alter equilibrium 
GLUT1 labeling. The protection afforded GLUT1 from labeling occurs within the 
physiological concentration of ATP found in human erythrocytes. There is no change in 
the rate of biotinylation regardless of the concentration or type of nucleotide. When the 
same dose-response conditions were examined in the presence of 2 mM AMP, the 
! 
Ki(app )
ATP  
was 2-fold greater, at 3.8 mM. Assuming AMP competitively antagonizes ATP inhibition 
of biotinylation, we computed the 
! 
K
i
AMP  for antagonism of ATP-inhibition of GLUT1 
biotinylation to be 2.2 mM (see figure 4.5B). Although AMP binds to GLUT1 at the 
nucleotide-binding site, it does not alter GLUT1 accessibility to Sulfo-NHS-LC-Biotin, 
which appears to be an ATP specific response.  
Equilibrium labeling studies performed at a 20 molar excess of Sulfo-NHS-LC-Biotin to 
GLUT1 proteoliposomes followed by trypsin digestion, isolation of soluble fragments, 
RP-HPLC separation, and subsequent ESI-MS/MS indicate that specific cytoplasmic loop 
regions and residues specifically display reduced accessibility to labeling reagent in the 
presence of 4 mM ATP. Cytoplasmic GLUT1 lysine residues may be grouped into four 
regions: region 1 contains K225, K229, and K230; region 2 is K245; region 3 is 
comprised of K255 and K256, all of which are found in L6-7; region 4 contains C-
terminal K477.  
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Figure 4.5 Analysis of ATP-dependence on lysine modification. (A) Time course of 
GLUT1 labeling at 4°C, pH 7.4 by Sulfo-NHS-LC-Biotin (20:1 molar excess of probe to 
protein). GLUT1 proteoliposomes were pre-incubated for 30 minutes in Kaline, 4 mM 
AMP, or 4 mM ATP. Biotinylation kinetics are described by pseudo-first order kinetics 
where labeling equals B0 + B∞(1-e-kt). Inset: Average equilibrium labeling extent of at least 
three normalized labeling experiments done in triplicate ± SEM: Kaline, extent = 1.20 ± 
0.03; 4 mM AMP extent = 1.28 ± 0.05; 4 mM ATP extent = 0.73 ± 0.03. (B) Effects of 
nucleotides on GLUT1 biotinylation. Biotin incorporation extent and labeling reaction 
rate were plotted versus [AMP] or [ATP] present during labeling. Linear regression 
analysis indicates no correlation between [AMP] and labeling extent (R2 = 0.31), [AMP] 
and reaction rate (R2 = 0.29), and [ATP] and reaction rate (R2 = 0.3). Nonlinear regression 
using a modified Michaelis Menten equation provides the following labeling constants in 
the presence of variable [ATP]: labeling in the absence of ATP, B0 = 1.210 ± 0.007, 
maximum inhibition of labeling in the presence of saturating [ATP], Bmin = 0.72 ± 0.04 
and [ATP] inhibits labeling half-maximally at Ki = 2.0 ± 0.3 mM. ATP inhibition of 
labeling was measured in the presence of competing AMP. GLUT1 was labeled in the 
presence of increasing [ATP] at constant 2 mM [AMP]. Linear regression analysis shows 
no correlation between [ATP] and labeling rate (R2 = 0.014). Modified Michaelis non-
linear regression analysis provides: B0 = 0.9, Bmin = 0.6, and Ki = 3.8 ± 2 mM. Assuming 
AMP competitively inhibits ATP modulation of labeling, Ki(app) for AMP = 2.2 mM. 
167
0.6
0.8
1
1.2
1.4
0 1 2 3 4
[Nucleotide] mM
0
0.4
0.8
1.2
0 400 800 1200
Time (Minutes)
0
0.4
0.8
1.2
Control AMP ATP
B
io
ti
ny
la
ti
on
 E
xt
en
t 
(A
bs
41
5 
nm
)
*
B
io
ti
ny
la
ti
on
 E
xt
en
t 
(A
bs
41
5 
nm
)
A
B
Figure 4.5
Condition B0 B∞ k (min
-1)
Kaline 0.15±0.02 1.09±0.05 0.0023±0.003
4 mM AMP 0.16±0.01 1.20±0.03 0.0019±0.0001
4 mM ATP 0.098±0.009 0.66±0.02 0.0022±0.0002
Extent Vary [AMP]
Extent Vary [ATP]; [AMP] = 2 mM
Extent Vary [ATP]
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To examine localized changes in GLUT1 modification, we identified all peptides within a 
specific region that contain lysine residues, noted each m/z ratio, and isolated the 
intensity of each peak (area under the curve) using the Qual Browser program within X-
Calibur for labeling reactions that took place in Kaline, 4 mM AMP, and 4 mM ATP. 
Next, we summed the total intensity for labeled peptides and divided this value by the 
total intensity for all peptides. The reported % difference in labeling intensity is relative 
to the ATP value.  
Region 1 displayed no discernible change in the quantity of labeled peptide under any 
reaction conditions. Regions 2, 3, and 4, however, did display distinct decreases in lysine 
modification. K245 of region 2 displayed a 38% reduction in amount of labeled peptide 
detected (see Figure 4.6A (AMP) and 4.6B (ATP) for representative intensity and area 
images). Similarly region 3 displayed a 24% reduction and K477 of the C-terminal region 
4 experienced a 26% decrease in labeling efficiency. Overall, the lysine residues found 
within the C-terminal half of L6-7 and the C-terminus of GLUT1 display a 20-25% 
reduction in labeling by Sulfo-NHS-LC-Biotin (Figure 4.7).  
DISCUSSION 
ATP is the limiting reagent for primary active membrane transporters because the free 
energy released upon ATP hydrolysis is coupled to the movement of substrate against its 
concentration gradient as seen with proteins belonging to the ATP Binding Cassette 
(ABC) Superfamily [189]. Since GLUT1 is a passive glucose uniporter belonging to the 
Major Facilitator Superfamily (MFS), ATP hydrolysis is not necessary for solute 
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Figure 4.6 ATP and differential K245 accessibility to biotin labeling. GLUT1 was 
labeled to equilibrium by Sulfo-NHS-LC-Biotin in the presence of 4 mM AMP (A) or 
ATP (B). Proteoliposomes were digested with trypsin, and soluble peptides were 
examined by RP-HPLC-ESI-MS/MS. In each sample, two peptides containing K245 were 
isolated: the first (m/z = 1444.7 Da) with primary amino acid sequence 
R(232).GTADVTHDLQEMK(245).E, which was unlabeled and cleaved at K245 and the 
second (m/z = 2285.1 Da) with primary amino acid sequence 
R(232).GTADVTHDLQEMKEESR(249).Q, which was labeled (339.2 Da adduct 
covalently attached to K245) and cleaved at R249. The areas under each elution curve 
were obtained and analyzed as 
! 
%modified =
areamod ified
areaK245peptides"
. (A) Labeling 
conducted in the presence of 4 mM AMP. Peptide 1 Area () = 5.54x108, Peptide 2 Area 
() = 1.15x108, % modified peptide = 17.24%. (B) Labeling conducted in the presence of 
4 mM ATP. Peptide 1 Area () = 5.09 x108, Peptide 2 Area () = 5.73 x107, % modified 
peptide = 10.12%. 4 mM. K245 demonstrates a 41% decrease in labeling accessibility in 
the presence of 4 mM ATP. 
170
00.2
0.4
0.6
0 2 4 6
R
el
at
iv
e 
In
te
ns
it
y
Elution Sample
0
0.2
0.4
0 2 4 6
R
el
at
iv
e 
In
te
ns
it
y
Elution Sample
A
B
Figure 4.6
4 mM AMP
4 mM ATP
Unmodified Peptide
Modified Peptide
171
Figure 4.7 Decrease in GLUT1 lysine modification in the presence of 4 mM ATP. 
GLUT1 topography image to summarize all computations based upon the data isolated 
and analyzed as described in Figure 4.6. Region 1 (found on the N-terminal half of L6-7) 
considers lysine residues 225, 229, and 230; Regions 2 and 3 (found on the C-terminal 
half of L6-7) focuses on K245 and K255 and K256, respectively; Region 4 includes C-
terminal K477. –Δ%ATP represents the decrease in labeled peptides (versus all peptides 
containing regional lysine residues) found when GLUT1 equilibrium labeling by Sulfo-
NHS-LC-Biotin was conducted in the presence of 4 mM ATP. The –Δ%ATP ± SEM 
(four separate experiments) values for Region 1: 6.9 ± 3.4% (not significantly different ± 
4 mM ATP); Region 2: 37.6 ± 5% (reported to 95% confidence interval); Region 3: 24.1 
± 5% (reported to 90% confidence interval); Region 4: 25.5 ± 4% (reported to 95% 
confidence interval). 
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transport. The nucleotide, however, does play a significant role in regulating GLUT1-
mediated glucose transport, especially as observed in the human erythrocyte. Glucose 
transport asymmetry in red blood cells is directly caused by cytoplasmic ATP, as 
evidenced by studies with erythrocyte ghosts in which those ghosts lacking ATP display 
transport symmetry while ghosts resealed with 4 mM ATP demonstrate normal transport 
asymmetry [184]. Further characterization of the ATP-dependent GLUT1-mediated 
transport modulation illustrates that ATP binds near putative L8-9 and TM9, which are 
located at the interface between the lipid bilayer and the cytoplasm [64,135]. Based upon 
our observations in this study, it does not appear that ATP binding at this site is sterically 
responsible for reducing the sugar carrying capacity of GLUT1. It is more likely that 
ATP induces global conformational changes that reduce Vmax and Km value for sugar 
import, thus resulting in the ATP-dependent regulation of GLUT1-mediated glucose 
transport. 
GLUT1 has 36 potential trypsin cleavage sites that are conveniently distributed 
throughout the primary structure in both termini, multiple loops, and at the membrane-
aqueous interface of many transmembrane α-helices [155]. These locations are useful for 
identifying the regions that display reduced susceptibility to trypsin proteolysis when 
ATP is present in the reaction sample. Gel electrophoresis clearly shows that trypsin 
adequately digests GLUT1 in buffer, but that the addition of ATP reduces digestion 
efficiency as the half-life of this reaction increases by 10-fold, in a concentration-
dependent manner.  
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The global inhibition of trypsin digestion in the presence of 4 mM ATP manifests itself in 
the presence of more intense GLUT1 peptides arising from the N-terminus, the N-
terminal half of L6-7, extracellular L7-8, and the intracellular C-terminus. The C-terminal 
half of the protein (which includes the nucleotide-binding pocket) demonstrates a greater 
overall decrease in complete proteolysis (+ATP) as evidenced by the C-Ab and L7-8-Ab 
blots, which display either a greater signal intensity or a unique signal for peptides not 
observed when proteolysis occurs in the absence of ATP. The L-6-7 and N-terminal 
antibodies also detect ATP-dependent peptides. These peptides, however, are more likely 
due to ATP protection of potential trypsin cleavage sites that fall within nonregulatory, 
ATP-binding motifs. These sites of likely steric interaction include exofacial Walker 
motif residues GFSKLGKS (containing two potential trypsin cleavage sites) and an 
internal adenylate kinase motif including residues KSVLK (containing two trypsin 
residues) [135].  
We employed ELISA analyses to examine ATP-specific changes in IgG accessibility to 
full length GLUT1 protein. The results indicate that ATP inhibits the binding of the C-Ab 
and L7-8-Ab to full length GLUT1, while ATP does not antagonize GLUT1 recognition 
by antibodies recognizing the N-terminus or N-terminal half of L6-7. HEK cells can be 
transfected with wild type GLUT1 and isolated membranes display the same reduction in 
C-Ab binding observed in red cells, red cell membranes, and GLUT1 proteoliposomes. 
When the membranes from HEK cells expressing a GLUT1-GLUT4 chimera that 
replaces GLUT1 L6-7 with GLUT4 L6-7, but leaves the remainder of the membrane 
embedded α-helices and interconnecting loops intact are isolated, the interaction with 
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GLUT1 C-Ab is equal in the presence or absence of ATP. Although HEK cells 
expressing this construct display normal levels of glucose transport and cell surface 
expression relative to control, it appears as if GLUT1 L6-7 is required to mediate the 
ATP-dependent response.  
We pre-incubated GLUT1 with ATP prior to reaction with the NHS-biotin probe to 
determine if we could measure and localize ATP induced conformational changes to the 
transporter structure. GLUT1 displays a significant, global ATP-dependent decrease in 
lysine modification. We observed an approximately 40% decrease in GLUT1 NHS-biotin 
labeling efficiency when the reaction was carried out in 4mM ATP (versus competitive 
ATP antagonist AMP or kaline buffer). We were subsequently able to implicate specific 
ATP-sensitive GLUT1 lysine residues following trypsin-catalyzed proteolysis and ESI-
MS/MS.  
MS/MS quantitation studies show that K245, K255, K256, and K477 undergo a 
nucleotide-specific reduction in accessibility to NHS-biotin when labeled in the presence 
of 4mM ATP, whereas K225, K229, and K230 displayed no change in modification 
extent. The overall decrease in labeling as detected by quantitative mass spectrometry is 
approximately 25%. This implies that the majority of the global changes in accessibility 
can be attributed to these cytoplasmic residues, however, it is possible that additional 
changes are communicated to the extracellular loops or actual TM regions. Specifically, 
the L7-8 observations support ATP inhibition of K300 cleavage, however, this residue 
was difficult to isolate and quantify using the outlined MS technique. 
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Taking all of these observations together, it appears as if the GLUT1 C-terminus and the 
C-terminal half of L6-7 respond to ATP binding by undergoing a conformational change 
that reduces their respective accessibility to polar reagents. We propose a model where 
the GLUT1 C-terminal tail and L6-7 angle upward toward the cytoplasm-lipid bilayer 
interface, thereby modifying the translocation pathway. Figure 4.8 summarizes this idea 
by showing the putative locations of ATP-sensitive regions and residues that are 
protected from trypsin digestion (from Figure 4.2), antibody binding (from Figure 4.4), 
and covalent modification by Sulfo-NHS-LC-Biotin (from Figure 4.7).  
ATP has been proposed to inhibit glucose transport by increasing transporter affinity for 
sugar and introducing an additional sugar binding or occlusion step within the protein, 
which reduces Vmax for sugar import [28,85,185]. We envision the following series of 
conformational changes that mediate this response: the C-terminal tail interacts with L6-
7. The direct points of interaction likely include the primary sequence of at least K245-
K256, but lack K230 and regions more N-terminal, as suggested by MS and antibody 
binding observations. This interaction creates a cage structure that effectively inhibits 
glucose release into the cytoplasm as a result of the GLUT1-ATP interaction, thus 
regulating glucose transport (Figure 4.8). 
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Figure 4.8 Summary and model for ATP-mediated GLUT1 glucose transport 
regulation. Using the GLUT1 putative topography [64], the ATP-responsive domains 
are highlighted and drawn to reflect the proposed mechanism of ATP modulation. In the 
presence of AMP (left topography), all trypsin cleavage sites () and sites of antibody 
recognition sequence (colored rectangles; grey represents sites where IgG recognition was 
not detected; blue represents sites where IgG recognition was detected) are indicated with 
cytoplasmic L6-7 and the C-terminus extended into the cytosol. In the presence of ATP 
(right topography), the putative locations of ATP-sensitive regions and residues are 
highlighted: (grey ) represents cleavage sites protected from trypsin digestion (from 
Figure 4.2), colored rectangles: (green represents sites where IgG binding is unaffected by 
ATP and red represents sites where IgG binding is affected by ATP binding) represent 
changes in antibody binding (from Figure 4.4), and (red ) represents sites of decreased 
covalent modification by Sulfo-NHS-LC-Biotin (from Table 4.1). Taking all of these 
observations together, it appears that the GLUT1 C-terminus and the C-terminal half of L6-7 
respond to ATP binding by undergoing a conformational change that reduces their respective 
accessibility to polar reagents. We propose a model where the GLUT1 C-terminal tail (from 
K477 to the end) and L6-7 (all regions C-terminal to K245) interact by angling upward 
toward the cytoplasm-lipid bilayer interface, thereby modifying the translocation pathway. 
This model provides biochemical support for the observation that ATP inhibits glucose 
transport by introducing an additional sugar binding or occlusion step within the protein, 
which reduces Vmax for sugar import [28,85,185]. This interaction is proposed to create a 
cage that slows glucose release into the cytoplasm.  
 
178
Figure 4.8
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CHAPTER V 
 
 HUMAN TYPE 1 FACILITATIVE GLUCOSE TRANSPORT PROTEIN 
PRESENTS REDUCTANT-SENSITIVE CONFORMERS 
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Gail Patrick) 
  
Data presented in this chapter found in Figures 5.1, 5.2, and 5.3 and tables 5.1 and 5.2 
were collected and analyzed with Christopher A. Graybill, PhD. 
 
ABSTRACT 
The human type 1 facilitative glucose transport protein (GLUT1) displays cell-specific 
transport behavior, conformational states and electrophoretic mobilities. We investigated 
populations of GLUT1 conformational states and mobilities by gel electrophoresis and 
Mass Spectrometry (MS). GLUT1 was purified from human erythrocytes and 
deglycosylated using PNGaseF to produce two peptides that migrate as 49 and 41 kDa 
species upon SDS-PAGE. Both peptides cross-react with GLUT1 amino- and carboxy-
terminal peptide-directed IgGs and retain significant α-helical structure upon gel-elution 
as judged by circular dichroism. Mass analysis of 49 and 41 kDa peptides by MS results 
in mass recordings of 54 kDa. MS/MS sequence analysis of tryptic-, α-chymotryptic- or 
CNBr-digests of gel-eluted GLUT1 yields 90% sequence coverage. GLUT1 contains 6 
cysteine residues but none is fatty-acylated. Three cysteine residues (C133, C201, and 
C429) are alkylated by iodoacetamide in membrane-resident, non-reduced GLUT1. Two 
additional residues (C207 and C421) are alkylated following GLUT1-reduction. 
Nonreduced, alkylated, deglycosylated GLUT1 migrates as a 49 kDa peptide upon 
nonreducing SDS-PAGE whereas reduction/alkylation produces 49 and 41 kDa peptides. 
We conclude that C207, C421 and possibly C347 assume a primary role in GLUT1 intra-
chain folding by forming internal- or mixed-disulfides that promote the “49 kDa peptide” 
fold and the reductant-sensitive GLUT1 conformation. 
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 INTRODUCTION 
The Type 1 glucose transport protein (GLUT1) is a 54 kDa, Major Facilitator 
Superfamily (MFS) transport protein [189] expressed in the endothelial cells of the blood 
brain barrier [190,191], the perineurium [192] and the blood heart barrier [167,168]. 
GLUT1 is also expressed in astrocytes [191], cardiomyocytes [168,193] and erythrocytes 
[194] where it catalyzes passive uniport of pentose and hexose sugars [117]. GLUT1 thus 
assumes a principal role in cellular glucose import and glucose delivery to the brain, 
peripheral nerve and myocardium [167,195,196]. 
This central physiological function in combination with accessibility to biochemical 
[166,197] and molecular manipulation [49,155,190] has stimulated a significant body of 
work investigating GLUT1 higher order structure and transport mechanism. At this time, 
however, GLUT1 structure and mechanism are only partially understood 
[43,48,64,80,116,182,198-200]. Difficulties in characterizing GLUT1 function arise in 
part because GLUT1 catalytic behavior is cell-specific. For example, GLUT1 displays 
accelerated exchange transport and asymmetric net fluxes in human red cells [125] but 
net fluxes are symmetric in rabbit and rat erythrocytes [201,202] while accelerated 
exchange transport is absent when human GLUT1 is expressed in Saccharomyces 
cerevisiae [182]. Do cell-specific environmental factors or post-translational 
modifications influence GLUT1 function? Erythrocyte GLUT1 is a recognized substrate 
for serine-phosphorylation [203] and thiol-fatty-acylation [204]. Where examined, 
however, GLUT1 phosphorylation appears to be physiologically silent [203] and thiol-
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acylation is significantly sub-stoichiometric [204] suggesting that neither modification 
can account for variations in GLUT1 function. 
GLUT1 is glycosylated at Asn45 [45] and shows cell-specific glycosylation. Human red 
cell GLUT1 resolves as a diffuse protein band of Mr = 50-65 kDa upon SDS-PAGE 
which collapses to a 46 kDa species following deglycosylation [205]. Rat brain capillary 
GLUT1 and astrocytic GLUT1 resolve as 55 and 45 kDa species respectively [206]. 
Heterologously expressed human GLUT1 resolves as 52 and 49 kDa species in 
Saccharomyces [182] and as a 48 kDa species in Xenopus oocytes where it collapses to a 
39 kDa species following deglycosylation [45]. It appears, therefore, that both 
glycosylated and deglycosylated GLUT1 display cell-specific electrophoretic mobility. 
Anomalous electrophoretic behavior (Mrapp < theoretical Mr) may result in part from 
GLUT1 hydrophobicity causing the protein to oligomerize in sample buffer [182] and 
may increase GLUT1 SDS binding capacity. However, this cannot explain the different 
electrophoretic mobilities of deglycosylated human GLUT1 observed upon SDS-PAGE 
of erythrocyte and oocyte extracts.  
One factor that could contribute to cell-specific anomalies in GLUT1 SDS-PAGE 
mobility is GLUT1 redox state. Purified, nonreduced human GLUT1 forms noncovalent 
tetramers in non-denaturing detergents whereas reduced GLUT1 forms monomers and 
dimers [80,84,86,207]. Freeze-fracture EM analysis of membrane bilayer resident native 
and reduced GLUT1 reveals integral membrane particles of average diameter 10 and 6 
nm respectively [80,194]. GLUT1-sensitivity to reductant has been proposed to result 
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from a single intramolecular disulfide bridge between C347 and C421 leading to GLUT1 
oligomerization [86]. The results of some studies, however, question the functional 
significance of reductant sensitive, GLUT1 oligomers because wild-type- and cys-less 
GLUT1 catalyze similar rates of reductant-insensitive sugar transport when 
heterologously expressed in Xenopus oocytes [66]. 
The present study investigates the electrophoretic mobility of reduced and nonreduced 
deglycosylated GLUT1 and examines the accessibility of membrane-resident GLUT1 
cysteine sulfhydryl groups by mass spectrometric analysis of differentially alkylated 
GLUT1. We demonstrate the presence of reductant-sensitive GLUT1 folding states and 
show that specific intra-chain folds are associated with the accessibility of specific 
GLUT1 cysteine sulfhydryl groups. 
MATERIALS AND METHODS 
Materials Fresh, de-identified human blood was purchased from Biological Specialties 
Corporation (Colmar, PA). Protein determination assays, Pro Blue coomassie stain and 
Supersignal chemiluminescence kits were from Pierce (Rockford, IL). Glycerol-free 
endoglycosidase peptide-N-glycosidase F (PNGaseF) was purchased from New England 
Biolabs (Ipswich, MA). Nitrocellulose and Immobilon-P were purchased from Fisher 
Scientific (Hampton, NH). Purified rabbit anti-GLUT1 antibody (C-Ab) raised against a 
synthetic cytoplasmic carboxyl-terminal peptide of human GLUT1 (residues 480-492) 
was obtained from Animal Pharm Services, Inc. (Healdsburg, CA). Abgent, Inc. (San 
Diego, CA) produced two rabbit anti-GLUT1 antibodies, N-Ab and L7-Ab, raised against 
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synthetic peptides representing intracellular residues 1-13 and exofacial residues 
surrounding 299-311, respectively. Anti-GLUT1 antisera (δ-Ab) was raised against intact 
GLUT1 and exclusively recognizes exofacial epitopes [208]. All other reagents were 
purchased from Sigma-Aldrich (St. Louis, MO).  
Solutions Saline consisted of 150 mM NaCl, 10 mM Tris-HCL, and 0.5 mM EDTA, pH 
7.4. Lysis medium contained 10 mM Tris-HCl and 0.2 mM EDTA, pH 7.2. K-medium 
comprised 150 mM KCl, 10 mM Tris-HCL, and 0.5 mM EDTA, pH 7.4. Stripping 
solution contained 2 mM EDTA, 15.2 mM NaOH, pH 12. Tris medium contained 50 mM 
Tris-HCL, pH 7.4. Ammonium bicarbonate was 0.5% (63 mM), pH 9.0. Phosphate-
buffered saline containing Tween (PBS-T) comprised 140 mM NaCl, 10 mM Na2HPO4, 
3.4 mM KCl, 1.84 mM KH2PO4, 0.1% Tween, pH 7.3. 
Glucose transport protein purified from human erythrocytes Glucose transporter and 
endogenous lipids were purified from human erythrocyte membranes in the absence of 
reductant [84]. Purified, proteoliposome-resident GLUT1 was stored at -80ºC. Protein 
purity was assessed by SDS-PAGE, and function assayed by determination of GLUT1 
binding capacity for the transport inhibitor cytochalasin B (CCB). 
Gel Electrophoresis and Western Blotting GLUT1 protein was resolved on 8% 
polyacrylamide gels as described by Laemmli [162]. Immunoblot analysis using C-Ab (at 
1:10,000 dilution); N-Ab (1:250); L7-Ab (1:250) or δ-Ab (1:1,000) was as previously 
described [182].  
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GLUT1 Deglycosylation Aliquots of 50 µL purified GLUT1 (1 mg/mL in buffer) were 
incubated with 3 µL (1,500 activity units) PNGaseF for 1 hr at 37ºC. Deglycosylated 
GLUT1 was resolved using 8% SDS-PAGE. 
Sample Preparation for Mass Spectrometry Analysis Purified GLUT1 protein was 
separated from bulk, erythrocyte lipids using 8% SDS-PAGE. Coomassie-stained gel 
lanes guided protein band excision from unstained lanes. Gel slices were homogenized 
and incubated 16-72 hrs at 25ºC in HPLC grade H2O containing 0, 2, 4 % SDS or (4% 
SDS; 8% βME). GLUT1-containing supernatant was collected and GLUT1 isolated by 
chloroform/methanol/water precipitation [209]. Briefly, 300µL methanol, 100µL 
chloroform, and 200µL H2O were sequentially added to 100 µL of GLUT1-containing 
supernatant. The suspension was centrifuged (13,000 rpm; 10 min) to produce two phases 
with protein precipitate at the interface. The upper phase was aspirated and 200 µL 
methanol added to bottom phase to form a single phase. GLUT1 precipitate was 
sedimented by centrifugation (13,000 rpm; 5 min), the supernatant aspirated, and the 
pellet dried under nitrogen. Protein was resuspended to 1-5 mg/mL in 90% formic acid 
for MALDI-TOF-MS and LC-MS.  
Mass Spectrometry Data Collection For MALDI-TOF, the sample was applied to a 96 
well MALDI plate using a modified thin-layer technique. Samples were dried at ambient 
temperatures and pressures. All spectra were acquired using a Waters MALDI LR 
MALDI-TOF mass spectrometer in linear mode for intact protein samples. Pulse voltage, 
matrix suppression delay, and laser energy were adjusted to maximize resolution and to 
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minimize the signal-to-noise ratio. Spectra from 75 individual laser shots were averaged 
and smoothed using MassLynx 4.0 software. For LC-MS, 50-100 µg of sample in 90% 
formic acid was subjected to size exclusion chromatography (TSK-gel SW2000; 4 µm, 
125Å; 4.6 mm ID x 30 cm) using an isocratic gradient of chloroform:methanol:1% 
formic acid (4:4:1). Column eluant was injected into the mass spectrometer and the 
resulting spectra were deconvoluted using Waters MaxEnt 1 software. MALDI-TOF 
mass spectra were calibrated using the standards BSA (double and single charge states), 
aldolase and apomyoglobin. For each deglycosylated GLUT1 peptide spectrum, the Mw 
range of detected ions prior to smoothing is 54,174 - 54,667 and 27,083 - 27,319 for 
singly and doubly charged species respectively. The average ratio of singly to doubly 
charged species is thus 2.00029 ± 0.00041 (n = 19) indicating that mass analysis is 
consistent to within 0.015%. HPLC-ESI-MS Mw assignment was verified using purified 
commercial bacteriorhodopsin (BR) haloprotein yielding an Mobs of 26,784 (Mtheory = 
26,784) [210]. Commercial BR haloprotein is contaminated with trace bacteriorhodopsin 
apoprotein, detected as species with Mobs of 27,051, (Mtheory = 27,051). 
Preparation of Tryptic and α-Chymotryptic Digested GLUT1 Peptides Reduction and 
alkylation of membrane resident GLUT1 thiol groups was achieved using 10 mM 
dithiothreitol (DTT; 120 minutes at 37°C) followed by 54 mM iodoacetamide (60 
minutes at 20°C in the dark as described previously [86]). Unmodified or PNGase F 
treated (deglycosylated), reduced and alkylated GLUT1 proteoliposomes or gel-eluted 
protein were resuspended in K-medium (0.5 mg/mL, 55µL total reaction volume) or 
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water and digested with trypsin or α-chymotrypsin at a 10:1 ratio (GLUT1:enzyme, by 
mass) for 120 min at 30°C.  
HPLC Separation and Electrospray Ionization MS/MS Reverse Phase HPLC-ESI-
MS/MS analysis of fragmented GLUT1 was performed as described in Chapter III.  
Circular Dichroism Deglycosylated, purified GLUT1 was resolved using 8% SDS-
PAGE, and protein bands were eluted as previously described. Spectra were collected at 
room temperature using a Jasco J-810 spectropolarimeter from 300-180 nm at 20 nm/min 
with a data pitch of 0.5 nm. A 0.01 cm path length cuvette was used. Six spectra were 
averaged and control baselines subtracted. 
Determination of GLUT1 Free Sulfhydryl Content Reduced and nonreduced, purified 
GLUT1 (each at 100 µg/mL in 1 mL and exhaustively dialyzed to remove traces of DTT) 
were resuspended in TrisHCL medium or denatured in 0.5% SDS in 50 mM Tris-HC1, 3 
mM EDTA, pH 8.0, for 30 min. Solubilized, denatured protein was collected as 
supernatant by centrifugation (100,000 x g for 1 h at 4ºC) and quantitated. The free 
sulfhydryl contents of reduced and nonreduced GLUT1 were determined by using 
Ellman's reagent [211]. The reaction was initiated by addition of 100µL of freshly 
prepared 10 mM 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB). The course of the reaction 
at room temperature was recorded as the increase in absorbance at 412 nm. An extinction 
coefficient of 13,600 M-1.cm -1 at 412 nm for 2-nitro-5-thiobenzoic acid (NTB) was used 
to quantitate both reactions. All NTSB assays included the parallel, internal controls of 
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porcine insulin (three disulfides per molecule) and oxidized glutathione (one disulfide per 
molecule). 
RESULTS 
GLUT1 cysteine accessibility GLUT1 contains 6 cysteine residues (positions 133, 201, 
207, 347, 421 and 429; (14)). Native, proteoliposome-resident GLUT1 exposes 3.13 ± 0.2 
free thiol groups per GLUT1 monomer as assayed by DTNB (Ellman’s reagent) 
accessibility. Treatment with 50 mM DTT increases proteoliposomal GLUT1 free thiol 
content to 4.33 ± 0.4 thiols per GLUT1 monomer. By contrast, SDS-unfolded, non-
reduced GLUT1 exposes 2.8 ± 0.3 thiols per GLUT1 molecule while reduced and SDS-
denatured GLUT1 exposes 6.7 ± 0.4 thiols per monomer indicating that all cysteine 
residues are accessible to DTNB.  
GLUT1 electrophoretic mobility GLUT1 is glycosylated at asparagine 45 [45] causing 
the transport protein to smear as a diffuse band of molecular weight 50 to 65 kDa upon 
SDS-PAGE (see Figure 5.1A, lanes 1, 2 and 3). GLUT1-deglycosylation using N-
glycosidase F (PNGaseF) hydrolyzes the polysaccharide chain at the polypeptide 
backbone asparagine. Following PNGase treatment GLUT1 resolves as two distinct 
species on SDS-PAGE (Figure 5.1A, lanes 4 - 8). In Figure 5.1A, these peptides 
comprise a mobile band of 40 kDa, and a less mobile band of 47 kDa. In 9 separate 
experiments, the computed mass of the mobile band ranges from 36.5 to 43.9 kDa (mean 
± SEM = 40.7 ± 0.5 kDa) while the mass of the less mobile species ranges from 45.3 to 
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Figure 5.1 Effects of sulfhydryl chemistry on GLUT1 deglycosylation. (A) 
Deglycosylation in the presence of SDS & βME. SDS and βME were present during 
deglycosylation and concentrations are reported as % (v:v). Control lanes 1, 2, & 3 
contain glycosylated GLUT1 incubated in the absence of PNGaseF but at [SDS] and 
[βME] (%) of (0; 0), (0.5; 1), and (4; 8), respectively. Lanes 4 & 5 contain SDS (0.5 and 
4% respectively)-denatured GLUT1 exposed to PNGaseF. Lane 6 contains 
proteoliposome-resident GLUT1. The deglycosylation reaction of lane 6 was divided and 
each aliquot subsequently incubated with either (0%, 0%; lane 7) or (4%; 8%; lane 8). 
(B) Effect of SDS on the relative proportions of 41 (squares) and 49 (circles) kDa species 
observed upon GLUT1 deglycosylation. Deglycosylations were performed at fixed βME 
(1% - open symbols; 8% closed symbols) as described in Methods with increasing [SDS]. 
Ordinate: fraction of deglycosylated GLUT1; Abscissa: [SDS] in %. Lines drawn through 
the 1% βME data were computed by linear regression and have the following constants: 
41 kDa species, y = (0.47 ± 0.02) - (0.02 ± 0.01)[SDS], R2 = 0.687; 49 kDa species, y = 
(0.53 ± 0.02) - (0.02 ± 0.01)[SDS], R2 = 0.687. Curves drawn through the 8% βME data 
were computed by nonlinear regression assuming that relative content increases or 
decreases in a saturable manner according to the expression: y = ƒ0 + ƒ∆ 
[SDS]/(K+[SDS]) where ƒ0 is relative content at [SDS] = 0, ƒ∆ is relative content at 
saturating [SDS] and K is that [SDS] where y = ƒ0 + 0.5ƒ∆. The following results were 
obtained: 41 kDa peptide (filled squares), ƒ0 = 0.46 ± 0.05, ƒ∆ = 0.38 ± 0.08 K = 0.39 ± 
0.29; 49 kDa peptide (filled circles), ƒ0 = 0.54 ± 0.05, ƒ∆ = -0.38 ± 0.08, K = 0.39 ± 0.29. 
(C) Effect of βME on the relative proportions of 41 and 49 kDa species observed upon 
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Figure 5.1 (continued) GLUT1 deglycosylation. Deglycosylations were performed at 
fixed [SDS] (0.5% - open symbols; 4% closed symbols) with increasing [βME]. 
Ordinate: fraction of deglycosylated GLUT1; Abscissa: [βME] in %. Curves drawn 
through the data were computed by nonlinear regression assuming that relative content 
increases or decreases in a saturable manner according to the expression: y = ƒ0 + ƒ∆ 
[βME]/(K+[βME]) where ƒ0 is relative content at [βME] = 0, ƒ∆ is relative content at 
saturating [βME] and K is that [βME] where y = ƒ0 + 0.5ƒ∆. The following results were 
obtained: 0.5% SDS, 41 kDa peptide (open squares), ƒ0 = 0.40 ± 0.01, ƒ∆ = 0.61 ± 0.04 K 
= 9.0 ± 1.2; 49 kDa peptide (open circles), ƒ0 = 0.60 ± 0.01, ƒ∆ = -0.61 ± 0.04, K = 9.0 ± 
1.2. 4% SDS, 41 kDa peptide (filled squares), ƒ0 = 0.30 ± 0.01, ƒ∆ = 0.70 ± 0.17 K = 10.9 
± 3.1; 49 kDa peptide (filled circles), ƒ0 = 0.70 ± 0.01, ƒ∆ = -0.70 ± 0.17, K = 10.9 ± 3.1. 
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52.9 kDa (mean ± SEM = 48.6 ± 0.9 kDa). Henceforth, we refer to the mobile and less 
mobile species as 41 and 49 kDa proteins, respectively. 
Glycosylated GLUT1 electrophoretic mobility shows no significant change in the 
presence of low SDS (0.5%) or βME (1%), but displays increased mobility of leading 
edge peptides and more diffuse staining in the presence of 4% SDS and 8% βME (Figure 
5.1A, lanes 1-3). Deglycosylated GLUT1 was exposed to low and high SDS/βME 
concentrations either during (Figure 5.1A lanes 4-6) or following (Figure 5.1A lanes 7-8) 
deglycosylation. Increased SDS and βME cause a mobility shift favoring the 41 kDa 
peptide over the 49 kDa peptide. At 1% [βME] (open symbols Figure 5.1B), 
deglycosylated peptide mobility is independent of [SDS]. At 8% [βME] (Figure 5.1B, 
filled symbols), the 49 kDa species is reduced to a 41 kDa peptide in a saturable manner 
with increasing [SDS]. At low [SDS] (0.5%, Figure 5.1C, open symbols) or high [SDS] 
(4%, Figure 5.1C, filled symbols), the 49 kDa deglycosylated species is converted to the 
41 kDa form in a saturable manner with increasing [βME]. 
Deglycosylated GLUT1 was subjected to SDS-PAGE, the 49 kDa species was excised 
from the gel, eluted into 0%, 2%, and 4% SDS plus 4% and 8% SDS/βME to generate 
41, 49, 49, and 41 kDa species respectively (see Figure 5.2A) and the resulting samples 
were subjected to analysis by circular dichroism (Figure 5.2B). Samples eluted into 2% 
and 4% SDS exhibit spectral qualities consistent with the presence of α-helical content. 
Specifically, these include signal minima at 208 and 222 nm and a molar elipticity ratio 
value (195:222 nm) greater than 2.1 (Figure 5.2B; ([212])). Samples eluted into 0% SDS 
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Figure 5.2 GLUT1 secondary structure analyses by CD. (A) Deglycosylated purified 
GLUT1 was resolved using 8% SDS-PAGE, and excised protein bands were eluted into 
buffer containing 0% (lane 2), 2% (lane 3), 4% (lane 4) SDS and into 4% SDS + 8% 
βME (lane 5). (B) CD Spectra were recorded as described in the methods. Ordinate: 
mean residue elipticity in degree.cm2.dmol-1 x 10-3. Abscissa: wavelength, nm. Spectra of 
peptides eluted from lanes 2, 3 and 4 are indicated. 
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do not display these α-helical characteristics as prominently. CD spectra of samples 
eluted into 4% SDS and 8% βME were uninterpretable owing to the high concentration 
of reductant in the sample. 
Identity of deglycosylated species Multiple deglycosylation products could result from 
GLUT1 proteolysis, physiologic covalent modification, artifactual covalent modifications 
or multiple intra-chain folds of identical molecular species. Deglycosylation in the 
presence of serine protease inhibitors does not alter the appearance of 49 kDa and 41 kDa 
peptides (data not shown). PNGase F concentration, total reaction time, and reaction 
temperature were each adjusted without effect on the multiple banding. Calf alkaline 
phosphatase (CAP), which alters the mobility of phosphorylated proteins by catalyzing 
their dephosphorylation and thereby altering protein mass/charge ratio and SDS binding 
[213,214], is without effect on GLUT1 electrophoretic mobility (data not shown). Gas 
chromatography-mass spectrometry (GC-MS) of deglycosylated GLUT1 does not detect 
significant GLUT1 fatty acyl chain modifications (GLUT1:long chain fatty acid molar 
ratios observed = 1:0.03). These results suggest that 41 and 49 kDa GLUT1 
deglycosylation products do not result from GLUT1 proteolysis, 
phosphorylation/dephosphorylation or thiol fatty acylation. 
Immunoblot analysis of deglycosylated GLUT1 suggests that 49 kDa and 41 kDa GLUT1 
bands represent identical molecular species. The antibodies tested were: N-Ab, directed 
against GLUT1 residues 1-13; L7-Ab, directed against GLUT1 residues 299-311 
(putative extracellular loop 7); δ-Ab, directed against nonreduced, nondenatured GLUT1 
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and which recognizes exofacial GLUT1 epitopes [208]; and C-Ab, directed against 
GLUT1 residues 480-492 (Figure 5.3). All 4 antibodies recognize the 49 and 41 kDa 
peptides suggesting that full-length GLUT1 is present in both bands. In these experiments 
and those of Figure 5.2, the 41 kDa peptide appears to be the major deglycosylation 
product.  
Glycosylated GLUT1 and the 49 kDa and 41 kDa GLUT1 deglycosylated species display 
nearly identical amino acid compositions that are also consistent with the predicted amino 
acid composition of intact GLUT1 (Table 5.1). The unexpectedly high glycine and 
tyrosine contents of 41 and 49 kDa peptides respectively likely result from the use of 
glycine-containing buffers during gel electrophoresis and from TRIS contamination 
which produces a large artifact peak that co-elutes with tyrosine on the amino acid 
analyzer [215,216]. 
Mass Spectrometry of GLUT1 The theoretical Mw of deglycosylated, full length GLUT1 
is 54,118. Analysis of gel-eluted 49 and 41 kDa GLUT1 peptide mass by MS yields Mw 
values of 54,440 and 54,435 respectively (Table 5.2). Experimental mass (accurate to at 
least 0.015%) therefore exceeds GLUT1 theoretical mass by as much as 322 Da (0.59%). 
If the 49 and 41 kDa species are derived from GLUT1 - a hypothesis supported by 
immunoblot and amino acid analyses - what is the origin of the extra mass associated 
with GLUT1 peptides? 
Tables A2.1 and A2.2 summarize the results of HPLC MS/MS sequence analysis of 
tryptic and α-chymotryptic fragments of gel-eluted GLUT1 respectively. GLUT1 
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Figure 5.3  Immunoblot analysis of intact and deglycosylated GLUT1. Panels (A), 
(B), (C), & (D) represent immunoblots using C-Ab, N-Ab, L7-Ab, and δ-Ab, 
respectively. Lane 1 is glycosylated GLUT1 and lane 2 is GLUT1 deglycosylated under 
denaturing conditions (0.5% SDS, 1% NP-40, and 1% βME). The mobility of molecular 
weight standards is indicated to the left of each blot. The computed mass (kDa) of 
selected peptides and their mobilities are indicated in italics and by arrows respectively at 
the right of each blot. 
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Legend for Table 5.1 Amino acid analysis of intact and deglycosylated GLUT1. 
Deglycosylated, eluted GLUT1 was separated on 8% SDS-PAGE and electrophoretically 
transferred to a PVDF membrane. Peptides were stained using amido black then 49 kDa 
and 41 kDa deglycosylated peptides and glycosylated GLUT1 were excised for amino 
acid analysis (Harvard Microchemistry and Proteomics Facility, Cambridge, MA). 
Peptides (2.4-7.6 pmol) were hydrolyzed in 6N HCL and derivatized to 
phenylthiocarbamyl (PTC)-amino acids for analysis using an Applied Biosystems 420A 
Amino Acid Analyzer. The table displays the amount of amino acid present in each 
sample relative to the total amino acid composition of the sample (% of total). Results are 
shown for: apredicted amino acid content of GLUT1; bamino acid content of glycosylated 
GLUT1; camino acid content of the 41 kDa deglycosylation product; damino acid content 
of the 49 kDa deglycosylation product. Glycine and tyrosine contents may be elevated in 
some samples owing to the glycine and Tris contents of the various buffers employed. 
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amino acid atheory bGLUT1 c41 kDa d49 kDa
ala 7.1% 9.3% 8.4% 8.6%
arg 4.4% 6.1% 5.5% 5.6%
asx 4.4% 5.8% 5.5% 6.0%
glx 9.4% 4.6% 5.9% 6.2%
gly 9.6% 9.5% 18.7% 8.5%
his 1.0% 1.5% 1.4% 1.4%
ile 7.7% 6.9% 6.0% 6.2%
leu 12.1% 13.1% 11.1% 11.8%
lys 3.3% 5.4% 4.7% 4.8%
met 3.5% 2.2% 2.2% 2.2%
phe 8.1% 7.2% 6.1% 6.1%
pro 4.8% 4.8% 4.2% 4.1%
ser 7.3% 7.4% 6.4% 7.5%
thr 5.4% 4.3% 4.0% 3.8%
tyr 2.7% 2.8% 1.9% 9.2%
val 9.2% 9.1% 8.0% 7.9%
Table 5.1
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Legend for Table 5.2 Full-length deglycosylated GLUT1 mass as detected by Mass 
Spectrometry. aMw was measured by MALDI-TOF or by ESI-MS analysis. bThe more 
mobile, 41 kDa deglycosylated GLUT1 peptide was obtained by eluting the 49 kDa 
species into SDS- and βME-free ddH2O. cThe less mobile, 49 kDa deglycosylated 
GLUT1 peptide was obtained by eluting the 49 kDa species into ddH2O containing 2% 
SDS. d41 and 49 kDa species were mixed in equal proportions for MALDI-TOF. 
eGLUT1 was eluted into SDS (4%) + βME (8%) for ESI-MS measurements. Results are 
shown as the mean ± SEM. 
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sequence coverage is extensive, corresponding to 59% (tryptic digests) and 71% (α−
chymotryptic digests) yielding combined sequence coverage of 90%. Five of six total 
cysteine residues (C201, C207, C347, C421 and C429) are resolved in these analyses 
(cysteine 133 was not detected) and, with the exception of C347, each is observed both as 
unmodified cysteine and as a cysteine-acrylamide adduct (cys-S-β-propionamide or Cys-
S-Pam). C347 alone was observed as unmodified cysteine. Thus any specific GLUT1 
molecule in the sample could contain as many as 4 modified cysteine residues or as few 
as zero. CNBr digestion of formic acid dissolved, eluted GLUT1 provides less extensive 
(20%) sequence coverage by MS/MS (Table A2.3). This may result from the great length 
of several GLUT1 CNBr fragments that complicates MS/MS sequence analysis. CNBr 
sequence coverage includes GLUT1 peptide 121 – 142, containing cysteine residue 133 
in both unmodified and cys-S-β-propionamide forms. Hence all GLUT1 cysteine residues 
barring C347 may be observed as unmodified cysteine and as a modified cysteine 
containing an acrylamide adduct. Furthermore, of the 9 serine residues detected in CNBr 
fragments, 7 serine residues are observed both as unmodified and formylated residues. 
Hence electrophoresis and formic acid exposure can result in variable GLUT1 mass 
additions within any given sample ranging from 0 to as great as 1,363 Da (36 
formylations + 5 acrylamide adducts; see Table 5.3). This may explain the divergence 
between experimental and predicted GLUT1 masses obtained upon MALDI-TOF and 
ESI-MS analysis of full-length GLUT1. 
Are deglycosylated GLUT1 species and cysteine classes related? We subjected GLUT1 
to alkylation and or reduction/alkylation prior to gel electrophoresis to avoid variable 
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Legend for Table 5.3 Summary of GLUT1 ESI-MS/MS sequence coverage (trypsin 
and α-chymotrypsin, CNBr digests) and covalent modification to gel-eluted GLUT1. 
aIndicates the N-terminal cleavage site. bIndicates the C-terminal cleavage site. Total 
indicates the number of residues sequenced in the peptide. cIndicates the total sequence 
coverage that is also expressed as % coverage assuming human GLUT1 comprises 492 
residues. dIndicates a compilation of cysteine residues identified in tryptic and α-
chymotryptic digests (Column 1) or in CNBr digests (column 2) of GLUT1 and whether 
the cysteine is resolved as efree cysteine or as facrylamide-modified cysteine. ND 
indicates that the residue was not detected. gIndicates serine or threonine residues 
detected in CNBr digests of GLUT1 and whether the residue is resolved as an unmodified 
amino acid or as a formylated amino acid. ND indicates that the residue was not detected. 
hIndicates total GLUT1 sequence coverage obtained from tryptic, chymotryptic and 
CNBr digests of GLUT1. 
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Trypsin CNBr
11 126 115 1 13 12
153 183 30 77 142 65
212 218 6 244 251 7
225 229 4 351 364 13
232 333 101 97
458 492 34 % Coverage 20%
290
% Coverage 59%
hCNBr, Trypsin, and α-Chymotrypsin
eCys-SH fCys-S-Pam
Unmodified Modified
S4 Yes Yes
α-chymotrypsin S5 Yes Yes
T9 Yes yes
8 26 18 S80 Yes Yes
48 61 13 S82 Yes ND
72 86 14 S95 Yes ND
90 115 25 S106 Yes Yes
127 132 5 S113 Yes Yes
152 214 62 S118 Yes Yes
215 228 13 T136 Yes ND
231 251 20 T137 Yes ND
278 291 13 S248 Yes Yes
292 320 28 T352 Yes ND
336 363 27
373 409 36 Cysteine residues
416 492 76 C133 Yes Yes
350
% Coverage 71%
dCysteine Residues eCys-SH fCys-S-Pam 1 142 141
133 ND ND 152 229 77
201 Yes Yes 231 333 102
207 Yes Yes 336 364 28
347 ND Yes 373 409 36
421 Yes ND 416 492 76
429 Yes Yes 460
% Coverage 93%
aStart bEnd Total
aStart bEnd Total
aStart bEnd Total
aStart bEnd Total
cTotal
cTotal
cTotal
cTotal
Table 5.3
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blocking of free thiols by acrylamide. GLUT1 was treated ± reductant (10 mM DTT, 2 hr 
at 37ºC), washed in reductant free medium then alkylated using 54 mM iodoacetamide 
(60 minutes at 20°C in the dark). Iodoacetamide-reactive GLUT1 thiols were identified 
by MS/MS sequence analysis of tryptic and α-chymotryptic digests of iodoacetamide-
alkylated, proteoliposomal GLUT1 (Table 5.4; Figure 5.4). Alkylated cysteine residues 
C133, C201 and C429 are detected in nonreduced GLUT1 but alkylated C207, C347 and 
C421 are not detected. Following GLUT1 reduction by DTT and subsequent alkylation, 5 
of the 6 total GLUT1 cysteine residues are resolved as alkylated species (Figure 5.4, 
Table 5.4; only C347 is not observed). Unmodified cysteine residues were not detected in 
GLUT1 proteoliposome samples. Peptides containing alkylated histidine, methionine or 
tyrosine residues were not detected. 
Is GLUT1 SH-group availability associated with specific GLUT1 electrophoretic 
mobility? GLUT1 was deglycosylated then either: 1) processed no further; 2) reduced, 3) 
alkylated without reduction or 4) reduced and alkylated. Following these treatments, 
deglycosylated GLUT1 was subjected to reducing and nonreducing SDS-PAGE (Figure 
5.5). The result is the generation of two peptides that migrate with Mrapp 49 and 41 kDa 
upon reducing SDS-PAGE. The 49 kDa peptide dominates under nonreducing SDS-
PAGE unless deglycosylated GLUT1 is first reduced then alkylated in which case both 
49 and 41 kDa species are observed. This suggests that alkylation of reductant-sensitive 
GLUT1 cysteine residues C207 and C421 prevents their re-oxidation upon nonreducing 
electrophoresis. 
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Figure 5.4 MS/MS analysis of accessible GLUT1 thiols. Sequential trypsin and α-
chymotrypsin (10:1 protein:enzyme) digests of alkylated (A) or reduced and alkylated 
(B) GLUT1 proteoliposomes. Boxed residues indicate the identity of the N-terminal 
amino acid and match the y-ion series peaks (blue peaks) in the spectrum below. (A) 
Alkylated peptide from nonreduced GLUT1 containing cysteine 429. Doubly charged ion 
MS/MS spectrum of this triply charged ion with a precursor mass of 4162.3 Da. The 
sequence includes residues 423-456 with cleavage sites at F422 and K456 
(F.QYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETK.G) and a +57 Da adduct at 
cysteine 429. Retention time = 41.98 minutes; MS/MS Scores: XCorr = 5.561, ΔCn = 
0.622, Sp = 942.2, and RSp = 1. (B) Alkylated peptide from reduced GLUT1 containing 
cysteine 421. MS/MS spectrum of the singly charged ion with a precursor mass of 726.3 
Da. The sequence includes residues 417-422 with cleavage sites at F416 and F422 
(F.IVGMCF.Q) with a +57 Da adduct on the cysteine residue. Retention time = 11.10 
minutes; MS/MS Scores: XCorr = 1.542, ΔCn = 0.434, Sp = 399.3, and RSp = 1. 
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Legend for Table 5.4 MS/MS analysis of cysteine accessibility to iodoacetamide in 
GLUT1 proteoliposomes. aGLUT1 was deglycosylated and subjected to sequence 
analysis by α-chymotryptic digestion, HPLC- separation of proteolytic fragments and 
subsequent MS-MS analysis. Prior to proteolysis, GLUT1 and alkylation, GLUT1 was 
treated bwithout our cwith DTT reduction (see methods). Samples were then alkylated 
with iodoacetamide and subjected to proteolysis/MS-MS analysis. dThe table illustrates 
whether each specific GLUT1 cysteine residue is not detected (ND), detectable as an 
alkylated (yes) species or as a free sulfhydryl (no). 
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133
201
207
347
421
429
bReduced 
GLUT1
aNon-reduced 
GLUT1
GLUT1 Cysteine
Residue
yes
yes
yes
ND
yes
yes
cyes
no
yes
ND
no
yes
Table 5.4
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Figure 5.5 Effects of alkylation/reduction on degylcosylated GLUT1 mobility. Lanes 
1 through 5 were resolved under reducing conditions (sample buffer contained 3.65% 
βME). Lanes 6 through 9 were resolved under nonreducing conditions. Lane 1 contains 
glycosylated GLUT1. GLUT1 was deglycosylated then treated the following treatments 
were made: lanes 2 & 6 - Kaline for 2 hr at 37ºC followed by 1 hr at 20ºC with Kaline; 
lanes 3 & 7 - 10 mM DTT for 2 hr at 37ºC followed by 1 hr at 20 ºC with Kaline; lanes 4 
& 8 - Kaline for 2 hr at 37ºC followed by 1 hr at 20ºC with 54 mM iodoacetamide; lanes 
5 & 9 - 10 mM DTT for 2 hr at 37ºC followed by 1 hr at 20ºC with 54 mM 
iodoacetamide. The mobility of molecular weight markers (kDa) is indicated at the left. 
The calculated mass of GLUT1 peptides is indicated at the right of the gel. Locations of 
PNGaseF and RhD peptides are also indicated. 
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DISCUSSION 
The human type 1 facilitative glucose transport protein displays cell-specific transport 
behavior [182], conformational states [86,191] and electrophoretic mobilities [191] 
suggesting that cell-specific environmental factors or post-translational modifications 
influence GLUT1 folding and function. Recognized GLUT1 post-translational 
modifications include serine-phosphorylation [203] and thiol-fatty-acylation [204]. 
GLUT1 phosphorylation appears to be physiologically silent [203] and thiol-acylation is 
significantly sub-stoichiometric [204] suggesting that neither modification accounts for 
variations in GLUT1 function. GLUT1 sugar transport capacity and oligomeric state are 
reduced in red cells by reductants [86,217] and GLUT1-mediated sugar transport is 
inhibited by thiol-reactive compounds such as pCMBS and N-ethylmaleimide [66] 
suggesting that GLUT1 redox state affects GLUT1 structure and function. 
Membrane proteins often retain intra- and inter-chain structures in SDS that cause 
anomalous electrophoretic mobility [218]. Hemagglutinin (HA) ectodomain folding 
requires formation of six intra-chain disulfide bonds. Intermediate forms of HA 
containing fewer than 6 disulfides can be resolved by SDS-PAGE indicating that intra-
chain disulfides affect the compactness and/or SDS binding capacity of polypeptides, 
which, in turn, alters polypeptide electrophoretic mobility [219]. Lemmon et al [220] 
have demonstrated that dimerization of the glycophorin A (GpA) transmembrane α-helix 
during SDS-PAGE is spontaneous and highly specific and exploited this behavior to 
establish the sequence and structural determinants of the dimerization interface. NMR 
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studies confirm that the alpha-helical structure of the GpA transmembrane domain is 
retained in SDS [221] and the conclusions of these studies were later affirmed by the 
TOXCAT system in which determinants of transmembrane helix-helix oligomerization in 
a natural membrane environment were studied by a recombinant approach [222]. 
The goal of the present study was to determine whether reductant-sensitive GLUT1 
oligomeric structures and transport function are also associated with specific intra-chain 
folds. Our approach was to ask whether GLUT1 displays altered mobility upon 
reducing/nonreducing SDS-PAGE. Erythrocyte GLUT1 glycosylation is so 
heterogeneous, however, that the protein smears broadly during SDS-PAGE [166,197]. 
We therefore deglycosylated purified GLUT1 by use of PNGaseF which cleaves between 
the innermost GlcNAc and asparagine residues of high mannose oligosaccharides from 
N-linked glycoproteins [223]. This generates two peptides that migrate with Mrapp 49 and 
41 kDa upon reducing SDS-PAGE. The 49 kDa peptide is the major species observed 
during nonreducing electrophoresis. When deglycosylated GLUT1 is reduced then 
alkylated, both 49 and 41 kDa species are observed upon SDS-PAGE. 
Immunoblot and MALDI-TOF analyses confirm that both peptides are full-length 
GLUT1. MALDI-TOF analysis indicates that the peptides have near identical Mw values 
of 54,440. This Mw is significantly greater than the theoretical mass of deglycosylated 
GLUT1 (54,118) but MS/MS sequence analysis of tryptic, α−chymotryptic or CNBr 
digests of GLUT1 demonstrates that the additional mass results from formylation of 
serine and threonine residues during exposure to formic acid and from alkylation of 
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cysteine residues by free acrylamide during PAGE. Moreover, any given GLUT1 sample 
demonstrates both modified and unmodified amino acids at any specific serine, threonine 
or cysteine resulting in significant, internal sample mass heterogeneity. 
GLUT1 contains two classes of cysteine residues. The accessible class (C133, C201 and 
C429) presents sulfhydryl groups for alkylation by iodoacetamide whether GLUT1 is 
folded and fully functional in the lipid bilayer or unfolded in SDS. The inaccessible class 
(C207 and C421) is reactive only following GLUT1 reduction by DTT or βME. Although 
DTT and iodoacetamide react with the inaccessible cysteine residues in folded, 
membrane-resident GLUT1, Ellman's reagent (DTNB) is unable to react with all GLUT1 
cysteine residues unless the transporter is first unfolded in SDS and reduced. This may 
result from the significantly greater van der Waal's volume of DTNB (199 cm3/mol) 
versus iodoacetamide (53.5 cm3/mol) or DTT (74.7 cm3/mol), which might limit DTNB 
access to occluded cysteine residues in native GLUT1. Neither unmodified nor 
iodoacetamide-alkylated C347 were detected in ESI-MS/MS studies of proteoliposomal 
GLUT1 although this residue was detected with and without an acrylamide adduct 
following reducing SDS-PAGE, gel elution and CNBr digestion. C207 (not C201) 
presents the pCMBS-sensitive intracellular thiol when GLUT1 is heterologously 
expressed in Xenopus oocytes [66]. The present study, however, suggests that C207 is 
inaccessible without prior reduction whereas C201 is accessible.  
These observations support the hypothesis that the 41 kDa deglycosylated GLUT1 
peptide represents maximally-alkylated GLUT1 whereas the 49 kDa species contains 
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only alkylated C133, C201 and C429. We further suggest that the oxidation state of 
C207, C421 and possibly C347 are causally linked to GLUT1 electrophoretic mobility. 
When expressed in Xenopus oocytes, both wild-type and cys-less GLUT1 resolve as two 
peptides upon immunoblot analysis [68] - a 55 kDa species and a more mobile 45 kDa 
peptide. These may represent two glycosylated forms of GLUT1 as suggested by the 
authors. Wild-type GLUT1, however, resolves largely as the 55 kDa species whereas cys-
less GLUT1 resolves predominantly as the 45 kDa peptide. Reintroduction of a single 
cysteine residue at specific locations in GLUT1 membrane spanning helix (TM) 5 
increases the amount of 55 kDa peptide relative to 45 kDa peptide. These results are also 
consistent with the hypothesis that the electrophoretic mobilities of cys-less GLUT1 and 
fully alkylated GLUT1 are equivalent. What roles might C207, C347 and C421 play in 
GLUT1 intra-chain folding? Several possibilities exist. 1) Two of these residues form an 
internal disulfide bridge. 2) All 3 residues form mixed disulfides with other molecular 
species. 3) These cysteine residues are thiol-acylated by myristic or palmitic acid. While 
cysteine 207 is topographically well suited for thiol-fatty-acylation [48,64], the extent of 
GLUT1 modification is sub-stoichiometric (see [204] and here). Earlier peptide mapping 
studies have indicated that a disulfide bridge does not link GLUT1 amino- and carboxy-
terminal halves [86]. These observations suggest that GLUT1 cysteine residues C207, 
C347 and C421 form mixed disulfides with low molecular weight species (e.g. 
glutathione) or that C347 and C421 form a disulfide and C207 forms a mixed disulfide. 
217
CHAPTER VI 
 
DISCUSSION AND FUTURE DIRECTIONS 
INTRODUCTION 
Advanced research technology provides new tools to probe and explain complex 
biological systems. We have employed two such advances over the course of this 
research. First, we utilized a rapid quench flow device to measure the earliest stages of 
GLUT1-mediated glucose transport in red blood cells. Second, we developed and applied 
a mass spectrometry based technique to an experimentally difficult family of molecules, 
the integral membrane transport proteins. We used MS to provide optimal sequence 
coverage, peptide separation, and the ability to detect single amino acid modifications. 
Our findings first demonstrate that carriers form conformationally dynamic structures 
unlike their channel counterparts [52,165] and second, that the structural organization of 
GLUT1 presents distinct features that do not completely mimic the consensus helix 
packing model obtained by X-ray diffraction analysis of crystallized, but distantly related 
bacterial MFS transporters [5,33-35,39]. The techniques we have developed should allow 
us to answer more difficult and specific questions related to the structure-function 
relationship of carrier-mediated transport.  
GLUT1-MEDIATED TRANSPORT: “THE RAPID PHASE” 
Previous works have examined the rapid kinetics of glucose transport in erythrocytes 
[224]. These studies primarily focused on the half-turnover time for a single glucose 
transport event where the transporter converted from the e1 to e2 conformation and 
determining the number of GLUT1 molecules present per red cell [41,46]. We have 
extended these studies to consider the entire glucose transport import process [87,132]. 
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We were able to isolate a previously unidentified rapid phase of transport that precedes 
the fast and slow phases of glucose uptake into the erythrocyte. This rapid phase is a first 
order reaction, is protein-mediated (it is impeded by e1- and e2-inhibitors CCB and 
phloretin, respectively), and is completely independent of ATP modulating effects. 
Additionally, sugar transport measurements in unsealed red blood cells ghosts, previously 
treated with trypsin to remove cytoplasmic portions, and quenched by e2- and e1-
inhibitors phloretin and CCB showed substrate specific trapping of glucose within the 
membrane bound transporter. By observing glucose uptake rates at multiple temperatures, 
we were able to obtain the activation energies for each step. Tremendous conformational 
dynamics are required to mediate conversion from e2.S through the intermediate e(S) to 
e1.S, the sugar translocation steps. We propose that the rapid phase, whose kinetics we 
have measured and that we have trapped with inhibitors, represents the intermediate step 
in the e2-e1 conversion and may be schematically represented as e2+S2→e(S)→e1+S1. 
Recent crystallographic evidence showing MFS transporters locked in this arrangement 
have been observed for OxlT and EmrD, thereby offering support to the occlusion state 
model [5,34,39]. 
THE TRANSPORTER STRUCTURE-FUNCTION RELATIONSHIP 
These findings prompted the literature review presented in Chapter I to determine if there 
was a common structural basis for the functional mechanism observed among transport 
proteins. The structural and corresponding functional characteristics observed in 
crystallized membrane transport proteins illustrate that there are numerous ways to 
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catalyze substrate transport across the plasma membrane. The most common structural 
feature is the predominantly α-helical nature of each transmembrane domain. Although 
not all families have twelve transmembrane spanning helices like MFS transporters, the 
secondary structure and role of the α-helices in forming the pore pathway are quite 
similar. For many of these transporters, the general transport mechanism follows the 
Albers-Post model that describes MFS-mediated transport. The proteins present an 
outward facing, e2-like, substrate binding site that undergoes a series of conformational 
changes to eventually present the opposite, inward facing, e1-like conformation. Despite 
these similarities in basic transport mechanism, P-type ATPase and ABC transporters rely 
heavily on cytoplasmic domains and ATP binding to induce the conformational changes 
that catalyze transport. ABC transporters catalyze only unidirectional substrate transport, 
MCF transporters must exist as a dimer to undergo conformational changes, and CPA 
transporters minimize the extent of conformational changes required for substrate 
translocation, markedly increasing the turnover rate. It appears as if the structure function 
relationship is highly dependent upon cellular environments. Reviewing each mechanism 
with relation to the MFS transporters reveals why the study of GLUT1 by mass 
spectrometry provides a bridge for understanding MFS carrier-mediated transport. 
APPLYING MASS SPECTROMETRY TO THE STRUCTURE-FUNCTION RELATIONSHIP 
Recent success in analysis of membrane transport proteins is not limited to the 
application of three-dimensional crystallography. Mass spectrometry of membrane 
proteins is yielding increasingly useful results. It has become the primary technique for 
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proteomics studies attempting to identify all proteins within a given cell type or 
organism, or when comparing the appearance or quantity of specific proteins in healthy 
versus diseased cells [225]. As with crystallography, mass spectrometry has been more 
successfully applied to the study of hydrophilic proteins than to analysis of membrane 
embedded proteins such as transporters [106,107]. Successful identification of integral 
membrane proteins is lacking in many proteomics studies. Additionally, MS studies that 
focus upon the relationship between integral membrane protein structure and function are 
also limited. The extremely hydrophobic nature of the transmembrane domains, the 
tendency of these peptides to aggregate during HPLC separation, the presence of reactive 
cysteine residues, and the overabundance of contaminating soluble proteins found in 
cellular samples contribute to these problems [107]. A comprehensive literature review 
reveals that eukaryotic Aquaporin 0 and Band 3 (the erythrocyte anion transporter) and 
prokaryotic LacY, EmrE, and MOMP are the only integral membrane proteins for which 
intensive mass spectrometry experiments have been conducted [108-113]. Each of these 
studies has contributed in one way or another to improving MS techniques applied to 
integral membrane proteins. We will consider the findings of this thesis in terms of how 
much we have learned about GLUT1 in light of each of these previous studies.  
AQUAPORIN AND SEQUENCE COVERAGE 
Aquaporin 0 (AQP0) is an integral membrane protein containing 263 amino acids that 
comprise six transmembrane spanning domains with N and C-termini exposed to the 
cytoplasm. It functions as a water channel within the plasma membrane of mammalian 
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lens cells. By supplementing standard tryptic digests with pepsin digests at highly acidic 
pH values, AQP0 was sequenced in its entirety [109]. The utilization of pepsin digestion 
permitted the sequencing of large tryptic fragments that were previously identified only 
by the MALDI and LC-MS recorded m/z values. Complete sequence coverage is 
significant because all amino acid residues can potentially be studied for post-
translational or experimental modifications. We have achieved greater than 85% GLUT1 
sequence coverage by trypsin, α-chymotrypsin, and cyanogen bromide catalyzed 
proteolysis. This analysis covered all GLUT1 domains including intra- and extracellular 
loop regions, the amino and carboxy termini, and entire transmembrane helices. This 
provided us with the ability to study all regions of the protein and established a means to 
examining the GLUT1 structure function relationship. 
ANION TRANSPORTER AND COVALENT MODIFICATIONS 
The anion transporter (Band 3; AE1) exchanges chloride and bicarbonate ions across the 
human erythrocyte plasma membrane. AE1 has two distinct functional regions: a 
cytoplasmic N-terminal portion and a 55 kDa membrane spanning C-terminal domain 
that includes fourteen membrane-embedded segments, which are necessary and sufficient 
for functionality. Tryptic fragments of the entire 551 amino acid transmembrane region 
were observed through MALDI and LC-MS output as confirmed by MS/MS spectra for 
small peptides and m/z values plus N-terminal sequencing for larger peptides [108]. 
Previous studies had shown that AE1 contained reactive and accessible lysine residues. 
The separation protocol and MS techniques developed by Abe et al. combined with 
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peptide mapping and supplemental cyanogen bromide (CNBr) digests, resulted in the 
significant finding that identified specific lysine residues as the actual modified amino 
acid residues [108]. N-terminal sequencing and mass analysis of the modified peptides 
were employed to support these findings, but MS/MS spectra were lacking. We have 
succeeded in identifying specific GLUT1 lysine residues modified by Sulfo-NHS-LC-
biotin using MS/MS spectra that show the mass shift. 
MOMP AND SURFACE EXPOSED RESIDUES AND DISULFIDE BONDS 
The MS studies of human AQP0 and Band 3 mirror those performed on prokaryotic 
integral membrane proteins. Major outer membrane protein (MOMP) of Chlamydia 
trachomatis serovar F spans the outer bacterial membrane and functions as a simple 
diffusion porin [110]. Through digestion with trypsin, Glu-C, and Asp-N, the authors 
developed a new model for which residues were surface exposed versus buried within the 
β-sheet transmembrane region. Additionally, the cysteine residues were examined to 
show which formed disulfide bonds versus those that were reactive, and therefore 
unbound, prior to reduction. Peptide mass fingerprinting was used to identify the 
presence of two disulfide bridges, a finding that along with the discovery of previously 
undetermined surface exposed residues altered the previous membrane topology model. 
We were able to distinguish between surface exposed and membrane embedded GLUT1 
peptides as well as identify which cysteine residues are exposed under native versus 
reducing conditions. Unfortunately, we were unable to positively confirm the existence of 
a disulfide bond.  
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EMRE AND LACY AND MONITORING CONFORMATIONAL CHANGES 
Escherichia coli multidrug resistance protein (EmrE) and lactose permease (LacY) have 
also been subjected to MS analysis. EmrE is a small 110 amino acid protein with four 
membrane spanning domains and cytoplasmic terminal ends whose function is to 
exchange positively charged drugs for protons, thus granting these cells drug-resistance. 
LacY is a standard model for the major facilitator superfamily (MFS) of integral 
membrane proteins. This 417 amino acid protein has twelve membrane spanning α-
helices and the carrier exploits a favorable electrochemical proton gradient to catalyze net 
movement of D-galactopyranosides against a concentration gradient. Similar to AQP0 
and AE1, the entire sequence of LacY has been observed through either LC-MS/MS 
sequence identification or LC-MS peptide mass fingerprinting of peptides produced from 
a CNBr digest [113]. Of greater interest with regard to EmrE and LacY, however, are the 
observations that specific amino acid residues demonstrate altered accessibility to 
chemical modification either in the presence of substrate or with the introduction of point 
mutations within the binding cavity. By quantifying the percentage of modification of a 
particular residue in the presence or absence of substrates, it can be determined whether 
the residue of interest displays increased, decreased, or the same accessibility to the 
modifying agent [111-113]. These types of experiments cast light on both potential 
substrate binding sites and conformational changes that can occur as a result of the 
transport mechanism. We were able to identify specific GLUT1 cytoplasmic residues that 
were differentially modified in the presence of sugar transport modulator ATP. 
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APPLICATION OF MASS SPECTROMETRY TO GLUT1 
Our experiments using native GLUT1 proteoliposomes accomplished many of the 
aforementioned results, by using a single protein. These findings provided details 
supporting the general membrane topology predicted by homology modeling and cysteine 
scanning mutagenesis. More specifically, these data described the relative accessibility 
and solvent exposure of amino acid residues within each GLUT1 α−helix and allowed 
comparison with the helix packing motifs observed for crystallized MFS transporters 
LacY, GlpT, OxlT, and EmrD [5,33-35,39,64,74].  
Specifically, we could determine how the transmembrane helices were related in terms of 
experimental hydrophobicity. The high frequency of trypsin cleavage sites at 
membrane/aqueous solvent interfaces permitted isolation of many individual TMs. These 
observations allowed us to determine the likely role for each helix and provided a useful 
method for testing the helix-packing hypothesis. The transmembrane α−helices that were 
generally the most hydrophobic and the least accessible to protease (TMs 3, 6, 9, and 12) 
are likely tightly associated with the lipid bilayer. Those α−helices that are generally less 
hydrophobic, and more accessible to proteolysis (TMs 1, 2, 4, 5, 7, 8, 10, and 11) likely 
display variable degrees of interaction with the aqueous translocation pathway and the 
lipid bilayer.  
The organization of MFS transport proteins is proposed to have arisen from a gene 
duplication event [56]. This hypothesis speculates that the original precursor was an 
integral membrane protein with six membrane-spanning domains that presumably 
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functioned as a dimer. Upon gene duplication, the transport protein possessed twelve 
transmembrane domains. The N-terminal half of the protein (TMs 1-6) is linked to the C-
terminal half (TMs 7-12) by a large intracellular loop, known as L6-7. In essence the C-
terminal half serves as a mirror image of the N-terminal half, where TM1 is the 
structurally symmetric equivalent to TM7 and TM6 is the structurally symmetric partner 
of TM12. Additionally, many primary structure signature sequences, such as the RXGRR 
motif complementarily found in L2-3 and L8-9, support the gene duplication hypothesis.  
Although our results examining TM accessibility to proteolytic cleavage generally 
support the internal symmetry hypothesis, we observe phenomena inconsistent with this 
idea. First, TM4 and its proposed structurally symmetric α−helix partner TM10 
demonstrate drastically different accessibility to proteolytic digestion: TM4 has 4 
susceptible cleavage sites and 44% overall protease accessibility whereas TM10 only 
presents 1 susceptible cleavage site for 9% overall protease accessibility. We hypothesize 
that the arrangement of TM10 within each subunit of the membrane-resident GLUT1 
tetramer differs from the model due to a potential disulfide bond between TM9 and 
TM11 that would force TM10 away from the aqueous pore. Second, a portion of TM11 is 
released into aqueous solvent following proteolysis and sedimentation of the membrane-
associated fraction. Conversely, all peptides from the putative structurally symmetric 
partner TM5 remain associated with the membrane. This again could be the result of the 
alternative fold TM11 demonstrates due to the disulfide bond thus granting it a higher 
degree of interaction with the aqueous environment than its partner. Third, TM1 is 
released into the aqueous fraction following trypsin digestion, however its C-terminal 
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equivalent TM7 remains embedded within the membrane. TM1 and TM7 also 
fundamentally differ in that TM1 is associated with the small N-terminal tail whereas 
TM7 is located within the middle of the protein, surrounded by two TM connecting loop 
regions. Fourth, there appears to be minimal correlation between the relative 
hydrophobicity values (SSR) for each symmetry partner. One partner is generally more 
hydrophobic than the other despite their proposed reflective arrangement within the 
bilayer. Although many α−helix partners demonstrate similar digestion, solvent 
exposure, and peptide release patterns, there are clear examples of transmembrane 
domains that do not share characteristics reproduced across the N- and C-terminal halves 
of the protein. 
We did attempt to study GLUT1 proteolytic accessibility in its native environment using 
human erythrocytes and alkaline-washed erythrocyte ghost membranes. Human red cells 
were digested for 15-120 minutes with α-chymotrypsin, sedimented, and the aqueous 
fraction was examined using RP-HPLC-ESI-MS/MS. Unfortunately, some red cells lysed 
and released intracellular hemoglobin into the aqueous fraction. The large amount of 
contaminating hemoglobin peptides overwhelmed those surface-exposed GLUT1 
peptides presumably produced by α-chymotrypsin and prevented this analysis. When we 
performed the same studies using erythrocyte membranes, the anion exchange protein 
(AE1) contaminated much of the data acquisition. Our best results were obtained if we 
first lysed erythrocytes, performed limited trypsin proteolysis to remove the cytoplasmic, 
N-terminal AE1 domain, washed the ghosts in high alkaline medium, and then 
resuspended them in digestion buffer. Subsequent trypsin and α-chymotrypsin digestion 
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provided limited resolution of GLUT1 peptides that was far less comprehensive than the 
proteoliposome studies. We obtained a great deal of AE1 sequence coverage within these 
fractions. This provided evidence that membrane-embedded amino acid residues found in 
the α-helices of another mammalian transport protein interacted with the aqueous 
environment and were susceptible to proteolysis (Appendix 3; Figure A3.1 and Table 
A3.1). 
Under conditions where e1-binding transport inhibitor cytochalasin B is added to the 
digest buffer or when the insoluble fraction is resuspended in CCB, followed by a second 
sedimentation step, TM8 becomes released into the aqueous solvent fraction. Currently, 
however, we are unable to determine if the addition of 10 µM CCB releases all of TM8 
from the lipid bilayer, if TM8 release into the aqueous fraction is [CCB]-dependent, or if 
the majority of it remains embedded within the membrane. Unlike cytoplasmic peptides, 
which are present in large quantities, resolve very well, and are easily amenable to 
analysis by mass spectrometry, transmembrane proteins are more difficult to quantify. 
The LCQ mass spectrometer has served as a great instrument for quantifying peptide 
amount, but is less equipped for the rapid identification of multiple peptides. The LTQ, 
which scans peptide samples 10-100x faster than the LCQ, is far superior in peptide 
identification by MS/MS, but is less adept at quantifying peptide amounts in our hands. 
Resolving this problem may enhance our ability to grasp the greater details that these 
studies could provide. 
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COVALENT MODIFICATION 
To further assess GLUT1 accessibility and exploit the developed mass spectrometry 
technique, we employed a covalent NHS-ester biotin conjugate probe to study lysine 
accessibility. This was a particularly fortuitous choice because GLUT1 has 16 lysine 
residues distributed throughout the protein at the bilayer interface (at the terminal ends 
and loop regions of TM helices 1, 3, 5, 7, 12), in the N-terminus, in the C-terminus, and 
within the N- and C-terminal halves of L6-7 [24]. We employed a Sulfo-NHS-LC-Biotin 
tag that specifically modified the primary amine group found on the lysine side chain.  
The Sulfo-NHS-LC-Biotin probe has multiple advantages upon which we capitalized 
throughout these experiments (Figure 6.1). First, the Sulfo group causes the probe to fully 
dissolve in aqueous buffer eliminating the need to introduce organic solvents, thus 
maintaining native experimental conditions. Second, the NHS reaction with the lysine 
primary amine forms a covalent amide bond that is much stronger than the thiourea 
linkage formed by fellow lysine reactive probe fluorescein isothiocyanate. This is an 
important distinction because the bond formed by FITC was unable to withstand the 
ionization energy of the mass spectrometer, and it was not possible to identify specific 
lysine residues that were modified. Third, a covalent modification to a lysine residue adds 
a distinguishable 339.16 Da mass adduct. Within the same run, therefore, we could 
identify modified and unmodified lysine containing peptides. We used mass spectrometry 
software to quantify the intensity of each peptide to determine the ratio of lysine 
modification under varying labeling conditions. Fourth, the LC-linker region separates 
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Figure 6.1 Biotin labeling chemistry. The water-soluble Sulfo-NHS-LC-Biotin probe, 
manufactured by Pierce, was used to monitor lysine accessibility in GLUT1 
proteoliposomes. As described in the text, Sulfo-NHS-LC-Biotin was chosen because 
GLUT1 has sixteen lysine residues, the reaction chemistry produces a covalent MS/MS 
stable bond, and the reactive group (a N-Hydroxysuccinimide (NHS) ester) functions at 
neutral pH and is soluble under aqueous conditions to preserve physiological conditions. 
The majority of reactions used a 10 mM concentration of NHS-LC-Biotin dissolved in 
water that presented a 20-fold molar excess of probe:protein. The NHS ester covalently 
modifies the lysine side chain primary amine resulting in a covalent mass net addition of 
339.16 Da. Thus, a modified lysine residue registers as 467 Da versus 127.9 Da for 
unmodified lysine on an MS/MS spectrum. The confirmed reaction chemistry and mass 
addition facilitated identification of modified peptides. 
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the biotin reporter molecule from the reactive NHS ester, reducing steric hindrance that 
would inhibit labeling. We were able to take advantage of this feature when determining 
the differential labeling pattern of lysine residues found within the cytoplasm. Fifth, the 
biotin tag itself was a useful reporter molecule that could be detected by a streptavidin 
antibody conjugated to horseradish peroxidase using ELISA and western blots.  
We detected a preferential order of addition or extent of modification among the lysine 
residues found in the cytoplasmic aqueous fraction (K225, K229, K230, K245, K255, 
K256, K477). Under simple kaline buffer conditions, the C-terminus was most 
accessible, while the C-terminal half of L6-7 was least accessible when the concentration 
of labeling reagent was limiting. At saturating levels of probe, however, all lysine 
residues were equally labeled throughout the protein. Under native conditions, therefore, 
the C-terminus may be the most flexible and solvent-exposed of the cytoplasmic portions, 
but with enough reagent, all cytoplasmic regions are labeled to the same extent. This 
observation suggests that there is some degree of organization among these domains, but 
overall, they demonstrate a high degree of flexibility and interaction with the aqueous 
intracellular environment. Overall all of these findings encouraged us to examine the 
dynamic response of GLUT1 to different substrates, inhibitors, or modulators on the 
global (ELISA or western blot) and local (MS/MS) levels. 
We pre-incubated GLUT1 with D-glucose substrate (Appendix 3; Figure A3.2), CCB 
inhibitor (Appendix 3; Figure A3.3), and ATP modulator (Chapter IV) prior to reaction 
with the NHS-biotin probe to determine if these molecules induced conformational 
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changes within the transporter that would enhance or inhibit covalent modification. 
GLUT1 displayed a global increase in NHS-biotin labeling in a D-glucose specific 
manner, a minor change in labeling in the presence of CCB, and a sharp ATP-specific 
decrease in lysine modification. In contrast to D-glucose and CCB, we have observed 
residue and region specific changes in GLUT1 when ATP is added to these reaction 
mixtures. Our results suggest that in the presence of ATP, L6-7 and the C-terminus 
interact to reduce overall GLUT1 sugar carrying capacity. The fact that our proposed 
model is supported by three independent techniques, requires the GLUT1 L6-7 primary 
sequence, and provides MS data implicating exact residues that undergo changes in 
labeling efficiency is entirely consistent with transport observations and offer a plausible 
molecular mechanism by which these kinetic finding can be explained. 
Using mass spectrometry techniques coupled with traditional biochemistry approaches, 
we have conclusively shown that GLUT1 is a conformationally dynamic protein that 
responds globally to substrate, ligand, or modulator interactions. The similarities between 
the GLUT1 responses to CCB and ATP binding are of particular interest because they 
demonstrate a communication between distal protein domains. In Chapter III we 
discussed how trypsin digests conducted in the presence of CCB or when the membrane 
fraction is resuspended with CCB result in TM8 release from the membrane-embedded 
protein domains. Since CCB is proposed to bind to GLUT1 in the TM10-TM11 region 
[61] the release of TM8 indicates that these conformational dynamics are communicated 
to other parts of the protein. ATP is proposed to bind a nucleotide binding pocket that 
includes, but is not limited to the L8-9-TM9 region [135]. As we showed in Chapter IV, 
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ATP interaction with GLUT1 causes domains, separated by 100 amino acids of primary 
structure, to interact with one another thereby regulating the overall transport function. 
Our observations of global changes in lysine accessibility in the presence of D-glucose 
and CCB and overall accessibility of transmembrane regions to proteolytic agents support 
the hypothesis that GLUT1 undergoes a wide range of conformational changes to mediate 
glucose transport across the plasma membrane.  
HOW THIOL CHEMISTRY AFFECTS GLUT1 STRUCTURE 
Before examining cysteine accessibility by mass spectrometry, we conducted a thorough 
analysis of glucose transport protein electrophoretic behavior. After deglycosylating 
GLUT1 with PNGaseF to improve GLUT1 resolution on reducing SDS-PAGE, we 
resolved two species of GLUT1 in the gel. We found the pattern of GLUT1 resolution to 
be dependent upon the presence of reducing agents such as DTT and βME. Further 
analysis showed that the less mobile species was nonreduced while the more mobile 
species was completely reduced. This demonstrates that membrane resident GLUT1 is 
sensitive to reductant and that thiol chemistry likely plays an important role in 
determining or mediating its folding pattern. 
We further explored the accessibility of the six GLUT1 cysteine residues (C133, C201, 
C207, C347, C421, and C429) using mass spectrometry to determine how reductant 
affected the number and availability of reactive thiol side chains. According to Zottola et 
al. [86], GLUT1 may contain an internal disulfide bridge. If correct, we should have 
isolated a disulfide bond and confirmed its identity by mass and amino acid sequence by 
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this technique. If a GLUT1 intramolecular disulfide does exist, our lack of detection may 
result from insufficient resolution or the propensity of α-chymotrypsin to create multiple 
peptides containing the disulfide bond, thus preventing its quantitation. Our observations 
and previous findings, however, support the existence of a disulfide bond between C347 
and C421 [80,84,86]. When GLUT1 was alkylated in the absence of reductant, we 
detected far fewer peptides with cysteine modifications. C133, C207, and C429 are 
accessible to iodoacetamide regardless of whether or not the protein has been previously 
reduced. This observation indicates that these cysteine side chains are not involved in any 
thiol-mediated interactions, essentially eliminating them from participating in disulfide 
forming side chains. C201 and C421, however, are only detectable as modified residues 
following GLUT1 reduction and C347 is completely undetectable by this technique. 
Although we were unable to categorically identify the C347-C421 disulfide bond, our 
findings are consistent with its existence and role within controlling GLUT1 
oligomerization.  
FUTURE DIRECTIONS 
This discussion has offered our interpretation of the data collected, analyzed, and 
presented within this thesis. After considering these findings and the associated 
commentary, specific observations merit further consideration if we are to continue to 
improve our comprehension of carrier-mediated transport. In particular, the MS technique 
provides an avenue to investigate very specific questions relating to GLUT1-mediated 
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glucose transport and broad questions concerning how the structure-function relationship 
mediates the molecular workings of facilitated diffusion.  
The most interesting fundamental questions are – where do glucose, ATP, and CCB 
bind? Upon identifying the static binding site, the next question asks how binding 
influences transporter conformational states? It is conceivably possible to envision 
reactions that link these molecules to their respective binding sites within the transporter, 
followed by digestion, and identification of the substrate binding site. Biotinylated 
(glucose and ATP) and radiolabeled (CCB) molecules do in fact exist to examine this 
inquiry. Covalent probes with refined chemistries that have a predictable and preferential 
side chain reaction and mass addition would simplify this project and enable more 
computer and database searching. In the absence of these reagents (remember NHS-biotin 
labels any lysine residue with an available primary amine), the suggested probes allow 
definition of the elution conditions required to observe the reporter molecule-peptide 
conjugate, and thus help identify the modified peptides and its reported mass. The MS 
spectra can then be carefully reviewed to identify the peptide of interest and the MS/MS 
spectra can be combed to determine the modified amino acids. Once we gather where a 
substrate binds, we can more accurately model the substrate binding pocket by molecular 
docking procedures using three-dimensional homology models [226].  
These findings will help us to understand how basal glucose transport is catalyzed in all 
cell types. Furthermore, molecular structure-function relationships obtained with GLUT1 
could be applied to other transporters. It is possible to envision experiments that offer 
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biochemical clues for intelligent drug design preventing export from diseased cells or 
promoting targeted and specific uptake.  
Our studies provided biochemical details comparing the structural arrangement of 
GLUT1 transmembrane α-helices with the MFS helix-packing model. TM embedded 
helices 3, 6, 9, and 12 were almost completely resistant to proteolytic digestion. This is 
entirely consistent with a model that buries each helix, peptide backbone and side chain, 
in the lipid bilayer, completely isolating them from aqueous solvent except for the loops 
connecting them to the other TMs. All other lipid embedded TMs are predicted, in some 
form or another, to line the aqueous translocation pathway, and as a result the side chains 
directly interact with water, thus explaining their susceptibility to proteolytic enzymes. 
Proteolytic enzymes only have the capability of cleaving after certain side chains (as we 
have discussed trypsin specificity for peptide bonds following lysine and arginine 
residues). Even though each α-helix has ample potential cleavage sites, this restriction 
limits the ability of this technique to report back on each residue within the entire helix.  
Hydrogen-deuterium exchange studies coupled with mass spectrometry are seemingly the 
next step to define the translocation pathway and delineate the differences between 
residues exposed to the aqueous solvent in the e2, e( ), and e1 conformations. This 
technique takes advantage of differences in proton exchange rates based on location 
within the protein. Solvent exposed protons exchange at a much faster rate than those 
buried within the lipid membrane or involved in protein secondary structure [227]. Jung 
has shown that deuterium does exchange with upwards of 80% of peptide backbone 
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hydrogen molecules in GLUT1 [67]. This observation provides a solid basis for trying to 
identify and determine which residues in each TM are easily exchanged versus those 
which are resistant. Given our high degree of sequence coverage, we should be able to 
detect deuterium exchange based upon the 1 Da mass adducts for each hydrogen 
replaced. This type of experiment will further solidify the helix packing hypothesis. By 
examining deuterium exchange profiles in the presence of glucose, CCB, phloretin, or 
maltose, we can understand which residues of particular regions are directly or indirectly 
involved in dynamic changes and which portions form each conformation. 
We can further probe the GLUT1 residues directly involved in ATP modulation of 
glucose transport. In particular, it would be interesting to determine the precise amino 
acids that mediate the proposed interaction between L6-7 and the C-terminus. We can 
approach this question in two ways. First, we can create point mutations within GLUT1, 
which correspond to primary structure residues that fall between K245 and K256 or 
surrounding K477 in the C-terminus, and express these constructs in HEK cells. 
Transport assays, limited proteolysis, and IgG accessibility in the presence of ATP will 
more directly implicate the residues involved in this interaction. Second, we can test if 
K245, K255, K256, and K477 directly interact by using NHS reactive chemical 
crosslinkers of various linker lengths. Following this reaction, we would subject GLUT1 
to proteolysis and RP-HPLC-ESI-MS/MS to identify uniquely linked peptides. Lysine 
residues would be a starting point for the crosslinking reactions before branching out to 
test other reaction chemistries. 
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Finally, we would like to identify the disulfide bond proposed to exist between C347 and 
C421 using tandem mass spectrometry. This may be accomplished by using more 
specific proteolytic agents, more limited proteolysis, or a disulfide isolation technique to 
assist in identifying this bond and the residues involved in its formation. This idea would 
promote the formation of specific peptides (unlike what α-chymotrypsin produces) that 
would appear in a non-reduced sample, but disappear in a reduced sample. We would like 
to examine proteolysis patterns when GLUT1 is in its native tetrameric form and 
following reduction to determine if overall aqueous accessibility (particularly for TM10) 
changes when the putative disulfide bond is removed. Furthermore, we could apply 
isobaric tags for relative and absolute quantitation (iTRAQ) technology [228] to better 
quantify the cleavage susceptibility patterns in the presence and absence of reductant. 
These studies would provide direct experimental evidence to support the existence of the 
disulfide bond and would explain the diminished exposure of TM10 to the aqueous 
environment. 
FINAL CONCLUSIONS 
This thesis has strengthened the GLUT1 structure-function relationship and provided a 
new technique to further this investigation and to approach additional questions in the 
membrane transport field. The main discoveries included kinetically isolating a protein 
intermediate between the import and export conformational changes, strengthening the 
role of intramolecular bonds in controlling transporter structure and function, and 
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defining membrane topography and solvent accessibility demonstrated by the GLUT1 α-
helices. 
The future directions discuss how we may extend these findings to improve and enhance 
our understanding of how the structure-function relationship governs carrier-mediated 
transport. Integral membrane proteins, which comprise approximately 20% of the 
proteins coded for by the human genome, have distinct and necessary functions in all cell 
types. Their role in regulating interactions between the intra- and extracellular 
environments is absolutely vital for homeostasis and cellular survival. The 
pathophysiology of carrier-mediated diseases and the degree to which the total body 
suffers due to these conditions clearly illustrates the importance transmembrane proteins 
assume in ensuring a properly functioning system. We mentioned cystic fibrosis, 
GLUT1-deficiency syndrome, diabetes, drug addiction, and resistance to drug treatments 
as direct examples of how individual transporters establish and sustain homeostasis. The 
first step to addressing carrier pathophysiology is to understand how protein structure 
governs function, and in this regard, how diseases and other ailments interrupt this 
condition at the molecular level. This thesis presents techniques and findings that offer 
broad solutions to address these issues.  
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APPENDIX A1 
SUPPLEMENTARY MATERIAL FOR CHAPTER III 
HUMAN ERYTHROCYTE GLUCOSE TRANSPORT PROTEIN TOPOLOGY AND HELIX 
PACKING  
Legend to Table A1.1 Trypsin and α-chymotrypsin cleavage sites and full-length 
GLUT1 peptides. For each proteolytic fragment of GLUT1, columns 1 through 8 
indicate: the N-terminal amino acid preceding the N-terminal cut site, its residue number 
in GLUT1 sequence, its location in GLUT1 putative domain structure, the N-terminal 
amino acid preceding the C-terminal cut site, its residue number in GLUT1 sequence, its 
location in GLUT1 putative domain structure, the peptide sequence confirmed by MS/MS 
and the mass of the peptide respectively. 
 
A-2
Cut 1 AA# aTopology Cut 2 AA# aTopology Sequence Mass (MH+)
start 1 N-Terminus K 6 N-terminus -.MEPSSK.K 678.31
start 1 N-Terminus K 7 H1 -.MEPSSKK.L 806.38
K 6 N-Terminus R 11 H1 K.KLTGR.L 574.37
K 6 N-Terminus K 38 TM1 K.KLTGRLMLAVGGAVLGSLQFGYNTGVINAPQK.V 3273.81
R 11 H1 K 38 TM1 R.LMLAVGGAVLGSLQFGYNTGVINAPQK.V 2718.46
K 38 TM1 R 51 L1-2 K.VIEEFYN^QTWVHR.Y 1721.84
R 51 L1-2 R 89 L2-3 R.YGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNR.F 4020.12
R 51 L1-2 R 92 L2-3 R.YGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGR.R 4380.31
R 93 TM3 K 114 L3-4 R.NSMLMMNLLAFVSAVLMGFSK.L 2304.16
K 117 L3-4 R 126 TM4 K.SFEMLILGR.F 1065.58
R 212 L6-7 R 218 L6-7 R.FLLINR.N 775.48
R 218 L6-7 R 223 L6-7 R.NEENR.A 661.27
K 225 L6-7 K 229 L6-7 K.SVLK.K 446.30
K 230 L6-7 K 245 L6-7 K.LRGTADVTHDLQEMK.E 1713.86
K 230 L6-7 R 249 L6-7 K.LRGTADVTHDLQEMKEESR.Q 2215.08
R 232 L6-7 K 245 L6-7 R.GTADVTHDLQEMK.E 1444.67
R 232 L6-7 R 249 L6-7 R.GTADVTHDLQEMKEESR.Q 1945.89
R 249 L6-7 R 253 L6-7 R.QMMR.E 565.26
R 253 L6-7 R 264 L6-7 R.EKKVTILELFR.S 1375.83
K 255 L6-7 R 264 L6-7 K.KVTILELFR.S 1118.69
K 255 L6-7 K 300 L7-8 K.KVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 5143.86
K 256 L6-7 R 264 L6-7 K.VTILELFR.S 990.60
K 256 L6-7 K 300 L7-8 K.VTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 5015.76
R 264 L6-7 K 300 L7-8 R.SPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 4044.18
R 269 TM7 K 300 L7-8 R.QPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 3469.90
K 300 L7-8 R 330 H8 K.AGVQQPVYATIGSGIVNTAFTVVSLFVVER.A 3122.69
K 300 L7-8 R 333 L8-9 K.AGVQQPVYATIGSGIVNTAFTVVSLFVVERAGR.R 3406.85
K 300 L7-8 R 334 L8-9 K.AGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRR.T 3562.95
K 456 H12 R 468 H12 K.GRTFDEIASGFR.Q 1355.65
R 458 H12 R 468 H12 R.TFDEIASGFR.Q 1142.55
R 458 H12 end no cut C-Terminus R.TFDEIASGFRQGGASQSDKTPEELFHPLGADSQV.- 3621.71
R 468 H12 end no cut C-Terminus R.QGGASQSDKTPEELFHPLGADSQV.- 2498.18
K 477 C-Terminus end no cut C-Terminus K.TPEELFHPLGADSQV.- 1639.80
Table A1.1
A-3
Cut 1 AA# aTopology Cut 2 AA# aTopology Sequence Mass (MH+)
L 8 H1 M 13 H1 L.TGRLM.L 577.31
M 13 H1 L 21 TM1 M.LAVGGAVL.G 699.44
L 21 TM1 F 26 TM1 L.GSLQF.G 551.28
Y 28 TM1 E 42 L1-2 Y.NTGVINAPQKVIEE.F 1511.81
Y 28 TM1 Y 44 L1-2 Y.NTGVINAPQKVIEEFY.N 1821.94
W 48 L1-2 L 61 L1-2 W.VHRYGESILPTTL.T 1485.81
Y 52 L1-2 L 61 L1-2 Y.GESILPTTL.T 930.51
E 54 L1-2 L 61 L1-2 E.SILPTTL.T 744.45
W 65 TM2 F 72 TM2 W.SLSVAIF.S 736.42
F 72 TM2 F 81 TM2 F.SVGGMIGSF.S 854.41
F 81 TM2 F 86 TM2 F.SVGLF.V 522.29
L 122 TM4 F 127 TM4 L.ILGRF.I 605.38
F 127 TM4 Y 132 TM4 F.IIGVY.C 564.34
L 162 TM5 L 169 TM5 L.GIVVGIL.I 670.45
L 214 L6-7 E 220 L6-7 L.LINRNEE.N 887.46
L 231 L6-7 L 241 L6-7 L.RGTADVTHDL.Q 1084.54
L 231 L6-7 E 243 L6-7 L.RGTADVTHDLQE.M 1341.64
L 231 L6-7 M 244 L6-7 L.RGTADVTHDLQEM.K 1472.68
L 231 L6-7 E 247 L6-7 L.RGTADVTHDLQEMKEE.S 1858.86
E 247 L6-7 M 251 L6-7 E.SRQM.M 521.25
M 252 L6-7 F 263 L6-7 M.REKKVTILELF.R 1375.83
M 252 L6-7 L 260 L6-7 M.REKKVTIL.E 986.64
F 263 L6-7 Y 268 TM7 F.RSPAY.R 593.30
Y 268 TM7 L 273 TM7 Y.RQPIL.I 626.40
L 273 TM7 L 278 TM7 L.IAVVL.Q 514.36
L 278 TM7 L 284 TM7 L.QLSQQL.S 716.39
L 284 TM7 F 291 TM7 L.SGINAVF.Y 707.37
F 298 L7-8 Y 308 TM8 F.EKAGVQQPVY.A 1118.58
Y 308 TM8 F 320 TM8 Y.ATIGSGIVNTAF.T 1150.61
F 320 TM8 F 326 H8 F.TVVSLF.V 665.39
F 379 TM10 W 388 H10 F.EVGPGPIPW.F 951.49
W 388 H10 E 393 L10-11 W.FIVAE.L 578.32
W 388 H10 F 395 L10-11 W.FIVAELF.S 838.47
F 395 L10-11 F 409 TM11 F.SQGPRPAAIAVAGF.S 1341.73
A 402 TM11 F 409 TM11 A.AIAVAGF.S 648.37
F 460 H12 F 467 H12 F.DEIASGF.R 738.33
F 467 H12 E 480 C-Terminus F.RQGGASQSDKTPE.E 1360.65
F 467 H12 L 482 C-Terminus F.RQGGASQSDKTPEEL.F 1602.77
F 467 H12 F 483 C-Terminus F.RQGGASQSDKTPEELF.H 1749.84
F 467 H12 L 486 C-Terminus F.RQGGASQSDKTPEELFHPL.G 2097.04
F 483 C-Terminus end no cut C-Terminus F.HPLGADSQV.- 923.46
L 486 C-Terminus end no cut C-Terminus L.GADSQV.- 576.26
Table A1.1 (continued)
A-4
Legend to Table A1.2 Trypsin and α-chymotrypsin derived GLUT1 peptides 
released into supernatant. The columns indicate: the N-terminal amino acid preceding 
the N-terminal cut site, its residue number in GLUT1 sequence, its location in GLUT1 
putative domain structure, the N-terminal amino acid preceding the C-terminal cut site, 
its residue number in GLUT1 sequence, its location in GLUT1 putative domain structure, 
the peptide sequence confirmed by MS/MS and the mass of the peptide respectively. 
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Cut 1 AA# aTopology Cut 2 AA# aTopology Sequence Mass (MH+)
start 1 N-Terminus K 6 N-terminus -.MEPSSK.K 678.31
start 1 N-Terminus K 7 H1 -.MEPSSKK.L 806.38
K 6 N-Terminus R 11 H1 K.KLTGR.L 574.37
L 8 H1 M 13 H1 L.TGRLM.L 577.31
R 11 H1 K 38 TM1 R.LMLAVGGAVLGSLQFGYNTGVINAPQK.V 2718.46
M 13 H1 L 21 TM1 M.LAVGGAVL.G 699.44
L 21 TM1 F 26 TM1 L.GSLQF.G 551.28
Y 28 TM1 Y 44 L1-2 Y.NTGVINAPQKVIEEFY.N 1821.94
Y 28 TM1 W 48 L1-2 Y.NTGVINAPQKVIEEFYNQTW.V 2351.17
K 38 TM1 R 51 L1-2 K.VIEEFYN^QTWVHR.Y 1721.84
W 48 L1-2 L 61 L1-2 W.VHRYGESILPTTL.T 1485.81
Y 52 L1-2 L 61 L1-2 Y.GESILPTTL.T 930.51
W 65 TM2 F 72 TM2 W.SLSVAIF.S 736.42
F 81 TM2 F 86 TM2 F.SVGLF.V 522.29
L 122 TM4 F 127 TM4 L.ILGRF.I 605.38
R 212 L6-7 R 218 L6-7 R.FLLINR.N 775.48
R 218 L6-7 R 223 L6-7 R.NEENR.A 661.27
K 225 L6-7 K 229 L6-7 K.SVLK.K 446.30
K 230 L6-7 K 245 L6-7 K.LRGTADVTHDLQEMK.E 1713.86
K 230 L6-7 R 249 L6-7 K.LRGTADVTHDLQEMKEESR.Q 2215.08
L 231 L6-7 E 243 L6-7 L.RGTADVTHDLQE.M 1341.64
L 231 L6-7 M 244 L6-7 L.RGTADVTHDLQEM.K 1472.68
L 231 L6-7 E 247 L6-7 L.RGTADVTHDLQEMKEE.S 1858.86
R 232 L6-7 K 245 L6-7 R.GTADVTHDLQEMK.E 1444.67
R 232 L6-7 R 249 L6-7 R.GTADVTHDLQEMKEESR.Q 1945.89
R 249 L6-7 R 253 L6-7 R.QMMR.E 565.26
Table A1.2
A-6
Cut 1 AA# aTopology Cut 2 AA# aTopology Sequence Mass (MH+)
M 252 L6-7 F 263 L6-7 M.REKKVTILELF.R 1375.83
M 252 L6-7 L 260 L6-7 M.REKKVTIL.E 986.64
R 253 L6-7 R 264 L6-7 R.EKKVTILELFR.S 1375.83
K 255 L6-7 R 264 L6-7 K.KVTILELFR.S 1118.69
K 256 L6-7 R 264 L6-7 K.VTILELFR.S 990.60
F 263 L6-7 Y 268 TM7 F.RSPAY.R 593.30
L 278 TM7 L 284 TM7 L.QLSQQL.S 716.39
L 284 TM7 F 291 TM7 L.SGINAVF.Y 707.37
F 298 L7-8 Y 308 TM8 F.EKAGVQQPVY.A 1118.58
K 300 L7-8 R 330 H8 K.AGVQQPVYATIGSGIVNTAFTVVSLFVVER.A** 3122.69
Y 308 TM8 F 320 TM8 Y.ATIGSGIVNTAF.T 1150.61
F 379 TM10 W 388 H10 F.EVGPGPIPW.F 951.49
W 388 H10 F 395 L10-11 W.FIVAELF.S 838.47
F 395 L10-11 F 409 TM11 F.SQGPRPAAIAVAGF.S 1341.73
K 456 H12 R 468 H12 K.GRTFDEIASGFR.Q 1355.65
R 458 H12 R 468 H12 R.TFDEIASGFR.Q 1142.55
R 458 H12 end no cut C-Terminus R.TFDEIASGFRQGGASQSDKTPEELFHPLGADSQV.- 3621.71
F 467 H12 L 482 C-Terminus F.RQGGASQSDKTPEEL.F 1602.77
F 467 H12 F 483 C-Terminus F.RQGGASQSDKTPEELF.H 1749.84
F 467 H12 L 486 C-Terminus F.RQGGASQSDKTPEELFHPL.G 2097.04
R 468 H12 end no cut C-Terminus R.QGGASQSDKTPEELFHPLGADSQV.- 2498.18
K 477 C-Terminus end no cut C-Terminus K.TPEELFHPLGADSQV.- 1639.80
F 483 C-Terminus end no cut C-Terminus F.HPLGADSQV.- 923.46
L 486 C-Terminus end no cut C-Terminus L.GADSQV.- 576.26
F 483 C-Terminus end no cut C-Terminus F.HPLGADSQV.- 923.46
L 486 C-Terminus end no cut C-Terminus L.GADSQV.- 576.26
Table A1.2 (continued)
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APPENDIX A2 
SUPPLEMENTARY MATERIAL FOR CHAPTER V 
HUMAN TYPE 1 FACILITATIVE GLUCOSE TRANSPORT PROTEIN PRESENTS  
REDUCTANT-SENSITIVE CONFORMERS 
 
Legend for Table A2.1 Trypsin digest of gel-eluted GLUT1 as detected by ESI-
MS/MS. aGLUT1 was gel-eluted and subjected to trypsin digestion followed by 
definitive sequence analysis by MS/MS. M* indicates an oxidized methionine residue 
(+15.99 Da). bm/z is the mass to charge ratio of the isolated peptide prior to 
fragmentation. cTryptic site indicates the amino acid at the N-terminal tryptic cleavage 
site. dResidue # 1 indicates the specific GLUT1 residue at the N-terminal tryptic cleavage 
site. eTryptic site 2 indicates the amino acid at the C-terminal tryptic cleavage site. 
fResidue # 2 indicates the specific GLUT1 residue at the C-terminal tryptic cleavage site. 
gThis peptide is detected only in deglycosylated GLUT1. 
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aTryptic Peptides bm/z
cTryptic
Site 1
fResidue
#2
eTryptic
Site 2
dResidue
#1
R.LMLAVGGAVLGSLQFGYNTGVINAPQK.V 2718.46 R 11 K 38
gK.VIEEFYNQTWVHR.Y 1720.84 K 38 R 51
R.YGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNR.F 4020.12 R 51 R 89
R.YGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGR.R 4380.31 R 51 R 92
R.YGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRR.N 4536.41 R 51 R 93
R.RNSMLMMNLLAFVSAVLMGFSK.L 2460.26 R 92 K 114
R.RNSM*LMMNLLAFVSAVLMGFSK.L 2476.26 R 92 K 114
R.NSMLMMNLLAFVSAVLMGFSK.L 2304.16 R 93 K 114
R.NSM*LMMNLLAFVSAVLMGFSK.L 2320.16 R 93 K 114
R.NSMLMMNLLAFVSAVLMGFSK.L 2304.16 R 93 K 114
R.NSMLMMNLLAFVSAVLM*GFSK.L 2320.16 R 93 K 114
R.NSMLM*MNLLAFVSAVLM*GFSK.L 2336.15 R 93 K 114
R.NSMLMMNLLAFVSAVLMGFSKLGK.S 2602.36 R 93 K 117
R.NSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGR.F 3648.92 R 93 R 126
R.GALGTLHQLGIVVGILIAQVFGLDSIMGNK.D 3034.71 R 153 K 183
R.FLLINR.N 775.48 R 212 R 218
K.SVLK.K 446.30 K 225 R 229
R.GTADVTHDLQEMK.E 1444.67 R 232 K 245
R.GTADVTHDLQEM*K.E 1460.67 R 232 K 245
R.GTADVTHDLQEMKEESR.Q 1945.89 R 232 R 249
R.GTADVTHDLQEM*KEESR.Q 1961.89 R 232 R 249
R.QMMR.E 565.26 R 249 R 253
R.EKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 5401.00 R 253 K 300
K.KVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 5143.86 K 255 K 300
K.VTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 5015.76 K 256 K 300
R.SPAYR.Q 593.30 R 264 R 269
R.SPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 4044.18 R 264 K 300
R.QPILIAVVLQLSQQLSGINAVFYYSTSIFEK.A 3469.90 R 269 K 300
K.AGVQQPVYATIGSGIVNTAFTVVSLFVVER.A 3122.69 K 300 R 330
K.AGVQQPVYATIGSGIVNTAFTVVSLFVVERAGR.R 3406.85 K 300 R 333
R.TFDEIASGFR.Q 1142.55 R 458 R 468
R.QGGASQSDKTPEELFHPLGADSQV.- 2498.18 R 468 end 492
Table A2.1
A-10
Legend for Table A2.2 α-Chymotrypsin digest of gel-eluted GLUT1 as detected by 
ESI-MS/MS. aGLUT1 was gel-eluted and subjected to alpha-chymotrypsin digestion 
followed by definitive sequence analysis by MS/MS. M* indicates an oxidized 
methionine residue (+15.99 Da). C# indicates a Cys-S-Pam residue (cysteine with an 
acrylamide adduct; +57 Da). bm/z is the mass to charge ratio of the isolated peptide prior 
to fragmentation. cα-Chymo site indicates the amino acid at the N-terminal tryptic 
cleavage site. dResidue # 1 indicates the specific GLUT1 residue at the N-terminal 
chymotryptic cleavage site. eα-Chymo site 2 indicates the amino acid at the C-terminal 
tryptic cleavage site. fResidue # 2 indicates the specific GLUT1 residue at the C-terminal 
α-chymotryptic cleavage site. 
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L.TGRLMLAVGGAVLGSLQF.G 1790.00 L 8 F 26
M.LAVGGAVL.G 699.44 M 13 L 21
W.VHRYGESILPTTL.T 1485.81 W 48 L 61
Y.GESILPTTL.T 930.51 Y 52 L 61
F.SVGGMIGSF.S 854.41 F 72 F 81
F.SVGLF.V 522.29 F 81 F 86
F.GRRNSMLMMNLLAFVSAVLMGFSKL.G 2786.47 F 90 L 115
N.SMLMMNLLAFVSAVLMGFSKL.G 2303.20 N 94 L 115
F.IIGVY.C 564.34 F 127 Y 132
F.RGALGTLHQLGIVVGILIAQVF.G 2275.36 F 152 F 174
L.SIIFIPALL.Q 986.63 L 167 L 199
F.GLDSIMGNKDLWPLLLSIIFIPALL.Q 2752.57 F 174 L 199
F.GLDSIMGNKDLWPLLLSIIFIPALLQCIVLPFCPESPRF.L 4369.36 F 174 F 213
L.QC#IVLPFC#PESPRFL.L 1890.89 L 199 L 214
F.C#PESPRFL.L 1019.46 F 206 L 214
L.INRNEENRAKSVL.K 1542.83 L 215 L 228
L.RGTADVTHDLQEMKEESRQM.M 2361.09 L 231 M 251
L.QLSQQL.S 716.39 L 278 L 284
L.QLSQQLSGINAVF.Y 1404.75 L 278 F 291
Y.YSTSIFEKAGVQQPVY.A 1816.91 Y 292 Y 308
Y.STSIFEKAGVQQPVY.A 1653.85 Y 293 Y 308
F.EKAGVQQPVY.A 1118.58 F 298 Y 308
F.EKAGVQQPVYATIGSGIVNTAF.T 2250.18 F 298 F 320
Y.ATIGSGIVNTAF.T 1150.61 Y 308 F 320
L.HLIGLAGMAGC#AILMTIALALLEQLPW.M 2890.54 L 336 W 363
F.GFVAFFEVGPGPIPW.F 1619.83 F 373 W 388
F.EVGPGPIPW.F 951.49 F 379 W 388
W.FIVAELF.S 838.47 W 388 F 395
F.SQGPRPAAIAVAGF.S 1341.73 F 395 F 409
F.IVGM*CFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTF.D 5232.75 F 416 F 460
F.QYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTF.D 4566.46 F 422 F 460
F.QYVEQLC#GPYVFIIFTVLLVLFFIFTYFKVPETKGRTF.D 4637.46 F 422 F 460
F.DEIASGF.R 738.33 F 460 F 467
F.RQGGASQSDKTPEELFHPLGADSQV.- 2654.28 F 467 end 492
aα-Chymotryptic Peptides bm/z cα-ChymoSite 1
cα-Chymo
Site 2
fResidue
#2
dResidue
#1
Table A2.2
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Legend for Table A2.3 Cyanogen bromide digest of gel-eluted GLUT1 as detected 
by ESI-MS/MS. aGLUT1 gel-eluted GLUT1 was dissolved in formic acid and subjected 
to CNBr digestion followed by definitive sequence analysis by MS/MS. M. indicates the 
N-terminal cleavage site.  M@ indicates a homoserine lactone at the C-terminal 
methionine cleavage site (-48.1 Da). M~ indicates a homoserine at the C-terminal 
methionine cleavage site (-30.1 Da). S^ indicates a formylated serine residue (+28 Da). 
T^ indicates a formylated threonine residue. C# indicates a cys-S-Pam residue (cysteine 
with an acrylamide adduct; + 71 Da). bm/z is the mass to charge ratio of the isolated 
peptide prior to fragmentation. cResidue # 1 indicates the specific GLUT1 residue at the 
N-terminal CNBr cleavage site. dResidue # 2 indicates the specific GLUT1 residue at the 
C-terminal CNBr cleavage site. eModification indicates the formylated or acrylamide-
modified residue. fThe sequence of this peptide was confirmed from partial b and y ion 
series spectra but the peptide mass indicates an unknown modification. 
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M.EPSSKKLTGRLM@.L 1298.75 1 13 0
M.EPSSKKLTGRLM~.L 1316.75 1 13 0
M.EPSS^KKLTGRLM@.L 1326.75 1 13 S5
M.EPS^SKKLTGRLM@.L 1326.75 1 13 S4
M.EPSSKKLT^GRLM@.L 1326.75 1 13 T9
M.EPS^S^KKLTGRLM@.L 1354.75 1 13 S4, S5
M.IGSFSVGLFVNRFGRRNSM@.L 2096.12 77 96 0
M.IGS^FSVGLFVNRFGRRNSM@.L 2124.12 77 96 S80
M.LM*MNLLAFVSAVLM~.G 1538.82 96 110 0
M.M*NLLAFVSAVLM@.G 1276.70 98 110 0
M.M*NLLAFVS^AVLM@.G 1304.70 98 110 S106
M.NLLAFVSAVLM@.G 1129.66 99 110 0
M.NLLAFVS^AVLM@.G 1157.66 99 110 S106
M.NLLAFVSAVLMGFS^KLGKSFEM@.L 2369.27 99 121 S113
M.GFSKLGKSFEM@.L 1182.62 110 121 0
M.GFSKLGKSFEM~.L 1200.62 110 121 0
M.GFSKLGKS^FEM@.L 1210.62 110 121 S118
M.GFS^KLGKSFEM@.L 1210.62 110 121 S113
M.GFS^KLGKS^FEM@.L 1238.62 110 121 S113, S118
fM.LILGRFIIGVYCGLTTGFVPM.Y 2270.24 121 142 0
M.LILGRFIIGVYC#GLTTGFVPM@.Y 2293.29 121 142 C133
M.KEESRQM@.M 859.43 244 251 0
M.KEES^RQM@.M 887.43 244 251 S248
M.TIALALLEQLPWM@.S 1450.83 351 364 0
aCNBR Peptide bm/z
dResidue
#2
eModification
cResidue
#1
Table A2.3
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APPENDIX A3 
SUPPLEMENTARY MATERIAL FOR CHAPTER VI 
DISCUSSION AND FUTURE DIRECTIONS 
Figure A3.1 AE1 accessibility to proteolytic cleavage (putative topography and 
graphic from [176]). Human red blood cells were washed, lysed, digested with trypsin to 
remove the cytoplasmic N-terminal domain (amino acids 1-358), reduced (10 mM DTT), 
alkylated (50 mM iodoacetamide), and digested with either trypsin or α-chymotrypsin. 
The entire ghost digest was subjected to RP-HPLC and ESI-MS/MS using the LTQ as 
described for GLUT1 proteolipsome analysis. The cleavage sites (represented by an X) 
indicate amino acids within the AE1 C-terminal domain that are accessible to proteolytic 
cleavage by trypsin or α-chymotrypsin, see Table A1.3 for further details. 
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Legend to Table A3.1 Trypsin and α-chymotrypsin digest of anion exchange protein 
1 (AE1). Columns indicate the location (within the C-terminal, membrane-embedded 
portion of the protein, amino acids 359-911) where the peptide can be found, the peptide 
sequence including the residues after which it was cleaved, and a description of where the 
cleavage sites are located: cytosolic, internal TM, interface (location where the lipid 
bilayer, the TM domain, and aqueous environment directly interact), lumen, and entire 
TM (indicating that the cleavage sites were in the cytosolic and lumenal regions and 
produced a peptide that included the entire TM). 
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Region Detected Sequence Comments
N-TERM Y.KGLDLNGGPDDPLQQTGQLF.G Cytosolic
N-TERM L.DLNGGPDDPLQQTGQLF.G Cytosolic
N-TERM LDLNGGPDDPLQQTGQ.L Cytosolic
N-TERM K.GLDLNGGPDDPLQQTGQLF.G Cytosolic
N-TERM K.GLDLNGGPDDPLQ.Q Cytosolic
N-TERM L.DLNGGPDDPLQQTGQLF.G Cytosolic
TM1 F.AALSPAITF.G Internal TM
L1-2 F.GGLLGEF.T Interface and Lumen
L1-2 F.NQMGVSEL.L Lumen and Interface
TM3 L.VVGF.S Internal TM
TM3 L.VFEEAFF.S Internal TM
TM4 Y.IVGRVWIGFWLILLVVLVVAFEGSF.L Entire TM
TM5 Y.TQEIFSFLISLIFIYETFSKLIKIFQDHPL.Q Entire TM
TM5 F.ISRYTQEIFSFLISLIFIYETFSKLIKIF.Q Entire TM
TM6 Q.GPLPNTALLSLVLMAGTFFFAMMLRKF.K Entire TM
TM7 L.RRVIGDFGVPISILIMVLVDFFIQDTY.T Entire TM
TM7 R.RVIGDFGVPISILIMVLVDFFIQDTY.T Entire TM
TM9 M.VKGSGFHLDLLLVVGMGGVAALFGMPWLSATTVRSVT.H Entire TM
TM9 F.HLDLLLVVGMGGVAAL.F Interface and Internal TM
TM9 F.HLDLLLVVGM.G Interface and Internal TM
TM9, L9-10 F.GMPWLSATTVRSVTHANAL.T Internal TM and Lumen
TM9, L9-10 L.VVGMGGVAALFGMPWLSATTVRSVTHAN.A Internal TM and Lumen
L9-10 W.LSATTVRSVTHANAL.T Interface and Lumen
L10-11 L.FKPPKYHPDVPY.V Cytosolic
L10-11 L.LFKPPKYHPDVPY.V Cytosolic
C-TERM L.DADDAKATF.D Cytosolic
C-TERM F.DEEEGRDEY.D Cytosolic
C-TERM F.DEEEGRDEYDEVAMPV- Cytosolic
Table A3.1
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Despite the global observations for D-glucose, we were unable to identify the specific 
residues responsible for displaying the global increase in lysine modification (see Figure 
A3.2). We focused on lysine residues found in L6-7 (K225, K229, K230, K245, K255, 
and K256) and the C-terminal tail (K477). It is unknown if the change in labeling was 
due to enhanced accessibility of one residue, multiple residues, or if some residues 
demonstrated enhanced labeling, while others became less available for modification. 
Additionally, one or multiple residues found at the extracellular TM interface, which are 
generally more difficult to quantitatively detect by mass spectrometry, may be 
responsible for the global labeling changes.  
The lack of detectable labeling variation in the presence of CCB may not be terribly 
surprising (Figure A3.3). We have previously noted that CCB is hypothesized to interact 
with GLUT1 at a site in between TM10 and TM11 [61, 79]. Furthermore, we have 
observed that TM8 is released from the membrane bilayer when the protein is digested in 
the presence of CCB. Although lysine 300 forms one of the cleavage sites responsible for 
TM8 release, there are no other lysine residues in this entire C-terminal region until K451 
found at the cytoplasmic end of TM12. It is possible that CCB binding does not affect the 
conformational dynamics of L6-7 or the C-terminus, and as a result, the absence of global 
labeling changes could be consistent with the current hypothesis for localized CCB 
binding. Undertaking residue specific studies or antibody binding experiments within the 
TM8-TM11 α-helical regions could determine if more localized conformational changes 
occur, if any enhancements within one region are offset by inhibition in a corresponding 
region, or if there are no conformational changes as a result of CCB binding. 
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Figure A3.2 Extent of GLUT1 lysine modification in the presence of sugars. Final 
extent of GLUT1 labeling by Sulfo-NHS-LC-Biotin (20:1 molar excess of probe to 
protein) at 4°C, pH 7.4 in the presence of sugars. GLUT1 proteoliposomes were pre-
incubated for 30 minutes in Kaline (red), 50 mM Mannitol (maroon), 50 mM D-Glucose 
(blue), or 50 mM Maltose (green) prior to labeling. The average equilibrium labeling 
extent of at least three normalized labeling experiments done in triplicate ± SEM: Kaline, 
extent = 1.02 ± 0.04; 50 mM Mannitol extent = 1.05 ± 0.05; 50 mM D-Glucose extent = 
1.33 ± 0.04; 50 mM Maltose extent = 1.19 ± 0.04. 
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Figure A3.3 Extent of GLUT1 lysine modification in the presence of cytochalasin B. 
Final extent of GLUT1 labeling by Sulfo-NHS-LC-Biotin (20:1 molar excess of probe to 
protein) at 4°C, pH 7.4 in the presence of cytochalasin. GLUT1 proteoliposomes were 
pre-incubated for 30 minutes in Kaline (red), 10 µM CCB (blue), 0.2% DMSO (green) 
prior to labeling. The average equilibrium labeling extent of at least three normalized 
labeling experiments done in triplicate ± SEM: Kaline, extent = 1.02 ± 0.04; 10 µM CCB 
extent = 0.97 ± 0.05; 0.2% DMSO extent = 0.93 ± 0.03. 
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